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Atrial fibrillation (AF) is the most common cardiac arrhythmia which is fast reaching 
epidemic measures. This thesis evaluates several aspects of AF: the role of AF 
screening, risk factor management in reversal of the AF substrate, impact of socio-
economic background and risk-factor management, gender and ablation outcomes, 
thrombogenic risk following ablation and anticoagulation treatments. 
Screening to detect AF prevalence and asymptomatic AF is increasingly being 
evaluated to reduce complications. Chapter 2 evaluates the results of a nationwide 
screening event. This study provides insight into detection rates around Australia and 
New Zealand. Additionally, due to the information collected we were able to establish 
the risk of AF development in individuals based on their risk factor profile. Screening 
enabled raised awareness of the AF and an opportunity to educate individuals on their 
individual risk factors. 
AF is well demonstrated to be a progressive disease. Many patients present with 
short paroxysmal episodes which over time become long-lasting and eventually 
persistent in nature. Chapter 3 presents the REVERSE-AF study which demonstrated 
that with increasing weight-loss there is an increase likelihood of AF reversal. Patients 
who were able to achieve >10% weight-loss were more likely to have AF reversal with 
88% of patients reversing from persistent to paroxysmal or no AF at follow-up.  
The role of socioeconomic determinants on risk factor management in AF is not 
well studied. Chapter 4 investigates the socioeconomic influence on patients 
undergoing risk factor management and AF outcomes. Despite evaluating many 
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factors of socioeconomic background, no specific factor demonstrated an association 
with AF freedom. Interestingly, we did note that married individuals were able to 
achieve greater weight-loss. This has important implications suggesting that socio-
economic boundaries are not determinants of the success of risk-factor management 
in AF. Socioeconomic status in not a barrier to successful risk-factor management in 
AF. 
Ablation has been shown to be successful in treating patients with AF. The 
difference between outcomes of genders is very varied in the current literature, with 
women often having worse outcomes. In chapter 5 we present the long-term follow-
up data, assessing ablation outcomes. This study found women present with more 
paroxysmal AF and a smaller atrium. Despite this, women are more likely to have AF 
recurrence over long-term follow-up. This data adds further weight for biological 
differences between genders in the outcomes of AF management. 
Stroke is one of the most devastating outcomes of AF; however, it has a complex 
pathophysiological basis. As such chapter 6 evaluates a large cohort of patients 
undergoing AF ablation to shed light on the impact of eliminating AF. Interestingly 
despite eliminating arrhythmia, a small group of individuals had a stroke during 
follow-up. This demonstrates that AF itself remains only one component of the risk of 
stroke in patients with AF; highlighting ongoing vigilance is needed in managing all 
stroke risk factors. Additionally, further caution and evaluation is required to cease 
anticoagulation after successful catheter ablation of AF. 
Finally, Non-vitamin K antagonists (NOAC) have become a popular method of 
anticoagulation for AF patients in the prevention of stroke. It has been suggested there 
is a significant discontinuation rate warranting the evaluation of non-pharmacological 
strategies for stroke prevention. Chapter 7 evaluates cessation rates in a single-centre 
v 
when prescription is undertaken in an integrated care setting. Interestingly, despite 
suggestions in the literature, we found with appropriate education and individual 
participation in decision making, the rate of cessation was low. Age and gender were 
independent predictors of NOAC cessation. This data highlights the need for improved 
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Chapter 1: Review of the Literature 
1.1 ATRIAL FIBRILLATION – GLOBAL BURDEN 
Atrial fibrillation (AF) has emerged as a global epidemic, affecting 33.5 million 
individuals worldwide, however this figure is likely to be an underestimate of the true 
burden of AF due to 70% of the data coming from the developed world.1 In addition, 
due to the nature of AF many individuals are unaccounted for due to the intermittent 
and variable nature of the symptoms associated with the disease. This high incidence 
is only predicted to increase over the years. The Anticoagulation and Risk Factors in 
Atrial Fibrillation (ATRIA) Study estimated that the United States alone accounts for 
2.3 million adults with AF and this is projected to rise to 5.6 million by 2050, with 
50% of these being 80 years or older.2 More recent projections suggest the US 
prevalence to rise to 15.9 million by 2050.3 Similarly, in Asia the prevalence is on the 
rise also, over an 11 year time period the prevalence increased 20 fold with an 
estimated on in five Chinese adults likely to have AF in their lifetime.4 In Australia 
the prevalence is estimated to be between 1.4 and 5%.5-7 The Busselton Study of 1770 
participants found the prevalence to be 4.9% in those aged over 60 years. A recent 
study of 8,272 individuals in the AusDiab study reported 1.4% of baseline ECG’s were 
in AF.7 Additionally prevalence data has been obtained using the seven international 
epidemiological studies and collated the statistics to estimate AF prevalence based on 
what would be most applicable to the Australian population. To do this they applied 
the international AF prevalence statistics to predict prevalence of over 600,000 
individuals by 2034.5  
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With this growing burden of AF comes a rise in AF-related morbidity, 
mortality and healthcare costs, which will consequently place a huge demand on the 
already overburdened healthcare systems. Studies from the United States highlights an 
increase of AF related hospitalisations by 23% over a 10-year duration.8 In Australia, 
we see similar trends with the number of hospital admissions due to AF is rising 
exponentially such that it is now a more common cause of hospitalisations than other 
cardiovascular causes including heart failure and acute coronary syndromes.9 The 
economic cost of this burden is staggering with millions of dollars being absorbed by 
this condition, related to a range of therapies from procedures, hospitalisations, 
medication use and complications such as stroke. In the United Kingdom the cost of 
AF in 1995 was between 244 and 531 million pounds and additionally it demonstrated 
this cost was set to increase.10 Indeed, it has also been shown that in the United States 
the cost is estimated to be between $6 and $26 billion annually.11 The cost of AF to 
our healthcare system in Australia, was approximately $873.8m between 2008-2009, 
with an annual cost of $5,200 per person.12 These alarming figures highlight the need 
for intervention and prevention to stem the rising incidence of AF, reduce AF 
morbidity and subsequently alleviate healthcare demands.  
 
1.1.1 Screening for AF 
In 2015 AF-Screen was established as an international collaboration in order to 
promote discussion and further research into screening for AF.13 This initiative 
includes multidisciplinary teams of electrophysiologists, cardiologist, general 
physicians, neurologist, nurses, allied professionals, epidemiologists, health 
economists and patient advocates from 31 countries. The consensus from this team of 
experts is that singe-timepoint screening is warranted and cost-effective. Additional 
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benefits may be obtained in screening those who are considered at higher risk of AF 
or >75 years of age.  
A recent method used to establish the prevalence of AF is systematic, 
community, high risk populations screening as well as opportunistic screening for AF. 
As per the European Heart Rhythm Association Consensus Statement in 201714 types 
of screening are defined as community screening this is done via the same method as 
systematic screening but involves screening of subjects living in a specific area. 
Systematic screening is single time point methodical pulse or ECG check as part of a 
routine consultation. High risk population screening is methodical screening of 
subjects presenting with critical characteristics such as screening within medical 
clinics and pharmacies with opportunistic screening is done to target large populations 
undertaken in various locations taking advantage of the circumstances. A large 
percentage of the population have asymptomatic AF with ill-defined or no symptoms, 
this is estimated at being approximately one-third of patients. Screening enables the 
ability to detect AF in these patients.15,16 Unfortunately, due to the nature of 
paroxysmal AF, screening precludes from detecting paroxysmal episodes, which are 
usually limited to clinical diagnosis and symptoms. In addition, there is a lack of 
randomised data in this area to show benefit in hard endpoints such as stroke or 
mortality. In 2016 the European Society of Cardiology (ESC) AF guidelines17 included 
screening for AF with a class 1 level B recommendation for opportunistic screening 
for patients >65 by use of pulse or ECG rhythm strip, and additionally a IIb level B 
recommendation for systematic ECG screening in those >75 years old or those who 
are at high risk of stroke.  
There have been many screening studies over the last two decades given the 
advances in technology over this time. The prevalence of detected AF has varied from 
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0.5% to over 5%; when these twenty-three prospective, cross sectional studies are 
combined the weighted average for newly detected AF was around 0.9% (95% CI; 0.7-
1.1).14 Additionally, given the aging population it is prudent to note that the prevalence 
of detected AF increases with age. This was demonstrated in a large cohort of over 
65,700 subjects from Belgium undertaken as part of ‘Belgian Heart Rhythm Week’ 
where the prevalence detected using handheld ECG found AF was 1.4%, this was 
further broken down by age. AF was detected in 1% of participants aged <65 compared 
to 6.5% in individuals aged 85-89, with AF being more prevalent in males.18 To date 
there has only been three studies from Australia which have been pilot studies 
assessing feasibility opportunistic screening.19-21 One was performed across 10 
pharmacies of 1000 participants who were aged ≥65 has been undertaken using 
handheld ECG, the prevalence of AF detected in this study was 1.5%.22 No systematic 
screening has been performed in Australia to date. 
It has been demonstrated that it is beneficial to screen at-risk populations, with 
studies having demonstrated that this will yield diagnosis of AF this would seem 
reasonable. It does appear to be less futile in the general public, particularly the 
younger population. It is perhaps with new technology such as the Apple watch that 
large scale mass screening may prove beneficial. 
 
1.1.2 Tools and Technology Used for Screening 
Although AF can be detected by regular pulse checks other irregularities can be 
mistaken for AF. It has been shown that the use of blood pressure monitors, ECG, and 
smartphone applications are superior forms of detection when compared with pulse 
palpation.23 To date the primary methods of AF detection has been ECG and Holter 
monitoring. ECG while useful clinically is too intrusive to undertake in mass screening 
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events. Holter monitoring requires fitting, programming then analysing, while this is 
suitable in a clinical setting this is not suitable for screening. Similarly, there has been 
patches that have been developed, these are less cumbersome than a standard Holter 
monitoring as they don’t require leads. The Zio Patch developed by iRhythm 
technologies is a waterproof, single use, continuous monitor that can be worn for up 
to 14 days. Once the recording is finished this is returned to the manufacturer who then 
return a report with results to the referring physician. There was an early study of 
comparing 24-hour Holter monitoring to the Zio Patch. This found that the Zio 
detected 57% more clinical events compared to the traditional Holter.24 More recently 
the mSToPs randomised clinical trial used the Zio Patch to detect asymptomatic AF 
after a duration of 4 months.25 The participants were randomised to either immediate 
monitoring or delayed monitoring. The study design was those in the immediate group 
wore the patch for 2 weeks then a second device after 3 months before reaching the 
primary endpoint. The delayed group had no monitor until the 4-month mark where 
they then underwent the same protocol of 2 weeks monitoring followed by a further 2 
weeks at 3 months. This demonstrated a detection of new incident AF cases in 3.9% 
of the immediate group compared to 0.9% in the delayed group. This device is not 
inexpensive which therefore makes it difficult to use for large scale screening event.  
Given the advances in technology we now have new easy and often 
inexpensive tools available to undertake single point screening. The common tools 
used for screening include the Zenicor EKG® (Zenicor Medical Systems) which is a 
small device that requires the patient placing their thumbs on two electrodes for 30 
second and obtains a single lead ECG which has been shown to correctly diagnose AF 
with a sensitivity in 96% and specificity in 92%.26 The MyDiagnostik (Applied 
Biomedical Systems BV, Maastricht, The Netherlands) tool is used commonly in 
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Europe.  This is a simple tool shaped like a wand which is held between an individuals 
hands and it has the ability to obtain a single lead ECG over 1 minute with a sensitivity 
of 94% and specificity of 93%.27 The Omeron HCG (Model HCG-801, Omeron 
Healthcare Europe, the Netherlands) monitor, which provides a single change 20 
second ECG by placing the device on the patient’s chest with a sensitivity of 99% and 
specificity of 76%.28 However due to the slightly invasive nature of this device it is 
not often used for opportunistic screening. One of the most common tools is the 
AliveCor (AliveCor Inc., USA) device which can be used with an app on any 
smartphone. This is used by placing fingers on the electrode and recording either 30 
or 60 second single lead ECGs. The sensitivity of has been found to be 98% and 
specificity 96%.29 The recent release of the Apple Watch with the ability to take a 
single lead ECG has prompted possibilities for large scale monitoring; also comes with 
the issue of people self-diagnosing or increasing appointments to primary care 
physicians due to lack of knowledge as to normal and abnormal readings. We will 
await the results of the Apple Heart Study being run with Stanford University, which 
is due for completion in early 2019. This study uses and Apple watch-based App and 
will look for irregularities in rhythm. If an abnormality is detected the participant is 
notified and they may be asked to wear an ePatch for 7-day monitoring. Due to the fact 
so many individuals have these devices this study has managed to recruit a staggering 
400,000 plus participants. This will be the largest mass screening ever undertaken and 
will lead the way for future studies. In time it is likely studies will be undertaken to 




1.2 RISK FACTORS FOR THE DEVELOPMENT OF AF 
Cardiovascular disease is estimated to be the cause of every 1 in 3 deaths in the United 
States.30 A recent study of almost 45,000 individuals showed the importance of seven 
lifestyle-based health metrics taken from the American Heart Association (AHA) 
recommendations; physical activity, healthy diet, glucose and cholesterol levels, 
smoking status, normal blood pressure and weight.31 This study showed that 99% of 
the population had at least one cardiovascular risk factor. A third were hypertensive, a 
third were overweight and 50% were inactive. This study demonstrates the penetrance 
of cardiovascular risk factors in the general population. 
Although it was believed that the increasing epidemic of AF was due to an aging 
population, there are many other comorbidities that potentially contribute to the 
growing burden of AF. AF results from a rather complex interplay between triggers 
and substrate. The major pathophysiological mechanisms which underly AF can be 
broadly categorised into: electrical, ionic, structural and autonomic remodelling. This 
can be due to various cardiac conditions and risk factors such as hypertension, heart 
failure, diabetes, dyslipidaemia, smoking, valvular heart disease and alcohol. More 
recently we have seen the emergence of other important risk factors, obesity, physical 
inactivity, obstructive sleep apnea, pre-hypertension, aortic stiffness and genetic 
profiles as potential triggers for AF. These mechanisms contribute to imitation and 
maintenance of AF by means of ectopic firing or drivers and re-entry substrate which 
is due to the abnormal atrial conduction. Certainly, AF itself can contribute to further 
remodelling this is a concept well known to us as ‘AF begets AF’.32 These risk factors 
are significant contributors to the development of AF and more likely to be the cause 
of the recent upsurge in AF incidence. The Atherosclerosis Risk in Communities 
(ARIC) study demonstrated that the risk of AF, dependent on co-existing risk factors 
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is additive with each additional component of the metabolic syndrome (waist 
circumference, elevated blood pressure, elevated triglycerides, low HDL cholesterol, 
impaired fasting glucose). This study demonstrated that there was an 67% increase in 
the risk of developing AF for individuals with metabolic syndrome.33 Notably, this 
study demonstrated that 56.5% of new AF presentations had ≥1 risk factor, with 
hypertension being the most prevalent.34 Additionally, it is shown that concomitant 
risk factors affect the type of AF that individuals present with. The German registry of 
over 9,500 patients demonstrated that predisposing risk factors were present in 88% of 
patients.35 They were able to show that with an incremental rise in risk factors there is 
a subsequently increased risk of developing persistent and eventually permanent AF. 
This highlights the dynamic impact that multiple risk factors play in the development 
and progression of AF disease. 
 
1.2.1 HYPERTENSION 
1.2.1.1 Hypertension and the Relationship with AF 
Hypertension is the most prevalent risk factor for AF, with an estimated prevalence of 
39% in the ARIC cohort 34 and 31% and 40% of males and females in the Framingham 
cohort, respectively.36 Additionally, the Framingham study highlighted the for each 
decade after the age of 50 the incidence of AF doubles with it reaching around 10% at 
the age of 80.37 Hypertension in the developed countries is the most prevalent 
cardiovascular disease and is known to affect 20-50% of adults.38 
Even with pre-hypertension, it has been demonstrated that there is a 28% 
increased risk of AF. In a large study of male participants, a baseline blood pressure 
(BP) of >140 mmHG had a 1.60-fold incident risk of AF compared to those in the 
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normotensive range. 39 Similar results were presented in the Women’s Health Study 
where women with a pre-hypertensive BP of 130-139 systolic and 85-89 diastolic had 
a 28% and 53% increased risk of incident AF when compared to women with a normal 
BP of <120 mmHG systolic and <65 mmHG diastolic.40 While these studies have 
shown that even pre-hypertension has an increased risk of AF, there is still no clarity 
on what is considered the optimal blood pressure for individuals with AF; it does seem 
that aiming for targets and management of pre-hypertension is imperative given it is 
shown that a target of 120 mmHG systolic BP reduces all-cause mortality and 
cardiovascular events,41 additionally by reducing the systolic blood pressure by 10 
mmHG this was also shown to reduces cardiovascular events and reduce all-cause 
mortality by 13% 42 thus highlighting the need for tighter monitoring and treatment of 
hypertension. 
Hypertension has been shown to be responsible for progression of atrial 
remodelling and the substrate therefore leading to AF.43,44 An early ovine study 
assessing a chronic hypertension model of 5 years found this resulted in significant 
conduction slowing, increase atrial fibrosis and evidence of cellular myolysis which in 
turn resulted in increase of AF.45 Surprisingly, even short durations of hypertension in 
an animal model was associated with significant effects on the atrium. This was done 
using the “one-kidney, one clip” induced hypertension technique.43 When compared 
to controls those in the hypertensive group demonstrated significantly higher blood 
pressure (p<0.0001). This short-term hypertension resulted in significant atrial 
remodelling. Electrophysiology studies showed an increase in effective refractory 
periods and conduction slowing in addition to atrial enlargement and dysfunction, 
interstitial fibrosis and inflammation. Another study using the same technique showed 
that over 5 weeks of induced hypertension there was significant atrial remodelling. 
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This was associated with increased arterial pressure and biatrial hypertrophy increase 
refractoriness additionally there was greater AF inducibility, significant conduction 
slowing and increase heterogeneity.46 In a rat model using spontaneously hypertensive 
rats (SHR), demonstrated the first evidence that hypertension was indeed associated 
with the substrate for atrial arrhythmias including left atrial fibrosis.47 This study 
provided the evidence that SHR were suitable for further studies assessing atrial 
remodelling due to hypertension. An additional study in SHR rats assessed the impact 
on the atria due to hypertension and aging the atria demonstrated significant atrial 
structural and electrical remodelling.44  
Mapping studies in humans have shown similar outcomes. Patients who were 
free from AF with chronic hypertension and left ventricular hypertrophy were 
compared to a control normotensive cohort.48 Patients underwent EP study, this 
demonstrated those with hypertension had atrial remodelling characterised by 
conduction slowing, regional conduction delay and increased inducibility of AF. It has 
been demonstrated however that this substrate may indeed be reversible. This was 
shown in the SHR rat model with the use of angiotensin II receptor blockade.49 
Hypertension is also responsible for left ventricular hypertrophy, left atrial 
enlargement and aortic stiffness all of which are causative factors of AF.50 Therefore 
studies indicate that therapies to target the substrate promote tight blood pressure 
control is imperative in managing patients with AF.  
 
1.2.1.2 Management of Hypertension 
The management of hypertension has developed over the years. Due to the nature of 
the condition we know that BP is a dynamic measurement and can vary significantly 
based on how, when and where the measurement is taken. Initially in 2014 the 
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American College of Cardiology (ACC) and American Heart Association (AHA) 
developed guidelines for the management, detection, evaluation and prevention of 
hypertension.51 The recommendations for management of hypertension was largely 
based on age. In individuals aged >60 the treatment for hypertension should be 
initiated if a BP was >150/>90 mmHg. For those <60 years of age treatment should be 
initiated to achieve a BP of <140/<90 mmHg. Pharmacological treatment should be 
based on the race and risk factors that individuals present with. In 2017, the American 
College of Cardiology and American Heart Association released guidelines whereby 
they reduced the hypertension target BP from 140/90 to 130/80 mmHg.52 This created 
some controversy on what the optimal level is. This definition was potentially based 
on the SPRINT trial whereby concerns were raised over the method of measurement, 
so they therefore set the target systolic BP as <130.41 To date there is very inconsistent 
data surrounding the optimal targets with inconsistent literature available.42,53-55  
Additionally, these guidelines suggest the optimal way to take a blood pressure 
is a 6-step process which if performed in the optimal setting would take around 15-
20mins. This is not feasible in a clinic setting and is not representative of daily BP. As 
such 24 ambulatory monitoring is suggested for those with suspected hypertension.52 
The current European Society of Cardiology/European Society of Hypertension 
(ESC/ESH) guidelines in hypertension released less than a year after the ACC/AHA 
guidelines suggest that optimal blood pressure is <120 mmHG systolic and <80 
mmHG diastolic, with normal being 120-129 and/or 80-84 mmHG, high normal is 
classified as 130-139 and/or 85-89. Grade 1 hypertension is 140-159 and/or 90-99 
mmHG, grade 2 is 160-179 and/or 100-109 mmHG and grade 3 hypertension is ≥180 
and/or ≥110 mmHG.56 The recommendations suggest that hypertension should not be 
based solely on the BP reading but rather that other additional cardiovascular risk 
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factors including age, smoking, sex, dyslipidaemia, diabetes, obesity, renal disease, 
family history, prior myocardial infarction, or transient ischaemic attack should be 
taken into consideration such that treatment of the cause is also addressed. Based on 
these a scoring system was established in the guidelines, this demonstrates for example 
a patient with symptomatic cardiovascular (CV) disease, renal disease or diabetes 
would present as a very high-risk patient with blood pressures in the high normal 
range. The guidelines suggest for the treatment of hypertension should include lifestyle 
changes and pharmacotherapy for those with diagnosed hypertension and who are at 
high risk by use of antihypertensive agents.  
 
1.2.1.3 Aortic Stiffness 
Recently the concept of arterial and aortic stiffness has been correlated with the 
development AF. This technique is a non-invasive and clinically validated 
reproducible method to assess aortic stiffness through central pulse wave analysis.57,58 
This technique allows for important measure of potential sub-clinical organ damage, 
allowing for enhanced patho-physiological relevance, which can’t be assess by 
peripherally derived blood pressures.57,59,60 It has been shown that increased arterial 
stiffness in hypertensive patients is a strong independent predictor of AF even after 
adjusting for age, 24-hour pulse pressure and left atrial diameter.61 The Framingham 
study demonstrated that increase augmentation index, brachial artery diameter and 
lower flow-mediated dilatation was associated with higher risk of incident AF. 
Additionally, arterial stiffness when adjusted for age, sex and hypertension (HR 0.79; 
95% CI; 1.02-1.28, p 0.02) was associated with increased incident AF.62 In lone atrial 
fibrillation patients undergoing AF ablation evidence of increased peripheral, central 
pulse pressures and augmentation index was significantly associated with higher rates 
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of AF recurrence.63 Additional benefits of central blood pressure is the potential it 
provides to diagnose pre-hypertension, therefore enabling early management. While 
this is a new area of interest there is still a strong need for more larger studies to provide 
further insight into the implications this has on patients with AF.  
 
1.2.2 OBESITY 
1.2.2.1 Overall Prevalence 
Obesity is a global epidemic that in turn contributes to hypertension, hyperlipidaemia, 
and diabetes. Early studies of data taken from 199 countries and territories showed 
obesity doubled from 6.4% up to 12% between 1980 and 2008.64 More current data 
demonstrates the global prevalence have seen these numbers continuing to increase 
with 2015 worldwide data estimating 107.7 million children and 603.7 million adults 
being obese.65 A large pooled analysis of 1.8 million participants from cohort studies 
across the world highlighted the impact that obesity has on coronary heart disease and 
stroke.66 This demonstrated a 50% and 44% increase risk for coronary heart disease 
for overweight and obese individuals respectively. Additionally, stroke rates were 
substantially higher 98% for the overweight and 69% for obese patients. Worldwide 
data assessing the rates of obesity in children and adolescents found that the mean BMI 
for girls in 1975 was 17.2 this rose to 18.6 in 2016, and for boys it was 16.8 in 1975 
rising to 18.5 in 2016.67 These figures suggest that obesity is now starting at a younger 
age, therefore this may influence the incidence of AF in younger populations. These 
staggering numbers will place a huge burden on our healthcare system given the causal 
relationship this has with other cardiovascular comorbidities, with an estimated annual 
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cost of $873.8 million between 2008-2009 in Australia12 and $66 billion annually to 
the United States healthcare system.68 
 
1.2.2.2 Relationship to AF 
The similarity in temporal trends of obesity and AF, suggest a potential cause and 
effect relationship. It is perhaps not surprising that with an increase in the prevalence 
of obesity we have seen a similar rise in the prevalence of AF, as many of the 
associated risk factors for obesity are the same as those of AF. A large study in 2004 
of 5282 patients over a follow up of 13.7 years, showed there was a 52% increase risk 
of new onset AF as a result of obesity.69 A recent meta-analysis risk of AF associated 
with obesity, in which there was a 29% increase in incident AF for every 5-unit 
increase in body mass index.70 The recent HUNT3 study undertaken in Norway found 
that overweight and obesity not surprisingly were associated with an 18% and 59% 
higher risk of AF respectively when compared to those with a BMI range between 18-
25.71 Obesity is associated with numerous co-morbidities. These include hypertension, 
diabetes, sleep apnea, cancers, and cardiovascular disease. Obesity has been 
demonstrated to be an independent risk factor for cardiovascular disease.72,73  Despite 
the corresponding risk factors between obesity and AF, obesity in itself remains an 
independent risk factor for AF.69,74-76  
Experimental studies in the ovine model have demonstrated short term weight 
gain results in progressive remodelling of the atria, this was show with a greater 
deposition of fibrous tissue, a greater expression of endothelin receptors and 
abnormalities in atrial conduction which in turn resulted in greater inducibility of AF.77 
A subsequent chronic ovine model of obesity extended these findings and describes a 
unique component of the substrate for AF. This study demonstrated a marked increase 
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in the pericardial fat volumes. Interestingly histological samples of the atrial 
myocardium from regions adjacent to the pericardial fat depots showed epicardial fat 
infiltrating the myocardium, potentially resulting in voltage abnormalities which 
disrupt normal conduction and promote AF.78  
Clinical data also demonstrates the relationship the role of obesity and 
epicardial fat in the promotion of AF. Early studies demonstrated that when compared 
to normal weight patients with obesity undergoing electrophysiological studies were 
significantly more likely to have increased LA pressure and volumes.79 Additionally, 
obese individuals had significant LA remodelling and impaired contractility. These 
variances were significant following adjustment for common risk factors such as 
hypertension, sleep apnoea and diabetes. More recently a larger cohort who were 
undergoing AF ablation were studied using cardiac magnetic resonance imaging and 
electroanatomic mapping of the LA prior to undergoing ablation.80 This study 
demonstrated that there was significantly more atrial remodelling, with areas of low 
voltage, conduction slowing and increased fractionation of electrograms. Interestingly 
in regions of epicardial fat depots there were more distinct changes noted, highlighting 
the role of epicardial fat in the promotion of AF. 
Not only does obesity result in the substrate for AF but it may have an important 
impact on the clinical management of obese individuals with AF. A recent study of 
3333 patients who were undergoing AF ablation demonstrated that patients with a BMI 
≥30 had a significantly higher recurrence rate of AF, highlighting indeed that it is 
crucial to target obesity as a first-line treatment prior to undergoing AF ablation.81  
 
1.2.2.3 Obesity Paradox 
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Previously there have been studies that suggest obese patients with heart failure, 
hypertension and coronary heart disease paradoxically do have better long-term 
outcomes when compared with non-obese patients.82-84 While the strong relationship 
between obesity and AF has been shown there is also on the other hand data suggesting 
an obesity paradox and AF. In 2016 the ARISTOTLE (Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fibrillation) study presented data 
from their large cohort of 17, 913 AF patients with at least 1 risk factor for stroke, 
these were randomized to either Apixaban or Warfarin anticoagulation. They 
concluded that both higher BMI (>25kg/m2) and waist circumference (>102cm for 
men and >88cm) for women was associated with a lower all-cause mortality and 
stroke.85 The obese cohort had many other comorbidities for AF such as hypertension, 
hyperlipidaemia and diabetes, and this may have resulted in early intervention 
therefore treating the risk factors and subsequently contributing to the paradox. 
Similarly, other studies have suggested the obesity paradox, with the AFFIRM (The 
Atrial Fibrillation Follow-up Investigation of Rhythm Management) study suggesting 
that overweight and obese patients (HR 0.40, 95% CI; 0.26-0.60; p <0.001 and HR 
0.77, 95% CI; 0.62-0.95; p=0.01 respectively) had a lower cardiovascular mortality 
compared to normal weight patients.86 Of note both these studies had younger cohorts 
in the obese categories. Given age is a factor for AF, this factor could have also 
contributed to the outcomes being greater in the obese cohorts.  Additionally, as AF is 
a progressive disease previous data has demonstrated that with each added 
cardiometabolic risk factor the risk of a more progressive disease increase 
proportionately,87 it is therefore hard to ignore that the short term follow-up in both 
these studies, 1.8 years for ARISTOTLE and 3 years for AFFIRM, may be erroneous 
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due to the progressive nature of this disease and the relationship of obesity to AF has 
been demonstrated in studies greater than 13 years.69,88  
With this contradicting data on obesity and its benefit for AF all-cause mortality 
and stroke, more research is required to understand if the “obesity paradox in AF” is 
indeed a factor to consider in the management of AF. 
 
1.2.3 PHYSICAL ACTIVITY 
It has been shown that the US sedentary rates have increased from 19%-52% in women 
and 11%-44% in men from 1988-2010.89 Exercise and physical activity have been 
widely reported to reduce cardiovascular disease incidence. Compared to sedentary, 
runners had a significantly reduced risk 30% and 45% of all-cause and cardiovascular 
mortality respectively.90 Interestingly, this reduction in risk was achieved by running 
as low as 5 to 10 minutes a day and slow speeds. Sedentary lifestyle has been shown 
to promote all risk factors for metabolic syndrome.91 Physical inactivity is known to 
promote obesity. It has been shown that early inactivity leads to subsequent obesity. 
Adolescents with decreased physical activity were a significantly higher risk of obesity 
(OR 3.9), there was a stronger risk of abdominal obesity (OR 4.8).92 Independent of 
obesity, physical activity predicts a lower risk of cardiovascular disease.93 A large 
randomised trial of obese >65 years of age, found that physical activity in this group 
combined assisted with significant reduction in BMI over the duration of the study.94  
Specifically for AF, greater levels of physical activity result in lowered incidence of 
AF.95,96 Similarly, poor cardiorespiratory fitness has been reported to increase the 
incidence of AF, even after adjustment for other risk factors.97  
Importantly, physical activity has also been reported to diminish the risk 
associated with other notable risk factors such as obesity.98,99 The HUNT3 study 
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interestingly showed that active obese individuals had a 22% lower risk of AF than 
those who were obese and sedentary, therefore suggesting physical activity seems to 
offset some of the risks associated with that of obesity and AF.71 A recent study has 
shown that physical inactivity was significantly independently associated with 
worsened AF severity.100 The Women’s Health Study found that women who engaged 
in strenuous physical activity up to 3 times a week had a 16% reduction in AF, however 
when corrected for BMI this was not so significant.101 The large Swedish 
Mammograph Cohort study which assessed 36,513 women at baseline found the 
incidence of AF over a long follow-up of 12 years  was 15% lower in those who 
exercised >4 hours weekly.96 Likewise the Women’s Health Initiative study looking 
at 81,317 women demonstrated over a follow-up of 11.5 years a 10% lower incidence 
of AF in those who exercised over those who did not.99 The Cardiovascular Health 
Study highlighted that moderate-intense physical activity was associated with a 28% 
lower incidence of AF.95 
Interestingly, the risk of AF paradoxically increases in those who engage in 
high volumes of exercise, such as endurance sports participants.102,103 High-intensity 
or elite athletes seem to present with similar risks of AF as those who demonstrate 
physical inactivity. Nordic skiers who participated in 5 high endurance events were 29 
more likely to develop AF compared to those who only undertook 1 race.104 Males 
who exercised vigorously 7 days a week presented with a 20% higher risk of AF than 
a no-exercise group.105  
There are limited studies which have researched the underlying mechanism 
which impact exercise on AF.106 Reduction in weight interesting even at modest levels 
demonstrated improvements in LA and LV function. The CARDIO-FIT study 
demonstrated that with improvements in exercise capacity as small as >2 MET gain 
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resulted in improvement of atrial remodelling.107 Additional benefits were seen in 
ablation outcome, with individuals who were able to achieve weight reduction >10% 
and improvement of >2 MET gains having a 13% higher AF freedom. It has been 
suggested that 3 potential mediators; ectopic triggers, modulators and altered atrial 
substrate may be responsible for promotion of AF with endurance sport.108 An increase 
in vagal tone subsequently could result in pulmonary vein triggers. Similarly, atrial 
stretch due to biatrial dilation play a role in the promotion of arrhythmogenesis.106  
Mechanisms that promote AF freedom also comes from the benefits of exercise 
training. Exercise results in a decrease in oxidative and inflammatory stress which 
results in improved autonomic balance, blood pressure control, glycaemic control, 
diastolic function and a decrease in visceral fat.106  
It would seem there is a U-curve association between exercise and AF with too 
little and too much increasing the risk of AF. The guidelines suggest moderate regular 
physical activity is recommended in the prevention of AF.109 
 
1.2.4 DIABETES MELLITUS 
In 2014 the International Diabetes Federation has estimated that by 2035 around 592 
million individuals will be affected by this disease. Studies have shown that there is a 
40% increase risk of AF in individuals who have type II diabetes mellitus.110 In a 
observational cohort, over a follow-up of just over 7 years, diabetes was associated 
with a 26% increase risk of AF in women.111  
A large study of almost 300,000 patients it was demonstrated that AF occurred 
in 15% of diabetes patients compared to only 10% in the control group this was 
significant even following multi-variable analysis suggesting a strong link between 
diabetes and AF.112 The Framingham study showed that in patients with diabetes there 
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was a 1.4 increased risk of AF in males and 1.6 fold increased risk in women following 
multivariate analysis.113 More recently a meta-analysis of the literature including both 
cohort and case-control studies demonstrated that there was 40% (RR 1.39, 95% CI; 
1.10-1.75, p<0.001) greater risk of AF in diabetes patients, following correction for 
publication bias the RR was 1.34 (CI; 1.07 to 1.68).114 
The role of type 1 diabetes in promoting the development of AF is not well 
studied. This is perhaps due to the population with Type 1 being a younger population. 
An interesting study out of Sweden, has for the first time shown an increased risk of 
AF in type 1 diabetes.115 Over 36,000 patients were studies in comparison to control 
patients and were followed for almost 10 years. The incidence of AF was higher in 
females than males (HR: 1.50, 95% CI; 1.30-1.72; p<0.0001) versus (HR: 1.13, 95% 
CI: 1.0.1-1.25; p=0.029), overall p=0.0019.   
There are several mechanisms that are believed to correlate diabetes and AF. 
Inflammation along with autonomic remodelling by impaired nerve blood perfusion 
and vagal activation, structural abnormalities with atrial dilatation, myocardial 
hypertrophy and interstitial fibrosis, electromechanical remodelling due to atrial 
fibrosis and interatrial electrical conduction delay and atrial electrical remodelling due 
to conduction abnormalities have all been associated as possible mechanisms.116-119 
However not only is there is a lack of human data in the area but additionally there are 
no large randomised control studies in this area. Early detection and improved diet are 




1.2.5 OBSTUCTIVE SLEEP APNOEA 
Obstructive sleep apnoea (OSA) is becoming increasingly recognised as a causative 
risk factor for AF. Sleep disordered breathing is a highly prevalent issue in 
cardiovascular disease with 45% of patient with hypertension, 50% with heart failure, 
60% with AF and 30% coronary disease all having OSA.120 Several studies have 
demonstrated a greater prevalence of OSA in patients with AF. Gami et al, showed 
that in patients with persistent AF who were referred for cardioversion, <10% had 
undergone a sleep study compared to the general cardiology control population 49% 
versus 29% (p=0.0004) had OSA.121 A more recent study found similar findings, 
suggesting the apnoea hypopnea index predicts the recurrence of AF. With patients 
who had an apnoea hypopnea index (AHI) >15 significantly more likely to have 
recurrent AF following cardioversion (p=0.003).122 
This work has been demonstrated in a rat model. In a study by Iwasaki et al who 
were able to show that repeated obstructive episodes of the airway was associated with 
repeated bursts of AF with ongoing repetitive episodes there was the eventual changes 
resulting in chronic cardiac remodelling in atrial substrate similar to what we observe 
in the clinical scenario, increase atrial size, AF induction, conduction slowing and 
atrial fibrosis.123 A study of pigs showed that by applying negative tracheal pressure 
during tracheal occlusion not only reversibly shortened atrial refractory periods but 
also promoted inducibility of AF.124-126 In a sheep model hypercapnia transitioning to 
normal blood-gas levels was found to be associated with atrial refractory and 
conduction recovery, which may explain the prevalence of AF in OSA and pulmonary 
disease.127  
In the human model, OSA has been shown to result in chronic atrial remodelling 
which could explain the relationship between OSA and AF. This has been shown in a 
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group of patients undergoing paroxysmal AF ablation, with a significant AHI 
compared to a reference-patient’s undergoing SVT ablation.128  This study 
demonstrated large areas of low voltage in patients with OSA along with atrial 
structural changes and abnormal conduction, this was significantly worse than seen in 
the control patients. The progressive atrial structural substrate may be a result of 
chronic comorbidities and risk factors such as obesity and hypertension.129 A recent 
study of patients with paroxysmal AF assessed the role of OSA in a cohort of patients 
undergoing ablation.130 Patients with OSA had an increase incidence of extra-PV 
triggers associated with structural and functional atrial remodelling. Successful 
ablation of these triggers improved outcomes and freedom from AF. Further studies 
demonstrated the relationship of OSA and obesity as independent risk factors for AF, 
highlighting that with an increase in BMI and apnoea-hypopnoea index there was a 
relative increase in AF frequency.131 In this study of over 3500 individuals, incident 
AF occurred in 14% of the patients over the follow-up of almost 5 years.  Stevenson 
et al showed that 62% of patients in the AF group compared to 38% of reference 
patients had moderate to severe sleep disordered breathing.132 This study compared 
patients with no past or current AF and demonstrated a significantly higher number of 
patients with OSA and AF than no AF 49% versus 32%, (p=0,0004). Additionally, 
with adjustment for common risk factors such as age, BMI, hypertension and heart 
failure, patients with AF doubled the risk of OSA (OR: 2.19; 95% CI 1.40-3.42). These 
studies demonstrate chronic risk factors such as hypertension, obesity and metabolic 
syndrome results in progression of the atrial substrate. This progression is due to the 
complex and dynamic arrhythmogenic atrial substrate promoted by obstructive 
apnoea’s and the frequency of nocturnal premature atrial contractions.133  
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A recent study examining the sleep apnoea monitoring algorithm in pacemaker 
patients has shown patients who had higher RDI had a 1.6-fold increased risk of an AF 
episode that corresponding day.134 By assessing the RDI from the pacemakers it was 
clear there was significant night-to-night variability in sleep disordered breathing. This 
raises the question as to the impact this may have on individuals who undergo single 
overnight polysomnography to diagnose sleep disordered breathing.  
 
1.2.5.1 Management of Sleep Apnoea 
Treatment for OSA is usually achieved with continuous positive airway pressure 
(CPAP) therapy. The large Outcomes Registry for Better Informed Treatment of AF 
(ORBIT-AF) trial of over 10,000 patients found for patients with AF 18% more 
hospitalisations were required.135  Similarly, they demonstrated that those with OSA 
who were using CPAP were less likely to have progression of AF disease to more 
permanent AF (HR 0.66%; 95% CI 0.46-0.94; p=0.02). 
There have now been several studies which have demonstrated that treatment 
of OSA reduces the risk of AF recurrence following catheter ablation. An early study 
assessing the role of OSA on ablation outcomes, showed that those with OSA were 
more likely to have recurrent arrhythmia.136 Among patients with paroxysmal AF 69% 
without OSA compared to 48% with OSA were free from AF at follow-up. Among 
chronic AF, 47% without OSA compared to 22% with OSA remained free from AF. 
In a recent study among patients who underwent pulmonary vein isolation, Fein et al 
identified 62 patients had a confirmed diagnosis of OSA.137 While 32 patients were 
“CPAP users” the remaining 30 patients were “CPAP non-users”. These were matched 
with patients without a history of OSA undergoing AF ablation and a group of AF 
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patients with OSA who were managed on CPAP but no AF ablation. This study 
showed AF free survival for patients with some interesting results. In the patient who 
doesn’t undergo AF ablation and has no OSA has a 66% AF free survival whereas if 
the patient with OSA and AF is treated with AF ablation and CPAP therapy their 
results are the same as an individual who has no OSA with a 72% AF free survival. 
Remarkably, patients who do not undergo AF ablation but having their OSA treated 
with CPAP was 33%; if one has an AF ablation without treatment of their OSA, they 
have the same AF free survival 37%, as the patient who had not had an AF ablation. 
These results while observational have been reproduced repeatedly in the literature and 
argues in favour of treating OSA to improve the outcomes of AF ablation. Similarly, 
another study assessing outcomes of ablation in patients using CPAP found 
comparable findings.138  In individuals undergoing AF ablation, those treated with 
CPAP therapy had significantly greater AF free survival this was almost comparable 
to those with no OSA (p=0.33). For those who had OSA but were not being treated 
with CPAP there was more AF recurrence following AF ablation (p=0.009). This study 
found that concomitant OSA was an independent predictor of AF recurrence HR: 2.61 
(95% CI: 1.12-6.09; p<0.05). 
An early meta-analysis of 6 studies, demonstrated that patients with OSA had 
a 25% increase risk of AF recurrence following ablation (RR 1.25, 85% CI: 1.08-1.45; 
p=0.003).139 While more recently another meta-analysis assessing the use of CPAP 
and AF recurrence confirmed the above studies. Those who used CPAP experienced 
less AF recurrence 24.9% versus 42.5%; RR 0.60, 95% CI: 0.51-0.70; p=0.000.140 
These meta-analysis highlight the role that OSA plays in AF recurrence and that 
appropriate treatment is imperative when managing patients with these conditions.     
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Despite these compelling results there has been no large randomised control 




The literature demonstrates that smoking results in an increase in sympathetic tone, 
inflammation, thrombus, endothelial dysfunction, atrial fibrosis and oxidative stress 
which are potential mechanisms for the development of AF.141-144 The Framingham 
study demonstrated the risk of AF for males smokers was 1.0 (95% CI; 0.8-1.4) and 
for females 1.4 (95% CI; 1.0-2.0).36 The ARIC Study has shown more than a 2-fold 
(2.05; 95% CI, 1.71-2.47) increase in the incidence of AF for current smokers. The 
risk of AF reduced for those who were former smokers and similarly the risk of AF 
decreased in those who ceased smoking (HR, 0.88; 95% CI, 0.65-1.17)145. The 
Rotterdam Study looked at a large cohort of individuals who were followed for a 
median of 7.2 years and had no AF at baseline to assess for the incidence of AF, 
following multivariate analysis there was an increased risk of AF in current smokers 
(RR 1.51, 95% CI; 1.07-2.12) and the same was seen for former smokers (RR 1.49, 
95% CI; 1.14-1.97), suggesting that cigarette smoking is related to an increased risk 
of AF development.146 More recently the REGARDS study, of over 11,000 
participants from the US over a 10.5 year follow up demonstrated quite a high 
incidence of AF 9.5% in smokers compared to 7.8% in non-smokers (p<0.001), this 
was associated with a 15% increased risk of AF. Following adjustment for 
cardiovascular risk factors this was no longer significant. There was a strong 
association between smoking and AF in subgroups such as young compared to old and 
those with and without prior cardiovascular disease, and blacks compared to whites, 
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suggesting that the relationship between smoking and AF is possibly arbitrated by 
these risk factors.147 
A recent meta-analysis demonstrated that there was a higher prevalence of AF 
in current smokers was RR 1.23 (95% CI; 1.08-1.39) additionally they estimated a 
6.7% and 1.4% increased risk of AF in men and women respectively based on the 
studies included in their analysis. This study also recognised that smoking cessation 
reduced the risk of AF but did not eliminate it.148 Interestingly, was another meta-
analysis which was aimed to assess the risk of AF in males compare to females. This 
highlighted that smoking is a significant risk factor for AF (RR 1.24; 95% CI: 1.12-
1.36, p<0.001). This demonstrated that men RR 1.38 (95 CI; 1.21-1.57, p<0.001) were 
more likely to develop AF than women 1.28 (95% CI; 0.93-1.76, p=0.1356).149  
 
1.2.7 ALCOHOL 
The mechanisms by which alcohol is attributed to the initiation of AF can be associated 
with the direct cellular effects on atrial myocytes with acute oxidative stress and 
autonomic function by sympathetic activation and change in heart rate variability, with 
long term alcohol consumption together with cardiovascular risk factors responsible 
for LA remodelling and dilation, with an increase in LA pressure and fibrosis.150 There 
have been varied findings relating to the proarrhythmogenic influence of alcohol 
intake, likely due to significant heterogeneity in the method for measuring and 
reporting alcohol intake. The Malmo Diet and Cancer study reported an association of 
incident AF in men who consumed high levels but this was not seen in women.151  The 




Mechanisms for this relationship are not clearly defined. One study outlined 
the ‘holiday heart syndrome’ suggesting that the prolongation of the PR, QRS and QTc 
intervals may promote re-entry.153 A meta-analysis of the literature showed that based 
on the intake of alcohol those with high consumption had an increased risk of AF (HR 
1.34, 95% CI; 1.20-1.49, p<0.001) for moderate intake the risk of AF was increased 
for males but not females (HR 1.26, 95% CI; 1.04-1.54, p=0.02 and HR 1.03, 95% CI; 
0.86-1.25, p=0.37) respectively. For low alcohol intake there was no associated risk of 
AF (HR 0.95, 95% CI; 0.85-1.06, p=0.37).154 More recently the Norwegian Hunt Study 
of over 47,000 participants showed a curvilinear association between alcohol and the 
risk of AF, there was almost no increase risk with up to 7 drinks per week but this 
increase significantly with more than 14 drinks per week (1.28 95% CI; 1.07-1.73). 
They demonstrated that if alcohol was consumed at up to 1 drink per day for women 
and 2 per day for men there was essentially no risk of AF 0.07% (95% CI; -0.01-0.13). 
The overall AF incidence with alcohol intake compared to non-drinkers was 1.6% 
(95% CI; 0.6%-2.7%).155 A recent publication has demonstrated that in 75 patients 
with regular moderate alcohol consumption there was associated lower atrial voltage 
and conduction slowing suggesting these electrical and structural changes may explain 
AF in patients with moderate regular alcohol intake.156 These studies while 
heterogeneous do demonstrate a direct influence of alcohol as a risk factor for the 
development of AF. 
 
1.2.8 CAFFIENE 
The association between caffeine and atrial fibrillation requires further studies. Early 
studies have varied results. The Multifactor Primary Prevention Study found 
consumption of 1-4 cups of coffee daily was associated with a risk of AF (OR 1.24, 
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95% CI: 1.00-1.54).157 There was no association though when drinking >4 cups daily. 
The large Danish Diet, Cancer and Health Study found that regardless of the amount 
of caffeine consumed there was no increased risk of AF or atrial flutter.158 
A very early study undertaken in mice was able to demonstrate that with 
administering extremely high doses, 15mg/kg of caffeine,159 there was subsequent 
sympathetic overdrive resulting in tachycardia, ventricular ectopy and consequently 
ventricular fibrillation. There has been one study undertaken in dogs where caffeine 
was intravenously injected at a dose of 1-5 mg/kg, this surprisingly resulted in reduced 
inducibility of AF.160 In a similar model undertaken in humans who were received oral 
caffeine at a dose of 5mg/kg prior to undergoing electrophysiology study for 
supraventricular tachycardia this also demonstrated inability to induce arrhythmia.161  
Given caffeine is a stimulant it is perhaps not surprising that the assumption is 
made that it would therefore be pro-arrhythmic. Caffeine effects the sympathetic 
activation, intracellular calcium trafficking, adenosine receptors and is and 
antioxidant.162 The increase of intracellular calcium potentially results in enhancing 
the automaticity of atrial pacemaker cells therefore potential resulting in atrial 
arrhythmia.    
Systematic review and meta-analysis of 7 observation studies with 115,993 
individuals found no associated with an increased risk of AF (OF 0.92, 95% CI; 0.82-
1.04).163 There was a slight significance suggesting that caffeine may have a protective 
effect. Another meta-analysis pooled together 6 large studies with a cohort of 
228,465.164 The primary results found that there was a weak association with reduced 
risk of AF (RR 0.90, 95% CI; 0.81-1.01, p=0.07). Habitual caffeine intake showed an 
inverse relationship with a 6% decrease risk of AF for every 300 mg/d increment in 
habitual intake.  
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More recent data has suggested that a higher intake of caffeine is associated 
with a lower incidence of AF.165 This was a long study of 12-year incidence, high 
intake was defined as >320 mg/day. There was stepwise new incident cases of AF 
based on intake: 10.2% for low intake and 2.2% for high intake (p<0.001).  
Despite significantly lacking data and evidence many clinicians advise on 
caffeine avoidance. Based on the literature it is suggested that caffeine intake of up to 




Hyperlipidaemia also has been demonstrated to show an association with AF, to date 
the data has been varied and inconsistent.166-168 Similarly studies have also suggested 
there is a cholesterol paradox with low levels of cholesterol associated to an increased 
risk of AF.169,170 The Japan the Niigata Preventive Medicine Study was a large study 
which demonstrated following multivariate adjustment low HDL was associated with 
a risk of AF in women but not men (HR 2.86, 95% CI; 1.49-5.50 and HR 1.35, 95% 
CI; 0.77-2.38) respectively.166 In addition with every 10 % decrease in HDL women 
had a 28% higher risk of AF. Neither triglycerides or other lipid rations were associated 
with a risk of AF. The ARIC Study which had a long follow up of up to 18.5 years 
showed a 20% increase risk of AF associated with low high-density lipoprotein (HDL), 
although elevated triglycerides were not associated with AF.33 Similarly a subsequent 
analysis of this cohort demonstrated lower incidence of AF in those with higher low-
density lipoprotein (LDL) and total cholesterol, although HDL and triglycerides were 
not independently associated with AF following multivariate analysis.168 In a 
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combination of two large community based cohorts, the Framingham Heart Study and 
Multi-Ethnic Study of Atherosclerosis cohorts it was observed that following 
multivariate adjustment HDL was associated with a lower risk of AF (HR 0.64, 95% 
CI; 0.48-0.87) in higher levels of HDL compared to lower levels of HDL. However, 
triglycerides were associated with a higher risk of AF based on increased levels (HR 
1.60, 95% CI; 1.23-2.05) but total cholesterol and LDL were not associated with a risk 
of AF.167 Adding to the heterogeneous literature, the Women’s Health Study 
demonstrated a paradoxical association between AF and lipoprotein measures. 
Following adjustment for risk factors there was an inverse relationship for several 
measures namely, LDL (0.72, 95% CI; 0.56-0.92, p 0.009, total LDL particles (HR 
0.77, 95% CI; 0.60-0.99, p 0.045) and small LDL particles (HR 0.78, 95% CI; 0.61-
1.00, p 0.05) with an overall p <0.05.171 More recently a large study of over 88,500 
participants in the Kailuan Study found and inverse association with TC and LDL and 
incident AF.172 This was a long-term study of over 7 years, which found higher TC 
(HR: 0.60, 95% CI; 0.43-0.84) and LDL (HR: 0.60, 95% CI; 0.43-0.83) were following 
multivariate adjustment inversely associated with incident AF. While HDL and TG 
were not shown to be associated with incident AF. Given the vast differences and gaps 
in the data, there is a need for further studies are required to determine the role of blood 
lipids on AF risk. 
 
1.2.10 FAMILIAL AF 
The genetic or hereditary impact on AF has been one of ongoing research and largely 
remains unknown. In 1997 a study undertaken in families with AF to assess the 
potential genes, highlighted they were not able to conclude definitively the genes 
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responsible but were able to show that screening was a rapid process and could be used 
to find the potential link.173 A recent study of Europeans looking at genetic risk score 
based on ancestry using 5 large prospective studies.174  They were able to determine 
that genetic risk scores were associated with incident AF after adjusting for clinical 
risk factors for those in the highest quartile of scoring having up to 67 higher risk of 
new-onset AF. This was also associated with around a two-fold increased risk of 
cardioembolic stroke.  
The first gene that was directly linked to hereditary AF was the mutation of the 
KCNQ1 gene.175 From here there has a multitude of genes that have been associated 
with AF, this area is continuing to evolve and new genes seem to be found, there is not 
always the ability to replicate findings.176-179 The recent PREVEND study found 3 
known-AF gene variants (rs6666258, rs6817105 and rs10821415) were associated 
with AF that was self-terminating, this was not the case for persistent non-terminating 
AF.180 
A very recent large trans-ancestry meta-analyses assessing common and rare 
variant was able to identify 12 new loci which are seen to implicate genes which affect 
cardiac structural and electrical remodelling.181  
A recent overview of genetics and AF by Fatkin et al, eloquently looks at the 
current knowledge available regarding genetics and AF. This demonstrates 25 ion 
channel related genes, 13 transcription factors, 9 associated with myocardial structural 
components, 8 signalling or protein genes, and 6 gene loci with no particular gene 
identified.182 The effect these genes have on AF are genetic, pathophysiological and 
mechanistic through ion channels, transcription factors and myocardial structural 
components which lead to repolarisation, refractoriness, cell identity differentiation 
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and proliferation as well as cell-cell coupling, conduction heterogeneity all of which 
lead to automaticity and re-entry followed by AF.182   
While the genetic factor is a somewhat complex relationship, studies have 
shown there is a relationship between genetics and AF, albeit still not overly 
conclusive. This remains an area of ongoing investigation which is largely uncharted 
and requires a significant amount more research and studies to fully understand the 
genetic link. 
 
1.3 MECHANISMS AND PROGRESSION OF ATRIAL FIBRILLATION 
1.3.1 Mechanisms of AF 
While AF is a complex disease there is several key mechanisms that are believed to be 
associated with atrial structural remodelling. This begins at a cellular level, with the 
downregulation of calcium and upregulation of potassium, this results in shortening of 
the atrial refractory period and AF cycle length.183,184  Electrical remodelling is a result 
of this given that the electrophysiological properties of the atria are administered by 
ion channels, pumps, and exchanges.32  These instabilities may mediate AF and in 
effect alter autonomic tone to propagate AF.185,186 Structural remodelling in many 
patients will begin before the onset of AF.187 This process can be due to many factors 
including fatty infiltration,80,188,189 amyloid deposition,190,191 inflammation,192 and 
fibrosis32,187,193-195. Electrical dissociation between the muscle bundles and local 
conduction heterogeneity are a result of structural remodelling.196 These changes can 




1.3.2 Mechanisms Promoted by Risk Factors 
Age one of the most common risk factors for AF. It has been shown that age is 
associated with electrical and structural remodelling which resulted in a greater 
propensity for AF.197 Hypertension has been well described to result in an abnormal 
atrial substrate. Atrial fibrosis, atrial enlargement, atrial fibrosis, increase in AF 
duration, conduction slowing, increase conduction heterogeneity, and cellular changes 
has been shown in many models.43-45,48,198-200 Several animal studies have shown the 
correlation between obesity and AF. Obesity results in many of the modifiable risk 
factors. Studies in the ovine model have shown that by increasing the weight of the 
animals there is a great increase in fibrous tissue which is associated with increase 
inducibility and abnormal conduction.77 Further studies have shown, also in a sheep 
model, obesity resulting in epicardial fat infiltration, which promoted in significant 
atrial remodelling and fibrosis which resulted in propensity for AF.78 A recent human 
study has demonstrated through MRI and EP study obesity was associated with 
electroanatomical remodelling of the atria, this was more distinct in areas adjacent to 
epicardial fat depots.80 During sleep, obstructive apnoea’s cause the upper airway to 
collapse, this results in swings in intrathoracic pressure which has been attributed to 
myocardial stretch in the heart, therefore promoting AF.129,201 Atrial remodelling has 
been shown in a human model whereby patients with OSA had significant atrial 
enlargement, reduction in voltage and widespread conduction abnormalities, which 
lead to the propagation of AF.128 Exercise has positive influences on the heart by a 
decrease in inflammatory and oxidative stress, this in turn leads to improvement in 
blood pressure and glycaemic control, improvement in autonomic balance and 
diastolic function and decrease in visceral fat.106 There is an increase in 
arrhythmogenesis as a result of atrial stretch and an increase in vagal tone as a potential 
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mechanism for pulmonary vein triggers.106 Several other risk factors have shown to 
promote AF due to structural and electrical atrial remodelling.202  
 
1.3.3 Progression of the AF Substrate 
Atrial fibrillation is known to be a progressive disease. While initially many patients 
present with paroxysmal episodes over the course of time these episodes become more 
persistent and eventually transpire into more sustained forms of AF.87,203 It was 
initially considered that this progression was due to the arrhythmic process whereby 
“AF begets AF”;203 recent data has also implicated risk factors in the progression of 
the disease. Progression of the atrial substrate therefore may be more related to the 
underlying risk factors of the individual. Several studies have demonstrated the 
correlation between fibrosis and risk factors, along with aging, congestive heart failure, 
obstructive sleep apnoea, hypertension, and obesity has been known to promote 
fibrosis and progress the atrial substrate.48,77,78,123,128,197,204  
Indeed, it would seem that the more concomitant risk factors an individual has 
the more likely they are to have more persistent episodes of AF.35,205 In a large cohort 
of patients demonstrated that 17% of patients progressed from paroxysmal to 
permanent AF over a 5 year follow up.205 This study found that a BMI ≥ 30 was 
associated with a 1.5-fold increase risk of progression from paroxysmal to permanent 
AF. The large German registry found that only 18.7% of patients had permanent AF 
in the absence of risk factors.35 This increased based on the number of risk factors a 
patient had. With 54.8% of patients who had five or more concomitant risk factors 
presenting with permanent AF. A systematic review of AF progression found that at 1 
year there was a 10-20% progression of AF disease in patients with AF.206 For longer-
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term studies this increase with progression rate from 50-55% after 12 years. For 
patients who underwent ablation the rate of progression was lower at 5 years of follow 
up 2.4-2.7%.   
A recent study demonstrated that even following successful ablation of AF.207 
In this study patients undergoing AF ablation were compared to control patients 
undergoing SVT ablation. At baseline the AF patients had significantly great areas of 
low voltage (p<0.001), conduction slowing (p=0.005), increased fractionation 
(p<0.05) and left atrial dilation (p=0.01). Following a successful AF ablation and in 
the absence of any arrhythmia the patients underwent further EP study to assess 
progression. This demonstrated that despite no AF, the AF patients had greater areas 
of low voltage associated with persistent conduction slowing (P=0.005) and an 
increase in fractionation (p<0.001). This suggests there is progression of the atrial 
substrate suggesting progressive injury to the atrial myocardium despite the cessation 
of arrhythmia. 
While there is much data to support the progression of AF disease the ability 
to reverse the AF substrate is still in its infancy and we await the results of several 
studies in this area.  
 
1.4 SOCIOECONOMIC STATUS AND ATRIAL FIBRILLATION 
Socioeconomic status (SES) is commonly used to assess an individual’s social position 
in and according to the World Health Organisation is defined as circumstances in 
which people are born, grow, live, work, and age, along with the systems put in place 
to deal with the illness.208 It is known that poorer health is the results of poorer 
socioeconomic circumstances, however this can vary dependent on the medical 
36 
 
condition.209 The impact of wealth has been associated with mortality outcomes, with 
less wealth associated with a 62% increased risk of deaths among the least wealthy.210   
 
1.4.1 Cardiovascular Health 
The key factors used to assess the social determinants in patients with cardiovascular 
disease include, socioeconomic position, race and ethnicity, social support, culture and 
language, access to care, residential environment.211 The markers of socioeconomic 
position  include material condition based on income and wealth, health, education, 
access to valued personal activities such as work, political voice, social connections, 
environment, physical insecurity such as crime or violence.211   
While SES has previously been associated with cardiovascular health. Low 
SES status has been linked to greater mortality. Previous studies have shown the 
correlation between SES and stroke rates, a significantly higher stroke rate among 
elderly women in a low socioeconomic stratum. Similarly, large cohort study 
individuals between 40 - 50 years, ischemic stroke was more prevalent in low SES 
neighbourhoods compared to high SES neighbourhoods.212  
The National Heart Foundation in Australia has recently released the 
Australian Heart Maps, which provides statistics from around the nation on various 
cardiovascular diseases.213 The data available, was collated in conjunction with 
Australian census data which enables correlation with socioeconomic status. The maps 
enable a breakdown by state or region and provides detailed statistics on admission, 
and a breakdown of heart disease risk factors of that area. An example of what is 
available is if one wanted data on Sydney, the maps demonstrate that 3.9% left school 
prior to completion of year 9, this compares to 11.3% the Australian national average. 
Sydney has a lower rate of admission 35 per 10,000 persons compared to the national 
 
37 
average of 48 per 10,000. The mortality heart disease mortality rate is 60 per 100,000 
compared to the national average of 68 per 100,000 persons. In terms of heart disease 
risk factors, there is a high prevalence of hypertension 43% much higher than the 
national average of 23%. Physical inactivity is significantly lower 57% compared to 
the national average of 66%. Obesity prevalence is 17% which is significantly lower 
than the national average of 28%. These maps contain in-depth and useful information 
of the cardiovascular impact of regions around Australia. 
 
1.4.2 Atrial Fibrillation 
There is limited data surrounding the association between AF and SES. While there 
have been several studies that have assessed the differences in race and AF 
development214-217, many of these did not look at social determinants such as income 
and education. The Atherosclerosis Risk in Communities (ARIC) Study prospectively 
followed over 14,000 patients who at baseline were free from AF.218 This study was a 
long study of 20.6 years follow-up, over this duration there was 12.5% incident AF 
diagnosed. This study demonstrated that low income was associated with a higher risk 
of AF with low education also a risk for women although this was not the case for men 
(HR: 1.88, 95% CI 1.55-2.28 and HR: 1.15, 95% CI 0.97-1.36, respectively). 
Interestingly, the risk of AF was higher for Caucasians compared to blacks for which 
socioeconomic status did not seem to be able to account for. 
Patients with AF and low SES has also been seen to have a higher mortality 
following adjustment for other co-morbidities.219 Another relatively large cohort from 
Sweden showed that in males with AF who were living in a low SES neighbourhood 
there was a higher relative risk of all-cause mortality (HR 1.49, 95% CI; 1.13-1.96)  
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compared to those who were in a middleclass neighbourhood. Additionally, there was 
a shorter time to death for those in the middle compared to low SES neighbourhood. 
 
1.4.3 Obesity and the Link to Socioeconomic Status 
The World Health organization has demonstrated that obesity rates in high income 
countries has not risen as quickly as those in middle- and low-income countries. Within 
Australian and indeed internationally there has been shown to be a significant 
relationship between obesity and SES.220-222 Given the established link between 
obesity and AF, taking into account SES may enable more targeted management of 
patients who present to our clinics with AF. 
 
1.5 GENDER DIFFERENCES IN ATRIAL FIBRILLATION 
1.5.1 Incidence and Prevalence of AF by Gender 
Although the prevalence of AF in males over a 20-year period rose 28%, females over 
the same period rose 35%.1 Several large studies have evaluated the specific sex 
prevalence and incidence of AF. There have been many studies using different 
methods of detection which show varying rates of AF incidence, these have been 
predominately from the US and Europe.3,223-228 When assessing this within the US, the 
two major studies, the Framingham Heart Study and the Olmstead County, Minnesota 
studies report the incidence of AF in women is 1.6 and 2.7 respectively compared to 
3.8 and 4.7 in men, per 1,000 person-years.3,229 The most familiar study the Global 
Burden Worldwide study1 which combined all published studies, found the incidence 
of AF in women to be 0.9 and 0.4 per 1,000 person years for the developed and 
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developing countries respectively. For men this was 1.23 and 0.54 per 1,000-person 
years for the developed and developing countries respectively. There is a significant 
lack of AF incidence data from the Asia-Pacific, Middle East, South American and 
African populations. 
As with the incidence of AF, Chugh et al once again showed in the Global 
Burden Worldwide study1 demonstrated the global prevalence of AF to 373.1 (per 
100,0000 population) for women, for males this 596.2 (per 100,000 population). 
Various studies have demonstrated country-based prevalence as with the above 
mentioned these are mostly from the developed countries and there are limited studies 
outside of the US and Europe.  
The age adjusted prevalence of AF in the Framingham study was 49.4 in 
women and 96.2 in men per 1,000 person-years.229 Due to the life expectancy of 
females being longer this results in the number of women with AF greater than men 
based on US Medicare data. This data suggests that in 2007 the prevalence of AF was 
10.3% in males and 7.4% in females.223     
In Europe there is data from various countries. There are two Rotterdam 
Studies in the Netherlands which found prevalence of 7.1% and 5.1% in females and 
8.6% and 6.0% in males.228,230 In Spain the overall prevalence was also slightly higher 
for women 4.5% compared to 4.4%.231 A couple of studies have been done in Germany 
with the results showing a prevalence of 1.9% in both for female and 2.4 - 4.6% in 
male.226,232 Sweden has several studies with varying prevalence from 0.06% to 9.2% 
in females compared to 1.3% to 16% in males, the large variation in prevalence could 
be due to the method in which the prevalence was obtained.224,233,234 The United 
Kingdom have several prevalence studies which has fairly consistent reports of 
between 0.3-1.29% in females and 0.27% to 1.49% in males.235-238 Other countries 
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have minimal data. Portugal doesn’t demonstrate any difference with a prevalence of 
2.5% for both males and females.239 Switzerland has a low prevalence in females 
0.54% compared to 1.23% in males.240 Denmark has a prevalence of 1.1% in females 
and 3.3% in males. Iceland demonstrated 1.5% for females and 2.3% for males.241 
There is one study from Northern Italy which found a high prevalence of 7.3% in 
females and 7.5% in males.242 Ireland had a significant difference in prevalence 
between sexes finding 4.8% in males compared to 1.4% in females.243 Scotland has 
quite extreme differences in prevalence rates from 0.56% up to 7.9% in females and 
0.75% up to 9.4% in males.10,244 The higher rates however were obtained by using 
hospital coding versus the lower rate which was obtained by ECG diagnosis. 
From the Asia Pacific region there is much less data. Two studies from China 
demonstrate similar prevalence from 0.63% to 0.63% in females and 0.66% to 0.78% 
in males.245,246 From Japan, three studies have prevalence at relatively the same 
ranging from 0.43% to 1.2% in females and 1% to 2.4% in males.111,247,248 
Additionally, there is a study from Korea with females prevalence at 0.4% and males 
at 1.2%,249 and Taiwan 0.7% and 1.4% for females and males respectively.250 
The prevalence of AF within Australia has been estimated at 6% in males and 
4.8% in females, with a projected increase of 1.25% in males and 0.85% in females by 
2034, suggesting fairly similar rates of increase exclusive of gender.5  
A recent review has shown the Asia Pacific projected prevalence is estimated 
to reach 49 million males and 23 million females by 2050, this is 12-fold higher than 
the equivalent predictors for men and women in the US.2,251,252  
To date there is minimal data from South American, Africa and the Middle 
East, with more studies needed to better understand the true prevalence of AF in these 
countries. It is also of course reasonable to surmise that based on the variety of 
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prevalence rates in the current data there is significant work that needs to be undertaken 
in the area of screening for AF prevalence and incidence. 
 
1.5.2 Gender specific risk factors 
1.5.2.1 Age 
Age is well known as a leading cause of AF, it has been associated with a two-fold 
increase in AF for every 10-year increase in age.36 There are many studies that 
demonstrate that women present with AF at an older age.229,253-256 This has been shown 
particularly when presenting for AF ablation women present later and are often 
significantly older than men.257-259 In 2 large European registry cohorts women were 
shown to not only be older but present with more heart failure with persevered ejection 
fraction, hypertension and valvular heart disease.255,260  
 
1.5.2.2 Obesity 
The Women’s Health Study demonstrated over 12 years of follow-up increase in BMI 
>30 resulted with an 18.3% attributable risk of AF.74 Interestingly this study also 
demonstrated that women who were able to reduce their weight to a BMI <30 they 
also reduced their risk of AF. The Framingham study demonstrated a 4% increase risk 
of AF per 1-unit increase in BMI for men (95% CI, 1-7%, p=0.02) and women (95% 
CI, 1-7%, p=0.009).69 Following adjustment HR: 1.52 (95% CI, 1.09-2.13, p=0.02) for 
men and 1.46 (95% CI, 1.03-2.07, p=0.03) for women. A similar result was seen in the 
Danish Diet, Cancer, and Health study where 1 unit increase in BMI conferred a HR 
1.08 (95% CI, 1.05-1.11) in men and 1.06 (95% CI, 1.03-1.09) in women.76 This data 
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all from large cohort studies highlights the importance of obesity as a major risk factor 
for AF in both sexes. 
 
1.5.2.3 Hypertension 
Hypertension is one of the key modifiable risk factors and this has been demonstrated 
to be higher in women. The European Observational Research Programme Pilot survey 
on AF of 3119 patients, examined the sex differences in presentation, treatment and 
outcomes. This demonstrated that females were older at presentations 71.7 ± 10.6 
versus 66.9 ± 11.7 (p<0.0001), more likely to have hypertension 74.7% versus 68% 
(p<0.0001).260 Similarly a large Health Claims and Medicare database study also 
demonstrated a significantly higher rate of hypertension for females 66.2% versus 
61.8% (p<0.001).258 The Women’s Health study was able to demonstrate that in a 
cohort of healthy women, systolic BP was shown to be a better predictor than diastolic 
BP with systolic blood pressure, following adjustment, strongly associated with 
incident AF 1.17 [95%CI, 1.08-1.27, p<0.0001].40   
 
1.5.2.4 Hormones 
There is limited data surrounding the relationship between sex hormones, it has been 
suggested that women may develop AF later in life due to the impact of progesterone, 
this has been demonstrated to shorten action potential therefore providing a protective 
mechanism against AF.261,262 The Multi-Ethnic Study of Atherosclerosis found that 
higher levels of testosterone was associated with the development of AF in men.263 
While lower testosterone has been demonstrated in the Framingham Heart Study to be 
associated with an increased risk of AF in males aged over 80 years old.264 In new-
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onset AF the use of hormone replacement demonstrated a decreased risk of myocardial 
infarction in a large cohort of women.265 While the Women’s Health Initiative Study 
found no difference in postmenopausal women who were randomised to placebo or 
oestrogen replacement.266 The Framingham Heart Study of women over 60 years old 
did not identify a particular age related to menopause which would contribute to a 
significantly increase risk of AF.267 There is a substantial gap in the knowledge of 
hormones and AF, to date no consistent data has suggest this to be a significant 
contributor to the time of onset or development of AF. 
 
1.5.2.5 Atrial Fibrosis 
Atrial fibrosis has been shown in animal data adverse remodelling of that atria both 
structure and function has resulted from persistent AF.268 Human data has shown 
higher levels of fibrosis associated with the presence of AF.269,270 Emerging data has 
suggested left atrial fibrosis as a marker for outcomes in AF ablation.271,272 There is 
limited data in this area given it is still an evolving area, to date in patients with long-
standing persistent AF demonstrated that women presented with more worsening of 
remodelling due to fibrosis in women compared to men, thus potentially mediating 
recurrence of AF following ablation.273 A recent study has found that women have 
more advance fibrosis, furthermore women who had prior history of stroke when 





1.5.3 Stroke and Mortality 
Women with AF tend to present more highly symptomatic and carry a significantly 
stronger risk of stroke, cardiovascular and all-cause mortality.273,275-277 Early data 
demonstrates that women with AF have been shown to have a 5-fold higher increase 
risk of ischemic stroke when compared to males.2,37 This is reflective of the fact that 
women score an extra point in the CHA2DS2-VASc score given the increased risk for 
women who have AF.278  
A recent large observational study demonstrated a 19% risk of stroke in 
females with AF, this also remained significant following adjustment for risk 
factors.279 Conversely, another study found that after multivariate analysis female sex 
was not significantly associated with stroke.280 It is potentially not just related to sex 
but rather the risk of AF and stroke is more age related. There are several studies which 
show an independent relationship of female sex and stroke for those age ≥65 281,282 
years to 75 years.279,283-285 While stroke is often associated with severe complications, 
it has been shown that women who experience stroke often present with more severity 
than males,286 with poorer long-term outcomes.287  
Recent data suggests that female sex may not in fact confer a significant risk 
in the absence of additional risk factors.288-290 A study of 3 nationwide registries found 
that sex was a prognostic factor for stroke in AF patients.284 It did reveal the risk for 
females was significant in those who had additional non sex-related risk factors for 
stroke. The recommendation as such was that for women in the absence of additional 
risk factors, female sex would not score 1. As such the recent Heart Foundation 
Guidelines in Australia has simplified the score by removing female sex from the 
CHA2DS2-VASc score – changing it to CHADS-VA.
291 Similar changes have also 
been made to the scoring used in the European Society of Cardiology (ESC) 
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guidelines.17 The ESC guidelines have shown evidence to suggest that female sex in 
the absence of other risk factors does not appear to increase the risk of stroke. 
Therefore, it is recommended that should a female score 1 due to sex and without other 
risk factors, anticoagulation should only be considered on an individualised bases 
following co-decision with the patients.  
The Framingham Heart Study reported AF being associated with a 1.9-fold 
increase in mortality for women compared to 1.5-fold for men. 15 The Olmsted 
County, Minnesota study reported double the risk of mortality for new onset AF.292 
Similar results were reported in the Copenhagen City Heart Study with the risk of 
mortality double for women compared to men.293 However, there is heterogenous data 
surrounding mortality given studies also report that the risk of mortality is higher for 
men not women.86,294-296 This data suggests perhaps that further studies may be 
required to tease out the role of female sex and stroke as well as the risk of mortality 
between genders and possible confounding factors. 
 
1.5.4 Symptomatic Differences 
There is a lot of literature to demonstrate that women not only present older and often 
with more comorbidities they also present with more atypical symptoms. A review 
reporting on symptomatic and asymptomatic AF has shown that the RR 0.57 of 
asymptomatic AF was less common in women compared to men.297 The European 
Observational Research Program demonstrated that women presented with more 
palpitations (08.2% versus 68.5%, p<0.0001), more fear and anxiety (14.6% versus 
10.5%, p=0.0007) and they had a higher proportion in European Heart Rhythm 
Association class III and IV (p=0.0012).260 The RACE study which assessed difference 
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in symptoms of patients with persistent AF demonstrated by using the SF-36 quality 
of life questionnaire assessing symptoms such as general health, physical functioning, 
pain, mental health, vitality, social functioning and emotional state. Women with AF 
had worse QoL compared to both healthy female subjects and males who had AF 
(p<0.05).298 The ORBIT-AF registry similarly found women to be older and have a 
higher CHA2DS2-VASc score, but yet they were more likely to be less asymptomatic 
32% versus 42.5% (p<0.001), with more palpitations, dyspnoea, light-headedness, 
fatigue and chest discomfort compared to males (p<0.001).257 Despite more 
comorbidities and symptoms, the management and treatment of women differs 
significantly. 
 
1.5.5 Treatment Differences 
The European Observational Research Program (EORP) study demonstrated that when 
compared to males females are more likely to be treated with rate control as opposed 
to rhythm control (p=0.002)298. The ORBIT-AF registry also demonstrated that 
women were less likely to undergo cardioversion (<0.001), AF ablation (p=0.04), 
receive β-blockers (p<0.001) but more likely to receive AV Node ablation for rate 
control (<0.001).257 Similarly, a short-term study of only 1 year of a large cohort also 
demonstrated that women were less likely than men to receive electrical cardioversion 
(14.9%versus 20.6%) and ablation (3.3% versus 6.3%  (p<0.001))275. It would seem 
women present with more commonly with fatigue and weakness which are fairly 
atypical symptoms this may impact on diagnosis time.299,300 A review of the Health 
Claims and Medicare database of over 21,000 patients undergoing index AF ablation 
(29% female) demonstrated that women were more likely to be re-hospitalised for AF 
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but less likely to undergo cardioversion or repeat ablation.258 With ablation emerging 
as a frontline treatment for AF, we can see that the rates of ablation have risen 
significantly over the years. Despite this fact, while the percentage of females 
undergoing ablation has risen 560% over 12 years, this is still significantly lower than 
that of males who tend to undergo more AF ablation than females.216 Conservative 
treatment tends to be undertaken in women with AF. More often women are treated 
with rate control measures in comparison to men who are provided rhythm control. 
Further larger studies may be required to better understand this and the impact it may 
play on outcomes of women.  
 
1.5.6 Ablation Outcomes 
One of the striking things in gender and AF is the disparity and heterogenous data 
surrounding that of ablation outcomes. While many studies have looked at outcomes 
of ablation there is limited data on gender differences, despite them all reporting older 
presentation and more comorbidities.  Of the studies which do report this the is low 
numbers of females in the cohorts, varying blanking periods and follow-up and in 
many cases a lack of clinical data. 
One of the earliest studies which addressed outcome differences found that 
despite the baseline differences there was no difference in the need to undergo repeat 
ablation, success rates of ablation or AF recurrence between males and females.301 Of 
note this was a small study with 221 patients of which only 71 were female. Since this 
the reports have been different. Results from the German Ablation Registry, which has 
one of the largest cohorts of females found that women presented with more 
paroxysmal AF 72% versus 61% (p<0.001) but yet less freedom from AF and/or 
antiarrhythmic drugs (p<0.001), and overall freedom from AF (p<0.05) following 
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ablation.259 Additionally, they found that there were more moderate complications 
(p<0.05) and persistence of symptoms (p<0.001) for women compared to men 
following ablation. Being a registry, they lack significant clinical and follow-up data. 
Another study of ablation outcome demonstrated the 1- and 4-year AF free rates 
following initial ablation were comparable between men (79.1% and 70.9%) and 
women (71.6% and 64.7%) however the final outcome did show worse outcomes for 
females (p=0.02).302 When assessing patients with long-standing persistent AF only a 
study with once again a small cohort, 73 females following both initial ablation 
(p=0.004) and overall freedom (p=0.087) females fared worse than males.303 In 
individuals with paroxysmal AF, despite once again more comorbidities there was no 
major difference following primary ablation with similar maintenance of sinus rhythm 
(p=0.24), following final procedure there was a significant change in women more 
likely to have failed ablation and have recurrence of AF (p=0.007).304 One of the 
largest cohorts of females with 518 females, found that there were 5 times more males 
than females that underwent AF ablation, despite this women were less likely to be 
free from AF at follow-up (p=0.001) and have more complications post operatively 
(p<0.001), of note they did have a short blanking period of 8 weeks.305 The recent Fire 
and Ice trial following multivariate analysis found female sex to be the strongest 
predictor of outcomes following ablation with almost 40% increased risk of ablation 
failure and a 36% increased likelihood of rehospitalisation at final follow-up regardless 
of ablation modality.306 Vallikati et al undertook a meta-analysis of 20 pooled studies 
looking at ablation outcomes.307 Despite significant heterogeneity in the studies 
included such as follow-up durations, blanking periods, and studies not primarily 
aimed at gender outcomes, this demonstrated women were more likely to have AF 
recurrence following AF ablation. What is striking in the meta-analysis is that 65% of 
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the studies included has less than 100 females in their cohorts. Additionally, 25% had 
sort follow-up of approximately 12 months, this highlights the paucity of data, lack of 
female inclusion (possibly due to lower numbers undergoing ablation) and lack of 
gender driven ablation outcome studies, suggesting more is needed to better 
understand the disparities in outcomes. 
 
1.6 LIFESTYLE MANAGEMENT 
1.6.1 Initial Randomised Pilot Study 
In 2013, a randomized clinical trial demonstrated that weight loss and risk factor 
management in overweight or obese individuals with AF, resulted in a dramatic 
reduction in patient symptoms and AF burden determined by ambulatory monitoring. 
In the group who underwent intervention with weight loss and lifestyle changes, there 
were also significant improvements in patient well-being, blood pressure, glycaemic 
control and cholesterol.308  
 
1.6.2 Method of Lifestyle and Risk Factor Management Delivery 
Several approaches could be used to achieve lifestyle and risk factor management in 
patients with AF. In the management of AF, to date, a dedicated risk factor clinic has 
been shown to yield the most impressive results.107,308,309 The program used to achieve 
these results focuses on all the primary modifiable risk factor targeting lifestyle and 
diet changes to achieve outcomes based on each individual patient’s particular risk 
factors. This begins with personalised assessment with patients maintaining a lifestyle 
journal recording food intake and exercise undertaking. This is reviewed, and 
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recommendations based on current diet to of diet and promotes high protein, low 
Glycaemic Index (GI) diet with calorie restriction, with portion control. Sodium 
restriction is encouraged particularly in patients with hypertension. Individuals are 
encouraged to exercise up to 30 minutes 3-4 times a week with an aim to increase this 
up to 250 minutes a week. Patients are screened for hyperlipidaemia which is initially 
managed by lifestyle and dietary changes if this is not achieved then statins or fibrates 
are introduced. It is important that all patients with AF undergo sleep studies to 
evaluate if this risk factor is a causative factor of AF, with CPAP initiated if the AHI 
is >30. Hypertension is managed aggressively with patients recording this 2-3 times a 
day with an aim of <130/80 mmHg 80% of the time on home monitoring readings. In 
addition, patients undergo a clinical stress test to ensure there is no exercise induced 
hypertension with BP remaining <200/100 mmHg. As with hyperlipidaemia, diabetes 
is also initially managed with dietary and lifestyle changes with Metformin introduced 
if HbA1c is >6.5%, patients are also referred to endocrinologist for management. 
Smoking cessation is encouraged as well as reduce alcohol intake to 3 standard drinks 
a week.107 Not only was there a reduction in overall AF burden but there was also 
marked improvement in other risk factors, patients with hypertension, were able to 
significantly reduce the use of or cease antihypertensive medications, their cholesterol 
improved, as did glucose intolerance.  
 
1.6.3 Impact of Risk Factor Management on Ablation Outcomes 
The Aggressive Risk factor Reduction Study for Atrial Fibrillation and implications 
for the outcome of ablation (ARREST-AF cohort study) showed the benefits of risk 
factor management (RFM) on the outcomes of AF ablation.309 This study showed that 
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not only did AF frequency, symptoms and duration improve in the group undergoing 
risk factor management compared to the controls but there was also more favourable 
ablation outcomes with 62% AF freedom in the RFM group compared to 26% in the 
control group following single procedure. This was also replicated in multiple 
procedural outcomes with 87% in the RFM group and 48% in the control group free 
from AF at final follow-up. This study also looked at AF freedom at follow up with a 
step-wise improvement based on the degree of weight loss, with ≥10% weight loss 
associated with 46% AF freedom, compared to 13% in those who lost <3% weight 
without the use of anti-arrhythmic drugs or ablation.309 
 
1.6.4 Long-term Outcomes of Risk Factor Management 
In an ongoing cohort study analysis, the Long-term Effect of Goal-directed weight 
management in AF Cohort: A Long-Term Follow-up studY (LEGACY) highlighted 
the importance of long-term weight loss, and management of risk factors such as 
hypertension.107 It was shown that with a step wise reduction in weight there was a 
relative reduction in patient symptoms and overall AF burden. Importantly, in the 
group who lost ≥10% of their initial body mass, 46% patients remained free from AF 
without the use of rhythm control strategies over long term follow-up of 5 years. 
Interestingly, weight fluctuation was shown to offset, but not eliminate the benefits of 
weight loss on AF freedom.  
 
1.6.5 Role of Exercise and Risk Factor Management 
Several studies have attempted to address the benefits of exercise and cardiorespiratory 
fitness in the management of AF. The Impact of CARDIOrespiratory FITness on 
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Arrhythmia Recurrence in Obese Individuals with Atrial Fibrillation (CARDIO-FIT) 
study demonstrated the benefits of exercise by showing that patients who achieved a 
cardiorespiratory fitness gain ≥2 METs, significantly improved freedom from AF and 
alleviated AF specific symptoms, when compared to those with <2 METs.107 A recent 
randomized trial also demonstrated reduced AF burden with aerobic interval training, 
alongside fewer hospital admission and cardioversions.310 Although this was only a 
short exercise intervention study, those randomised to exercise training reported 
reduced AF symptoms, improved quality of life, and peak oxygen uptake.310 These 
studies support the prescription of exercise in the management of AF. 
 
1.6.6 Further Studies Addressing Risk Factors for AF 
In comparison to the benefits shown in these studies to improve blood pressure, the 
SMAC-AF study looked at the impact treatment in aggressive management of blood 
pressure would have in the reduction of AF symptom burden and prevent recurrence 
following ablation. Following ablation and the aggressive treatment of BP, there was 
no reduction in AF in patients with a BP >130/80 mmHg, and they found that the 
aggressive treatment consequently resulted in more hypotension.311 While this study 
demonstrated no real reduction in recurrence of AF, potentially due to only addressing 
one risk factors rather than all concomitant risks in the patient, it didn’t manage to 
assess if other substrates may have been the reason for this. Another study has 
suggested that undertaking renal artery denervation to manage severe drug resistant 
hypertension in patients undergoing AF ablation results in a significant improved 
control of blood pressure but also a significantly better control of AF.312 Therefore, it 
is feasible that in such extreme states, treatment of a single risk factor may have a role. 
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In terms of other risk factor clinics, the RACE 3 trial assessed cardiac 
rehabilitation in patients with AF focusing on pharmacotherapy.313 While not strictly 
a clinic which focused solely on risk factors, patients were provided general dietary 
and physical activity advice. This study demonstrated that patients who were 
randomised to targeted therapy in the intervention group were more likely to be in 
sinus rhythm at final follow-up. The also did note a small number of patients reversed 
their AF type from persistent to paroxysmal over the course of the study.  
In long-standing persistent AF patients, a study has demonstrated that in 90 
patients who underwent weight reduction management outcomes were not so 
significant.314  While there was significant weight loss over 12 months, they were 
unable to demonstrate improvement in symptoms, AF burden and ablation outcomes. 
An important limitation is that this is in longstanding persistent population, and 
therefore the question needs to be asked if it is ‘too little too late’. Additionally, the 
outcome was only assessed at 12 months, given the significant remodelling the atria 
would have undergone due to longstanding persistent AF, more time may be required 
to see the full benefit.  
In late 2016, the European Society of Cardiology Guidelines have included in 
the management of AF, risk factor modification and weight reduction as a Class II 
recommendation.17 These recommendations are based on recent studies, which have 
assessed the impact of weight and risk factor management on AF outcomes.  
While to date there is compelling data to support risk factor management there 
is a lack of studies from differing sites. These findings highlight the importance of 
weight and risk factor management in the first instance when treating patients with 
atrial fibrillation. Treatment of obesity, hypertension and associated risk factors not 
only assists with reduction in symptoms, AF burden, ablation outcomes, but may be 
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used to prevent the occurrence of AF, whilst likely contributing to improved general 
cardiovascular health.  
 
1.7 DELIVERY OF ATRIAL FIBRILLATION MANAGEMENT 
While Australian data shows that admissions for AF have over a 15-year period 
demonstrated a relative increase of 203%, compared to admissions for other common 
cardiovascular conditions, acute coronary syndromes 79% and heart failure 17%, 
nothing seems to have changed in managing these patients.9 Data taken from the Royal 
Adelaide Hospital assessing presentations demonstrated 55% of patients who 
presented had known AF, but yet were on inadequate anticoagulation. Additionally, at 
discharge 37% were still not adequately anticoagulated, over the subsequent year 26% 
of all cause readmission were for AF and there was a 10% mortality rate.315 In 
comparison heart failure has established clinics where by patients are able to be largely 
managed outside the hospital, this model has been demonstrated to be highly 
effective.316,317 This has been shown for some time, despite the relentless rise in AF 
prevalence and admissions no such management has been implemented.  
Current management is based on the AF guidelines which recommend 
anticoagulation based on CHA2DS2-VASc risk, rate and rhythm control, management 
of risk factors such as hypertension, diabetes mellitus, obesity and for those who 




1.7.1 Key Elements in AF Management 
The European Society of Cardiology have provided five domains of management for 
AF.17 1. Haemodynamic instability or limiting, severe symptoms; 2. Presences of 
precipitating factors and underlying conditions; 3. Stroke risk and need for 
anticoagulation; 4. Heart rate and need for rate control; 5. Symptom assessment and 
decision for rhythm control. Together these aim to improved haemodynamic stability, 
reduce cardiovascular risk, provide stroke prevention, improve symptoms and preserve 
LV function. Consequently, this provides patient benefit with improved life 
expectancy, quality of life, autonomy and social functioning. 
 
1.7.1.1 Anticoagulation 
The use of oral anticoagulation can assist in preventing ischemic strokes as well as 
prolonging life.318-320 Warfarin or vitamin K antagonists (VKA) the traditional form of 
anticoagulation, have been demonstrated to reduce stroke risk by two thirds and a 
quarter of patients have reduced mortality.318 Additionally, a large study of over 
94,000 patients found 84% of stroke patients who had a prior history of AF were not 
on therapeutic anticoagulation prior to stroke.321 However more recently the non-
vitamin K antagonists NOACs have emerged and increase in popularity as a preference 
for anticoagulation due to the lack of regular blood testing required and reduced 
interactions. Warfarin is a Vitamin K antagonist, in comparison all the NOACs are 
Factor Xa inhibitor except for Dabigatran with is a direct thrombin inhibitor. These 
drugs not only have a shorter time to effect compared to Warfarin but also have a 
shorter half-life. The NOACs are hepatically metabolised and predominately renally 
cleared.322 Supporting the preference for NOACs amongst recent guidelines with a 
Class I, level A recommendation for stroke prevention over VKA,109 several studies 
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have demonstrated superior efficacy with NOACs versus VKA.323,324 A meta-analysis 
performed in 2012 by Dentali et al demonstrated that when comparing NOACs to 
Warfarin, there was a 23% relative risk reduction for stroke and systemic embolism, 
14% relative risk reduction for major bleeds, and 11% relative risk reduction in total  
and cardiovascular mortality.325 Likewise a meta-analysis of the large randomised 
trials which assessed 42,411 individuals on NOACs, found similar results with a 
significant reduction in stroke by (19%), intracranial haemorrhage rates were halved 
and mortality reduced (10%), this demonstrated similar major bleeds but interestingly 
demonstrated an increase in gastrointestinal bleeding.319 Despite this we see that the 
NOACs have provided an alternative therapy for stroke prevention for patients with 
AF. 
A recent meta-analysis of integrated care has demonstrated that it is a highly 
effective method of management in the AF population.326 The method of care is that 
of the patient being the central focus, being provided education and tools to enable 
self-empowerment and management of their condition.17 The care of the patient is 
done with the assistance of their treating cardiologist/electrophysiologist, AF nurse 
and the use of decision support technology to assist with guideline adherence. Together 
this team utilises a multidisciplinary team were required including the primary care 
physician, exercise physiologist, sleep physician, dietician, pharmacist, 
endocrinologist, and psychologist.326  
 
1.7.1.2 Rate Control 
Rate control is recommended in the guidelines although they do also state that there is 
little robust data to support the best type and the intensity of rate control therapy.17 
This is due to much of the data coming from observational studies as well as short term 
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cross over trials.327-330 In the acute setting, particularly that of rapid new-onset AF, rate 
control is important. This is often delivered in the form of beta-blockers and diltiazem 
or verapamil as these have rapid effectiveness at high sympathetic tone.330-334 It is also 
important to firstly evaluate the cause of the rapid rates, by investigating if due to an 
infection, anaemia, endocrine imbalance or pulmonary embolism. The guidelines 
suggest in the setting of acute heart rate, left ventricular function should be evaluated, 
if there is signs of a decreased function or heart failure then low dose of beta-blocker 
is recommended, with the use of digoxin if required.17 For those with stable function, 
beta-blocker, diltiazem or verapamil is suggested with the addition of digoxin if 
required. Amiodarone is suggested as useful as a last resort therapy. Ongoing 
maintenance such as avoiding bradycardia and repeat echocardiography to further 
manage or determine choice of long-term maintenance is recommended. Urgent 
cardioversion should be considered for patients in rapid AF who are unstable.17 
It is unclear what the optima heart rate for AF patients is. The Rate Control 
Efficacy In the Permanent Atrial Fibrillation (RACE) II study randomised a large 
group of permanent AF patients to different heart rates.335,336 Despite this there was no 
statistical difference in the outcomes of clinical events in between the two groups. The 
Rate-control versus rhythm-control in atrial fibrillation (AFFIRM) study was designed 
to assess the two common factors in AF management.337 The outcomes of this 
suggested that rate control should be the primary approach to managing AF patients. 
Compared to rhythm-control it was associated with a decrease incidence of adverse 
events but did not have any difference in morality. When combined the RACE and 




In patients where medications fail, and the patients remains symptomatic an 
alternative therapy is that of atrioventricular node ablation and implantation of a 
pacemaker. Based on recent data from randomised trials rate control may have a 
limited role in patients with AF and heart failure.339-341 This procedure is considered 
to have minimal complications and the risk of long-term mortality is low.342,343 This 
procedure does remove the hearts natural pacemaker therefore the patient becomes 
entirely pacemaker-dependent for the remainder of their life as this is irreversible. 
 
1.7.1.3 Rhythm Control 
While it is often the consensus amongst clinicians is by maintaining sinus rhythm the 
outcomes of AF patients are improved, the data in fact all the clinical trials to date 
comparing rate and rhythm control have remained neutral.337,344-350 Despite this there 
is evidence to also demonstrate that antiarrhythmic drugs when compared to placebo 
double the rate of sinus rhythm.346,351-354 Pharmacological restoration by use of 
antiarrhythmic drugs is a useful method of reversion to sinus rhythm.355-357 In terms of 
the drugs of choice, flecainide along with highly potent amiodarone, have been shown 
to be more effective than sotalol.358-360 Aside from drugs, electrical cardioversion by 
the use of direct electrical current is a quick and effect method of sinus rhythm 
restoration.361,362 This is best performed when the electrodes are positioned anterior-
posterior as this generates a stronger shock field to the left atrium and has been shown 
to be more effective.363,364  
It is important to consider carefully the drug of choice as there can be 
significant side effect associated with anti-arrhythmic drugs. Amiodarone while highly 
effective can results in a myriad of potential organ damage including the liver, lung, 
cornea, skin, and thyroid gland. Flecainide is also effective,353,365  but should be 
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avoided in those with ischaemic heart disease or heart failure as it can promote 
ventricular arrhythmias.366 Sotalol is also very common but does come with the risk of 
torsades de pointes,367 so caution needs to be taken when introducing this drug. Other 
drugs that are commonly used outside of Australia are: dronedarone, propafenone, 
quinidine and dofetilide.  
For highly symptomatic patients and those who are resistant to anti-arrhythmic 
therapy catheter ablation is also used as a treatment for AF.368,369 Several studies have 
shown that compared to antiarrhythmic therapy catheter ablation is more effective in 
the maintenance of sinus rhythm.370-375 A recent review of the literature assessed the 
outcomes of AF ablation on persistent and long-standing persistent patients. This 
demonstrated that the single procedure efficacy was 43%, this increase to 69% 
following multiple procedure with and without antiarrhythmic drugs.376 However the 
procedure does come with risk of complications due to the invasiveness and length of 
the procedure. It has been shown in a systematic review comprised of over 83,000 
patients the overall complication rate was 2.9% with procedure related mortality 
0.005%.377  However, there are emerging signals in the literature that suggest that there 
may be greater benefits in some subsets of patients. The recent Catheter Ablation for 
Atrial Fibrillation with Heart Failure (CASTLE-AF) study has provided interesting 
results. Patients with heart failure had a significantly lower rate of the composite end 
point of death from any cause or hospitalisation for heart failure compared to standard 
medical therapy (HR: 0.62, 95% CI: 0.43-0.87, p=0.007).339  Similarly the Catheter 
ablation versus medical rate control in atrial fibrillation and systolic dysfunction 
(CAMERA-MRI) study in patients with idiopathic cardiomyopathy comparing 
ablation to rate control in persistent AF patients using loop recorders to assess 
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recurrence demonstrated an improvement in heart failure in the ablation arm assessed 
using CMR.340 
 
1.7.2 Integrated Care Approach 
To date the management of atrial fibrillation has been suboptimal, recently evidence 
has demonstrated that these strategies have been inadequate in the care of patients with 
AF. The Euro heart Survey has shown that despite the provided guidelines we are 
seeing poor adherence to these resulting in an increase in morbidity and mortality.294 
Recent data has shown the same outcomes, the Global Anticoagulation Registry in the 
field (GARFIELD) highlighted significant inadequacies.378 At diagnosis of AF 61% 
of patients were not prescribed anticoagulation. While anticoagulation was associated 
with a 35% lower risk of death, it was not prescribed in 37% patients who had a higher 
risk of AF due to CHA2DS2-VASc ≥2. Perhaps some of the reasons for the non-
adherence to guidelines is complex. There is a growing number of patients with 
multiple problems, healthcare systems are at capacity, there is an inability for a single 
professional to adequately perform management of AF, resultant in fragmented care.  
The chronic care model originally developed some time ago, found the need to 
develop alternative models of care than what was traditionally being undertaken.379 
This has provided the grounding for the integrated care approach. There have been 
several effective examples of chronic care models particularly that of heart failure380 
and acute coronary syndromes.381 To date, AF has not been managed as a chronic 
condition with recent studies highlighting the need for chronic care. Recent data 
suggests integrated care for patients with AF may be a solution to improve adherence 
and reduce hospitalisations.  
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A randomised controlled trial demonstrated that a multi-disciplinary integrated 
care clinic which is nurse-led, protocol driven, guideline-based clinic may provide 
better outcomes. Patients who were in the integrated care group showed a relative risk 
reduction of 35% of the primary composite endpoint of cardiovascular hospitalisation 
and mortality.382 A meta-analysis of integrated care in AF demonstrated that while 
there was a reduction in all-cause mortality and cardiovascular hospitalisations, there 
was no significant impact on AF-related hospitalisations or cerebrovascular events.326  
A pilot study, the Before and After study recruited patients from the emergency 
department.383 Those who presented due to AF were provided an appointment in a 
dedicated AF clinic within seven days of their presentation. This clinic was run by a 
nurse practitioner and electrophysiologist. Management was systematically 
undertaken to assess causative factors, symptoms, quality of life and stroke risk. 
Patients were provided a treatment plan, inclusive of rate, rhythm control and 
anticoagulation based on guidelines. Patients were then contacted by phone at three 
months and completed questionnaires. These patients were compared with a 
propensity matched cohort with a primary composite endpoint of all-cause death, 
cardiovascular hospitalisations and ED visits due to AF. The primary composite 
endpoints in this study were statistically significant (OR: 0.71, 95% CI; 0.50-1.0, 
p=0.049). 
An Australian study, the Standard versus Atrial Fibrillation specific strategy 
(SAFETY) study was a multicentre, randomised controlled study of patients admitted 
with chronic, non-valvular AF.384 The integrated care approach was that of a home 
visit by a cardiac nurse within two weeks of discharge, educational information 
package if required, referral to other healthcare providers where required and then the 
treating medical team were provided with recommendations of optimal treatment. The 
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primary endpoints were all-cause death or unplanned readmission. Interestingly the 
findings of this study were negative with no significant difference in the primary 
outcome of all-cause hospitalisations and mortality (HR: 0.97, 95% CI: 0.76-1.23). 
Despite this there were proportionately more days alive and out of hospital for those 
in the intervention group this did not result in prolonged event-free survival. 
 
1.8 THROMBOGENIC RISK FOLLOWING ABLATION 
1.8.1 Stroke and the Relationship with AF 
It is well documented that stroke is the most devastating complication of patients with 
AF with approximately one third of ischemic strokes attributed to atrial fibrillation.385 
It has been well established that AF is a risk factor for systemic thromboembolism, 
ischemic stroke, and transient ischaemic attack, with an almost five-fold increased 
associated risk.37 The mechanisms behind this is believed to be the formation of 
thrombus in the left atrium due to a decreased blood flow in the left atrial appendage.386 
While thrombus formation occurs primarily in the left atrium, the mechanisms are 
complex and somewhat poorly understood, with factors such as mechanical 
dysfunction, clotting, endothelial dysfunction, inflammation and platelet activation as 
potential contributors.387 
Vichow’s triad has described the three factors that are responsible for the 
development of thrombus being abnormal blood flow and stasis, endothelial 
dysfunction and hypercoagulability.388 The Vichow’s triad perhaps suggest that it is 
not only the abnormal blood flow but perhaps the role of the thrombus formation as a 
results of the fibrillation left atrium. As such the use of anticoagulation as a means of 
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thrombus prevention given the close relationship between stroke and AF, is one of the 
key components in the management of patients with AF. 
 
1.8.2 Risk of Stroke Following Ablation 
It is not clear if eliminating AF will result in a reduction in stroke risk.17 Despite this 
a large multicentre registry has demonstrated that successful elimination of AF 
following ablation resulted in lower stroke rates than those treated medically, indeed 
the rates of stroke and mortality were indifferent from the general population.389 
Similarly another study has shown favourable outcomes with comparable stroke rates 
between those following ablation and those without AF.390 A meta-analysis assessing 
the impact AF ablation has in reducing stroke in comparison to anti-arrhythmic therapy 
revealed in thirteen randomised control trial demonstrated that there was no difference 
in the rate of stroke or TIA between the ablation and drug therapy group.391  Several 
studies have looked at risk of stroke, a large Danish cohort study evaluated the risk of 
thromboembolism and serious bleed following anticoagulation use and ablation. This 
found over almost three and a half years of follow-up and the rate of thromboembolism 
with (0.56, 95%CI 0.40-0.78) and without (0.64, 95% CI 1.25-3.35) anticoagulation 
were comparable, with an incidence of 1.8% cases identified.392 The Swedish national 
health registry reports that 30% of patients had discontinued anticoagulation therapy 
within the first year following catheter ablation. This resulted in patients with a 
CHA2DS2-VASc score having a higher rate of ischemic stroke following 
discontinuation of warfarin, 1.6% versus 0.3% per year compared to those who 
remained on warfarin.393 A large multicentre study assessing cessation at 3-6 months 
following ablation demonstrated during follow up 0.07% of those off anticoagulation 
and 0.45% on anticoagulation had an ischemic stroke (p=0.06). While non-randomised 
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this does suggest a benefit to continuation of anticoagulation following successful AF 
ablation.394  
A sub-study of the TRENDS study  demonstrated in patients who were 
monitored at the time of their stroke, only 30% were in AF at the time of the event.395 
However, a recent meta-analysis has suggested that this lack of temporal association 
with arrhythmia may be a consequence of the type of data collection that was 
included.396 This suggested that subclinical AF predicts clinical AF and is associated 
with increased risk of stroke albeit lower than the risk descried for clinical AF. 
Therefore, perhaps while ablation reduces AF one of the leading causes of stroke this 
may not be related to a subsequent reduction in stroke risk. While cessation of 
anticoagulation following apparent successful ablation seems relatively safe, there still 
remains a lack of conclusive data, particularly in the absence of large randomised 
clinical studies. 
The answer may come when we see the results of the Optimal Anti-
Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation 
(OCEAN) trial.397 This is a prospective, multicentre, open-label, randomized trial, with 
a primary endpoint being composite of clinically overt stroke, systemic embolism, and 
convert stroked based on MRI. This study is currently enrolling patients and may assist 







Chapter 2: Screening Australia Wide for 
overAll pREvalence of Atrial 
Fibrillation: AWARE-AF Study 
2.1 INTRODUCTION 
It is well established that atrial fibrillation (AF) is emerging as a global epidemic with 
approximately 33.5 million individuals affected worldwide.1 In the Asia Pacific 
region, the prevalence of AF is higher compared to the rest of the world due to the 
proportionally higher aged population and the established increase in AF risk by 
age.251  A recent review has estimated that there will be over 70 million people with 
AF in the Asia Pacific region by the year 2050, which is 12-fold higher than what is 
predicted for the United States.2,251,252 In Australia, the prevalence of AF has only been 
estimated based on international epidemiological studies.5 Ball et al applied the 
international AF prevalence statistics to Australian adult population and predicted an 
AF prevalence of 6.4% (600,000 individuals) by 2034.  
Given there is a large percentage of the population who have asymptomatic AF 
estimated at approximately one-third of patients, screening potentially enables the 
detection of AF in these patients.15,16 Multiple studies have been undertaken to screen 
for AF; the majority were observational, with variable detection rates based on the 
population screened ranging from 0.8% up to 5.33% of detected AF.398,399 The 
prevalence of detected AF varied from 0.5% to over 5%, when these are combined the 
weight average for newly detected AF was around 0.9% (95% CI; 0.7-1.1).14 In 
addition to detection of individual cases, screening for AF undertaken by organisations 
like Arrhythmia Alliance, StopAfib and Hearts4Heart which partner with patients, 
government and medical organisations, help increase public awareness. In Australia, 
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as part of the Heart Rhythm Society AF awareness week to raise knowledge of the 
disease and associated risk factors in conjunction with screening for individual cases, 
we collected prospective data on risk profile, predictive risk and screened individuals 
for AF. 
In this study, we report on the clinical characteristics and outcomes of 
screening that took place in Australia and New Zealand over 2016-2018. We aimed to 
evaluate the risk prediction of AF in the general population through the use of the 
CHARGE-AF risk score,400 determine the detection rate of AF on single point ECG 
screening, and assess blood pressure (BP) control in the community and describe the 
distribution of different stages of hypertension as per the European Society of 
Cardiology guidelines.56 
 
2.2  METHODS 
2.2.1 AF Screening Setting 
Screening was performed as part of AF Awareness Week, which is an annual event 
undertaken across Australia and New Zealand. This campaign was established by the 
APHRS/HRS and undertaken with the assistance of Hearts4Heart a patient advocacy 
group for heart rhythm disorders in Australia.  
Screening stations were positioned in hospital foyers and pharmacies 
throughout Australia and New Zealand inviting the general public. If agreeable, a 
participant was seated, consented to the process and the following was recorded: an 
automated BP, a single lead ECG on a handheld device and a health questionnaire. 
ECG recording, BP measurement and education delivery were undertaken voluntarily 
by doctors, nurses, pharmacists and allied professionals. Of note due to the number of 
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centres (186) undertaking screening, some pharmacies (64) were limited to BP and 
questionnaire completion only with no access to ECG recording. The study was 
approved by the Human Research Ethics Committee of the Royal Adelaide Hospital 
and the University of Adelaide, Adelaide, Australia. 
 
2.2.2 Definitions 
Atrial Fibrillation: AF was defined as a supraventricular arrhythmia that is 
characterized by rapid and irregular activation in the atria without discrete P waves on 
the surface ECG.401 Diagnosis was confirmed by an electrophysiologist blinded to the 
individuals clinical characteristics.  
 
Exercise: Exercise was categorised using the criteria from the validated international 
physical activity questionnaire (IPAQ)402 as vigorous which included aerobics, 
running, fast cycling or fast swimming; and moderate which included brisk walking, 
moderate cycling and moderate swimming.  
 
Alcohol Intake: Alcohol intake was determined by self-reported number of standard 
drinks consumed on a weekly basis.  
 
Blood Pressure: To classify hypertension we used the current ESC guidelines as 
follows: systolic BP (SBP) <140 mmHG as normal; SBP 140-159 mmHG as grade 1 
hypertension; SBP 160-170 mmHG as grade 2 hypertension;  and SBP >180 mmHG 




2.2.3 AF Detection 
Two devices were used for ECG recording and analysis. One was the AliveCor 
KardiaMobile (AliveCor Inc., USA) which is a validated device for detecting atrial 
fibrillation29 and is used by placing fingers on small electrodes and recording a 30 
second single lead ECG on a smart phone. The other device used was the PM-10 ECG 
device (Contec Medical Systems, China; Figure 1). All ECGs were reported by a 
cardiologist and suspected AF episodes were manually adjudicated by two 
electrophysiologists. All participants were provided a copy of their risk score and a 
recommendation to follow. This included focusing on their individual risk factors and 
in the event of AF detection seeking a review from their general practitioner. 
 
2.2.4 Health Condition Questionnaire 
In order to calculate an AF risk score, patients were asked to complete a questionnaire 
regarding their individual health status (Figure 2). Collected information included date 
of birth, height, weight, smoking status, prior diagnoses of hypertension, diabetes, 
heart failure, myocardial infarction, stroke, obstructive sleep apnoea, cardiac surgery, 
device implant, or prior AF diagnosis. Physical activity levels and alcohol intake were 
also recorded.  
 
2.2.5 AF Risk Score Calculation 
Individualised 5-year AF risk score was calculated, and participants were provided 
with a graphical risk of AF (Figure 3). To establish risk of AF development, the 
CHARGE-AF scoring system was used.400,403 This simple, validated scoring system 
provides a 5-year AF risk prediction based on age, race, height, weight, smoking, 
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systolic and diastolic BP, hypertension treatment, diabetes, history of heart failure and 
history of myocardial infarction. The CHARGE-AF has two models; the simple model 
which utilises the above measures and the advanced model which requires a 12 lead 
ECG. The simple model was used in this study. 
Additionally, the CHA2DS2-VASc score was used to predict the annual risk of 
stroke for patients with AF. Patients scored 1 point for chronic heart failure, 
hypertension, diabetes, vascular disease, age 65-74 years and female sex, and 2 for age 
≥75 and prior stroke/transient ischemic attack/embolism. Women without other stroke 
risk factors were scored 0.404  
 
2.2.6 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean ± standard deviation (SD) or median and 
interquartile range as appropriate. For categorical variables, differences between 
groups was compared using a Chi-squared test. Continuous variables were compared 
by independent t-test or Mann-Whitney U test where appropriate. A p-value of p<0.05 
was considered statistically significant. All statistical analysis was performed with 
SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA). 
 
2.3 RESULTS 
2.3.1 Baseline Characteristics 
A total of 2586 participants undertook screening. Of those, 2338 had complete data 
and were included in this analysis (Figure 4). Mean age was 53.2 ± 16.3 and the 
majority were female (68.4%). Mean body mass index (BMI) was 27.2 ± 5.4 Kg/m2 
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and 26.3% were obese (BMI≥30 Kg/m2) (Table 1). Mean BP measured 131.4 ± 17.8 
mmHG systolic and 79.8 ± 10.9 mmHG diastolic.  
 
2.3.2 AF Detection 
AF was detected in 4 participants, 3 of whom had a prior diagnosis and 2 were already 
on oral anticoagulants. The proportion of detected AF using the screening program 
was 0.2%. Of the detected AF cases (n=4), 2 were female and the mean age was 72 ± 
9 years and the mean BMI was 29.9 ± 6.1. Three patients had hypertension, mean BP 
for them was 134/84 mmHG.  
In terms of other findings on the day, there were 36 participants who had 
isolated ectopic beats, 106 in sinus tachycardia, 77 in sinus bradycardia, 19 had 
intraventricular conduction delay, 1 participant had an atrial couplet and 1 patient had 
a short non-sustained run of ventricular bigeminy.  
 
2.3.3 Prior Diagnosis of AF 
Participants were asked in the questionnaire if they had a prior history of AF. In total 
77/2338 (3.3%) of the cohort had a prior diagnosis of AF, 46 (59.7%) were female, 31 
(40.3%) male. Mean age 64 ± 13, with a mean BMI 29 ± 6. Not unsurprisingly, AF 
risk factors were more common in patients with a prior diagnosis of AF. For those with 
AF compared to without AF the prevalence was: hypertension 50.6% versus 21% 
(p<0.0001), diabetes 14.3% versus 7.3% (p=0.05), OSA 15.6% versus 5.9% 
(p=0.005). Those with AF also had a higher prevalence of prior stroke 14.3% versus 
1.6% (p<0.0001), prior surgery 16.9% versus 2.9% (p<0.0001) and pacemaker implant 




2.3.4 Risk Factors by Race 
Previous studies have demonstrated the importance of race in developing AF, with 
Caucasian race being associated with higher risk.403 In our study, the majority of the 
cohort were Caucasian (69%), followed by Asian (10%), and Indian (5%) with 10% 
not reported (Figure 5). Compared to non-whites, whites/Caucasians were 
significantly older (54.8 ± 16.1 versus 49.7 ±16.3 years, p<0.001) and had a 
significantly higher BMI (27.6 ± 5.6 versus 26.4 ± 5.1 Kg/m2, p<0.001). While there 
was no significant difference in hypertension prevalence (p=0.28), whites had a higher 
mean BP on the day 132.9±17.9 compared to 128±17.2 (p<0.001). Non-whites had a 
higher prevalence of diabetes 11.6% compared to 7.5% in whites (Table 1). 
 
2.3.5 CHARGE-AF Score 
Based on the questionnaire the median CHARGE-AF score for the population was 
0.54% [0.14-2.11]. This was significantly higher in whites 0.59 [0.17-2.2] compared 
to non-whites 0.41 [0.1-1.66] (p<0.001). This was reflective of a relatively low risk 
population, as demonstrated by the age and risk factors seen in these participants. Of 
interest when stratified by sex, males presented with a higher median risk of AF 1.05 
[0.23-4.25] compared to females 0.45 [0.11-1.42] (p<0.001; Figure 6). Similarly, 
males presented older 55 ± 17 versus 52 ± 16 (p=0.001), with higher mean blood 
pressure 136/82 versus 129/79, more sleep apnoea 18% versus 5.5% (p<0.001), 
diabetes (12% versus 7% (p<0.001) and myocardial infarction 6% versus 1% 




2.3.6 Hypertension Control 
As part of AF risk factor awareness, we aimed to assess participants’ BP control to 
raise awareness of hypertension and assess BP control across an unselected cohort. Of 
those with no prior diagnosis of hypertension, 76.6% had a normal BP, 19.7% had BP 
readings consistent with grade 1 hypertension, and 3.1% had grade 2 and 0.6% had 
grade 3 hypertension. Of those with a prior diagnosis of AF, 48.9% had normal BP’s 
on the day, while 36.4% had grade 1 hypertension and a further 14.7% had BP 
measurements consistent with grade 2 or 3 hypertension, indicating poor BP control 
despite self-reporting a diagnosis of hypertension (Figure 7).  
 
2.3.7 CHA2DS2-VASc Score 
Of the 77 patients with a prior diagnosis of AF, the mean CHA2DS2-VASc score was 
3 ± 2 with 6 (7.8%) having a CHA2DS2-VASc of 0. 19 (24.7%) participants had a 
CHA2DS2-VASc score of 1. 18 (23.4%) had a score of 2. 13 (16.9%) had a score of 3, 
and 21 (27.3%) scoring 4 or more. In this cohort 71 (92.2%) had a CHA2DS2-VASc 
score of ≥1. Of these who had a CHA2DS2-VASc >1, 44 (61.9%) were not on oral 
anticoagulation.  
 
2.3.8 Performance of Automated ECG Analysis 
The total number of ECGs performed in this event was 2089. 948 were screened using 
the AliveCor device and the remainder with the PM-10 device. Of those screened with 
AliveCor, 381 were excluded either due to short duration of recording below 30 
seconds (n=186), or due to inability to accurately match the ECG to the participants 
(n=195). Of the remaining 567 ECGs that were included, the automated algorithm 
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accurately detected the rhythm in 496 ECG, reported AF in 16, failed to classify the 
ECG in 55 participants. Following manual adjudication, only 2 of the suspected 16 AF 
cases were diagnosed as AF. When able to provide a classification (90% of the ECGs), 
the AliveCor automated algorithm had a sensitivity of 100% and specificity of 97.5% 
for detection of AF, with a positive predictive value of 12.5%. 
A further 1141 were performed using the PM-10 device. This did not display a 
machine generated diagnosis therefore there were no incorrect machine generated 
interpretation. 1016 were interpretable, and a further 123 were unable to be accurately 
interpreted due to artefact.  
 
2.4 DISCUSSION 
2.4.1 Major Findings 
There is a paucity of data on the community risk of AF in Australia. In addition, the 
utility of population screening is questioned. This study provides context in the setting 
of community awareness screening, identifying the following: 
1. Detection rate of AF following community screening is relatively low; 
2. The 5-year risk of developing AF as characterised by CHARGE-AF score was 
generally low (0.54%) 
3.  The predictive 5-year risk was significantly higher in the Caucasian population 
compared to non-Caucasian. Similarly males presented with a higher risk 
compared to females 
4. A significant proportion of participants with a prior diagnosis of hypertension 




5. Of the patients who had a history of AF, 60% who had a CHA2DS2-VASc >1 
were not on oral anticoagulation.  
6. The type of device used and process in which the ECG is attained is important 
due to significant amounts of artefact, with the AliveCor having a positive 
predictive value of 12.5%. 
 
2.4.2 Current Guideline Recommendations 
The European Heart Rhythm Association Consensus Statement in 2017 defines types 
of screening and recommends this as a useful way to detect undiagnosed AF.14 The 
2016 the European Society of Cardiology (ESC) AF management guidelines included 
a class 1 level B recommendation for opportunistic screening for AF for patients >65 
by use of pulse or ECG rhythm strip, and additionally a class IIb level B 
recommendation for systematic ECG screening in those >75 years old or those who 
are at high risk of stroke.17  
 
2.4.3 Screening Studies for Identification of AF  
There have been many screening studies over the last two decades largely due to the 
advances in technology over this time. It has been shown that the use of BP monitors, 
handheld ECG recording devices, and smartphone applications are superior forms of 
detection when compared with pulse palpation.23 AF detection large depends on the 
type of screening, population and number screened as shown by the differing rates of 
detection in previous studies. Proietti et al looked at over 52,000 participants as part 
of a voluntary community AF screening campaign in Belgium and found 1.1% new 
AF cases detected.18 Similarly, LePage undertook screening of the general public 
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following a media campaign and yielded only a 0.2% detection of AF.405 To date there 
has only been three studies from Australia assessing feasibility opportunistic 
screening.19-22 One was performed across 10 pharmacies of 1000 participants who 
were aged ≥65 undertaken using handheld ECG, and found the proportion of new AF 
individuals to be 1.5%.22 The Busselton Study of 1770 participants found a prevalence 
of 4.9% in those aged over 60 years. A recent study of 8,272 individuals in the AusDiab 
study reported 1.4% of baseline ECG’s were in AF.7 The prevalence in New Zealand 
was 1.7%, this rose to approximately 5% for those aged over 55 years.406 In Australia 
the prevalence is estimated to be between 1.4 and 5%.5-7  
 
2.4.4 Tools Used for Screening 
While detection of AF can be facilitated by regular pulse checks, other irregularities 
can be mistaken for AF. Common tools used for screening with various sensitivity and 
specificities include the Zenicor EKG® (Zenicor Medical Systems), sensitivity 96% 
and specificity 97%. The MyDiagnostik (Applied Biomedical Systems BV, The 
Netherlands), sensitivity 95% and specificity 93%. The Omron HCG (Model HCG-
801, Omron Healthcare Europe, the Netherlands) monitor, 98.7% sensitivity and 
specificity 76.2%. The AliveCor (AliveCor Inc., USA), sensitivity 98% and specificity 
97%.13,26-29 In our study, the AliveCor was able to provide an ECG classification in 
90% of ECGs, with a sensitivity of 100% and specificity of 97.5% for detecting AF. 
 
2.4.5 CHARGE-AF Score  
Interestingly in this study by using the predictive 5-year CHARGE-AF score we were 
able to demonstrate that Caucasians were significantly more likely to develop AF 
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compared to non-Caucasians. Additionally, we found that by use of the risk score 
males presented with more risk factors compared to females, this also corresponded 
with a significantly greater risk of AF. This has not been demonstrated previously in 
an Australian and New Zealand population. 
 
2.4.6 Blood Pressure Screening in the Community 
While a single time-point BP measurement in a less-than-ideal screening situation may 
not truly reflect the individual’s BP control, it was of interest that a significant 
proportion (3.3%) of patients with a prior diagnosis of hypertension had a systolic BP 
of >180 mmHg. This potentially indicates inadequate management of hypertension 




As with all opportunistic screening events, this study comes with innate selection bias. 
While providing potentially useful information regarding prevalence in a non-selected 
population, the screening was not performed in a systematic approach to allow 
epidemiological inferences. The individual AF detection could have been higher had 
there been more ECG-recording facilities more widely available across the screening 
sites. However, it is important to recognise that the aim of the campaign was not purely 
for individual AF detection, but also to improve public awareness for AF and its risk 
factors. The dynamic nature of BP makes assessing global BP control by a single time-
point BP reading very difficult. However, it remains alarming that a significant number 
of participants with prior diagnosis of hypertension had very high BP readings on 
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screening, and a further proportion likely have undiagnosed hypertension and were 
advised to seek medical attention. While this study was inclusive of all races, a much 
larger cohort would be required to establish AF prevalence, particularly in the 
Aboriginal, Torres Strait Islander and Maori ethnic groups who are generally under-
represented in such studies. 
 
2.6 CONCLUSIONS 
Screening for AF provided an opportunity to assess detection of AF in an Australian 
and New Zealand the general population. Screening enabled further awareness and 
education of AF and risk factors. This screening event found a very low detection of 
AF in the Australian and New Zealand population. Additionally, while the overall 5-
year risk prediction of AF was relatively low, males presented with a stronger risk of 
AF than females. The limitations identified in the detection and evaluation of risk 




2.7 TABLE AND FIGURE LEGEND 
 
TABLE 1: PARTICIPANTS CHARACTERISTICS 
Overall baseline characteristics of the participants, with the risk factors dichotomised 
by race 
TABLE 2: PREDICTIVE 5-YEAR AF RISK BY SEX 
 
FIGURE 1: TECHNOLOGY USED FOR SCREENING 
Example of the 2 devices used for screening along with the ECG tracing they produce. 
1A is the PM-10 developed by Contec Medical, this is used by placing the hands over 
the sensors to record ECG. 1B is the AliveCor Kardia device, this is used as displayed 
by placing fingers onto the sensors to record the tracing. 
FIGURE 2: EXAMPLES OF QUESTIONNAIRE  
Example of the original questionnaire used as well as an example of one of the Apps 
used for the questionnaire to establish risk factors for the participants. This provides 
an example of how the selection of exercise and alcohol were able to be selected. The 
guide for taking the ECG at the required time point and shown is the final outcome of 
risk of AF for the participant based on the CHARGE-AF scoring system. 
FIGURE 3: EXAMPLE OF APP USED 
Example of the application used for the screening, participants answered each question 
before it proceeded to the next one. The answers were then presented to the patient in 
an image to demonstrate to them the risk of developing AF over the next 5 years based 
on the CHARGE-AF score 
FIGURE 4: FLOW DIAGRAM 
Flow diagram of the participants screened and final cohort used for analysis. 
FIGURE 5: DISTRIBUTION OF ETHNICITY 
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Pie chart with the breakdown of the participants based on the ethnicity. 
FIGURE 6: PREDICTIVE 5-YEAR RISK OF AF BY SEX 
Scatter plot demonstrating predictive 5-year risk of AF development stratified by sex 
FIGURE 7: RESULTS OF HYPERTENSION SCREENING 










TABLE 1: PARTICIPANTS CHARACTERISTICS 







Age 53.2 ± 16.3 54.8 ± 16.1 49.7 ± 16.3 <0.001 
Female gender (%) 1599 (68.4) 1117 (69) 482 (67.1) 0.38 
Body mass index 27.2 ± 5.4 27.6 ± 5.6 26.4 ± 5.1 <0.001 
Smoking (%) 338 (14.5) 260 (16) 78 (10.9) 0.003 
Hypertension (%) 597 (25.5) 424 (26.2) 173 (24.1) 0.28 
Systolic blood pressure (mmHg) 131.4 ± 17.8 132.9 ± 17.9 128 ± 17.2 <0.001 
Diastolic blood pressure (mmHg) 79.8 ± 10.9 80 ± 10.8 79.6 ± 11.1 0.21 
Diabetes (%) 204 (8.7) 121 (7.5) 83 (11.6) <0.001 
Heart Failure (%) 46 (2) 29 (1.8) 17 (2.4) 0.35 
Myocardial Infarction (%) 68 (2.9) 50 (3) 18 (2.5) 0.44 
CHARGE AF Risk Score 0.54 [0.14 - 2.11] 0.59 [0.17 - 2.2] 0.41 [0.1 - 1.66] <0.001 
Known AF (%) 77 (3.3) 60 (3.7) 17 (2.4) 0.09 
AF on ECG (%) 4 (0.2) 3 (0.2) 1 (0.1) 0.92 
Sleep Apnea (%) 170 (7.3) 112 (6.9) 58 (8.1) 0.31 
Prior stroke (%) 54 (2.3) 42 (2.6) 12 (1.7) 0.17 
Surgery (%) 90 (3.8) 69 (4.3) 21 (2.9) 0.12 




TABLE 2: PREDICTIVE 5-YEAR AF RISK BY SEX 
 
CHARACTERISTIC MEN WOMEN P VALUE 
Risk Score (median) 1.05 [0.23-4.25] 0.45 [0.11-1.42] <0.001 
Age 55 ± 17 52 ± 16 0.001 
Body Mass Index 27.6 ± 4.7 27 ± 5.8 0.019 
SBP (mmHg) 136 ± 17 129 ± 18 <0.001 
DBP (mmHg) 82 ± 11 79 ± 11 <0.001 
Sleep Apnea (%) 82 (11.1) 88 (5.5) <0.001 
Smoking (%) 131 (17.7) 207 (12.9) 0.002 
Myocardial (%) 46 (6.2) 22 (1.4) <0.001 
Heart Failure (%) 24 (3.2) 22 (1.4) 0.002 
Hypertension (%) 200 (27.1) 397 (24.8) 0.249 
Diabetes (%) 88 (11.9) 116 (7.3) <0.001 













































Chapter 3: RegReSsive Effect of weight-loss 
and risk factor modification on 
AF: The REVERSE-AF Study 
3.1 INTRODUCTION 
Atrial Fibrillation (AF) is a progressive disease. Over the course of time, many patients 
progress from paroxysmal to persistent AF and eventually more sustained forms of 
AF.35,87,203 The association of cardiovascular risk factors with the development of AF 
has been known for some time.407 Whilst this phenomenon was initially considered to 
be part of the arrhythmic process,203 more recent data suggests that both the type of 
AF and the likelihood of progression to more persistent forms of AF, are determined 
by the number of concomitant risk factors that are harboured.35,205 Indeed, progressive 
atrial remodelling has been documented in patients after successful AF ablation, 
implicating a detrimental role of persistent risk factors.207 Previous studies have looked 
at risk factors that contribute to the progression of AF to more persistent forms; 
however, none of these assessed the impact of treating risk factors to reverse AF 
disease.  
In the Long-Term Effect of Goal-Directed Weight Management in an Atrial 
Fibrillation Cohort: A Long-Term Follow-Up (LEGACY) Study,107 we demonstrated 
that intensive weight and risk factor management had a dose-dependent effect on 
overall long-term freedom from AF. The impact of weight and risk factor modification 
on the progression of AF has not yet been characterized. Here we hypothesize that 
weight-loss and concurrent risk factor management not only reduces patient AF 





3.2.1 Study Population 
This study comprised consecutive patients with symptomatic AF referred to the Centre 
for Heart Rhythm Disorders at the University of Adelaide, Australia. The details of the 
study registry have been presented in the LEGACY study408. In brief, patients included 
in the analysis had a body mass index (BMI) ≥27kg/m2. The study excluded those who 
had a history of myocardial infarction or cardiac surgery in the previous 12 months, 
significant cardiac valvulopathy or ventricular dysfunction, active malignancy, auto-
immune or systemic inflammatory diseases, severe renal or hepatic failure, and <24 
months of follow-up. 
The study was approved by the Human Research Ethics Committee of the 
Royal Adelaide Hospital and the University of Adelaide, Adelaide, Australia. 
ANZCTR Clinical Trial Registration: ACTRN12614001123639. 
 
3.2.2 Weight-loss and Risk Factor Management 
All patients were offered participation in a dedicated physician-led clinic focused on 
weight and risk factors. The weight and risk factor management program used by our 
clinic has been previously presented408,409. This is a goal-directed, motivational, 
structured program where patients received one on one individualized counselling. 
Weight was initially managed by providing a tailored program. Patients maintained a 
lifestyle journal and were provided with a meal plan with an initial target of >10% 
weight-loss. Meal replacement was prescribed if patients lost <3% at 3 months. 
Patients were advised to undertake 30 minutes of exercise 3-4 times a week with the 
aim to increase this to 200 minutes per week. Hypertension was managed with salt 
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restriction and pharmacotherapy as required. Patients were encouraged to monitor 
blood pressure 2-3 times a day. We aimed for 80% of home blood pressure readings 
to be <130/80 mmHg, with the blood pressure during rest and exercise consistently 
<130/80mmHg and <200/100mmHg, respectively. This was corroborated by in office 
blood pressure readings, exercise stress testing screening for exercise-induced 
hypertension, 24-hour ambulatory monitoring and echocardiography to ensure the 
resolution of left ventricular hypertrophy. Cholesterol and glucose intolerance was 
managed initially with lifestyle measures; however, if this was not achieved 
pharmacotherapy was prescribed. Patients underwent sleep study with continuous 
positive airway pressure therapy prescribed if their apnea-hyopnea index ≥30/hour. 
Smoking cessation was encouraged along with alcohol reduction to ≤30g/week is 
advised.  
 
3.2.3 Weight-loss Definition 
As per LEGACY study,107 weight-loss groups were divided as follows:  
• Group-1: <3% weight-loss or weight gain;  
• Group-2: 3-9% weight-loss; and  
• Group-3: ≥10% weight-loss.  





3.2.4 Categorisation of Atrial Fibrillation 
Type of AF: Based on the patients clinical history and 7-day Holter monitoring results 
patients were divided into the following groups as defined by the Heart Rhythm 
Society Consensus Statement:410 
• Paroxysmal AF:  AF episodes that are self-terminating and last less than 1 
week; 
• Persistent AF: AF episodes either lasting >7 days or requiring termination by 
cardioversion, either with pharmacotherapy or by direct current cardioversion 
(DCC) after this time. 
To assess the change in AF type, AF type was taken according to the clinical status 
over the preceding 12 months. 
 
Burden of AF: To further categorize type of AF based on AF burden, episodes were 
divided per duration at baseline and in the last 12 months of follow up:  
• Paroxysmal AF: Episodes lasting ≤48 hours (Short PAF) and episodes lasting 
>48 hours but <1 week but spontaneously reverted to sinus rhythm (Long 
PAF).  
• Persistent AF: Episodes lasting ≥1 week (Short PrsAF) and <3 months and 
episodes lasting ≥3 months (Long PrsAF). 
 
3.2.5 Arrhythmia Management 
Management of AF was undertaken in a separate dedicated AF clinic independent of 
the weight management clinic. Usage of rate and rhythm control strategies was at the 
discretion of the treating physician.  Sotalol and Flecainide were preferred anti-
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arrhythmic drugs (AAD). Amiodarone was not routinely used. Ablation was advocated 
in patients who remained symptomatic despite use of AAD and risk factor 
management. The ablation technique utilized at our institution has been previously 
described.411 AF type and burden was determined by at least annual clinical review, 
12-lead electrocardiogram, device interrogation, and 7-day Holter monitoring. In 
patients undergoing ablation, procedural success was determined after a 3-month 
blanking period. Recurrent arrhythmia was defined as any atrial arrhythmia ≥30 
seconds. The earliest date with documented AF was set as the date of arrhythmia 
recurrence. Follow-up was standard for our clinic with a follow-up duration for each 
group 48.4±18.2, 46.0±16.7, and 48.3±18.4 months respectively (p: 0.3). 
 
3.2.6 Study Outcomes 
Primary outcome was change in AF category from baseline to the last year of review. 
AF status was determined by patient symptoms, 7-day Holter monitoring, ECG or 
implantable device. Secondary outcomes included AF episode burden as assessed by 
7-day Holter, need for single or multiple AF ablation procedures, AV node ablation 
and pacemaker implantation.  
 
3.2.7 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean ± SD. Differences between the weight-loss groups 
were assessed using ANOVA procedures for baseline characteristics. A repeated 
measure ANOVA was used to assess change over time. For categorical variables, 
change in status at follow-up was compared between groups using a Chi-squared test. 
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Two-tailed p<0.05 was considered statistically significant. Statistically significant 
predictor of progression of AF was assessed using a logistic regression model. 
Candidate variables with p<0.1 in univariate analyses were considered in multivariate 
regression models. Statistical analysis was performed with SPSS version 21.0 (SPSS, 
Inc., Chicago, IL, USA). 
 
3.3 RESULTS 
3.3.1 Baseline Characteristics 
As described in LEGACY,107 of the 1415 consecutive patients with symptomatic AF, 
825 patients had a BMI ≥27 kg/m2. After screening for exclusion criteria, the final 
cohort consisted 355 patients (Figure-1): 116 in Group-1 (<3% weight-loss), 104 in 
Group-2 (3-9% weight-loss) and 135 in Group-3 (≥10% weight-loss). Baseline 
characteristics and follow-up duration (48.3±18.4, 46.0±16.7 and 48.4±18.2 months 
respectively, p=0.3) were similar for all groups (Table-1). 
 
3.3.2 Effect of Weight-loss by AF Type 
Table-2 shows the effect of weight-loss on AF type. At baseline, Group-1: Paroxysmal 
61 (53%) and Persistent 55 (47%); Group-2 had: Paroxysmal 62 (60%) and Persistent 
42 (40%); and Group-3: Paroxysmal 73 (54%) and Persistent 62 (46%). At final follow 
up, Group-1: 48 (41%) progressed AF disease from paroxysmal to persistent; whereas 
only 1 (1%) patient went from persistent to paroxysmal AF, 37 (32%) had no change 
in AF type, and 30 (25%) were free from AF at final follow up. Group-2 had: 33 (32%) 
progressed from paroxysmal to persistent, 18 (17%) who reversed from persistent to 
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paroxysmal AF and 20 (19%) had no change in AF type, while 33 (32%) were free 
from AF at final follow up. Group-3: 4 (3%) patients progressed from paroxysmal AF 
to persistent AF, while 49 (36%) reversed AF disease from persistent to paroxysmal 
AF, 12 (9%) had no change in AF type, with 70 (52%) patients free from AF over the 
final year of follow up (p=0.001) (Figure 2 and 3).  
Weight-loss was a significant univariate and multivariate predictor of AF 
regression (p=0.001). On multivariate analysis, >10% weight-loss with accompanied 
risk factor modification was associated with significantly greater likelihood of 
transition from persistent to paroxysmal AF (OR 4.3 CI: 2.7-6.8, p<0.001). At 
baseline, there was no difference in mean number of AAD between the three groups: 
Group-1 0.8±1.0, Group-2 0.7±0.8, Group-3 1.0±0.9 (p=0.1). At final follow up, while 
all the groups had reduced AAD use, Group-1 0.4±0.6 (p=<0.001), Group-2 0.5±0.6 
(p=<0.001), this was significantly greater in Group-3 0.1±0.4 (p=<0.001; Table 2). 
 
3.3.3 Effect of Weight-loss on AF Burden 
In Group-1 with paroxysmal AF, 95% (19/20 patients) had progression from Short 
PAF to Long PAF and only 7% (3/41 patients) went from Long to Short PAF group 
(p<0.001). Those with persistent AF, 47% (19/40 patients) of Short PrsAF had an 
increase in episode duration to Long PrsAF and only 20% (3/15 patients) Long PrsAF 
went to short PrsAF (p<0.001).  
Patients in Group-2 with paroxysmal AF, 61% (8/13 patients) had progression 
from Short PAF to Long PAF and 69% (34/49 patients) went from Long to Short PAF 
group (p<0.001). Those with persistent AF, 58% (21/36 patients) of Short PrsAF had 
an increase in episode duration to Long PrsAF and 80% (4/5 patients) Long PrsAF 
went to short PrsAF (p<0.001). 
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In Group-3, none of the 21 patients progressed from short PAF group to Long 
PAF group and large number of patients had reduction in AF burden with 85% (44/52 
patients) who previously had Long PAF reducing to Short PAF group (p<0.001). All 
13 patients with Long PrsAF at baseline, had a reduction in burden and went into short 
PrsAF group and only 20% (10/49 patients) who previously had short PrsAF went into 
Long PrsAF (p<0.001).  
 
3.3.4 Pacemaker, AV Node Ablation or AF Ablation 
Weight-loss had a dose dependent effect on freedom from AF. At final follow-up in 
the overall total arrhythmia-free patients: 45 (39%) patients in Group-1 (5 [13%] 
without ablation, 15 [34%] with 1 ablation, and 25 [53%] with multiple ablations); 69 
(67%) patients in Group-2 (15 [22%] without ablation, 32 [46%] with 1 ablation, and 
22 [32%] with multiple ablations) were free from AF; and in Group-3, 116 (86%) 
patients were free from AF (53 [45.5%] without ablation, 44 [37.5%] with 1 ablation, 
and 19 [17%] with multiple ablations; Table 2). There were no differences in the 
number of patients requiring AV node ablation or pacemaker implantation between 
the three groups (p=NS). 
 
3.4 DISCUSSION 
3.4.1 Major Findings 
This study demonstrates that in over-weight and obese individuals with symptomatic 
AF, sustained obesity is associated with progression of the AF disease while 
progressive weight-loss has a dose dependent “reversal” of the AF disease process. 
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Weight-loss was associated with increased long-term freedom from AF, and a 
reduction in the need for ablation and the need for multiple procedures.  
 
3.4.2 Progression of AF 
AF is a progressive disease with the majority of patients progressing from paroxysmal 
to persistent and then permanent AF over time87,412. There are dynamic adaptive 
changes in the atria, enhancing the ability of the AF not only to sustain itself, but also 
to recur (“AF begets AF”)32. Although postulated that early cardioversion would 
prevent the remodeling due to AF and allow “sinus rhythm to beget sinus rhythm”, 
restoration of sinus rhythm with early repeated cardioversion reversed electrical 
remodeling but did not impact the maintenance of sinus rhythm413. Thus the role of a 
“second factor”, an atrial substrate responsible for propagation of AF has been 
implicated412. Indeed, abnormal atrial changes have been observed even in patients 
with apparently ‘lone AF’411. A recent study has observed a progressive atrial substrate 
even after successful catheter ablation of AF207. These findings argue in favor of an 
underlying atrial substrate responsible for AF that is promoted by inadequately treated 
or unrecognized risk factors414. Cardiac risk factors such as hypertension, diabetes 
mellitus, obesity and sleep apnea have been independently shown to increase incidence 
of AF40,69,74,131. Importantly, these have been associated with structural and electrical 
remodeling of the atria that forms the substrate leading to the development and 
progression of AF46,77,78,128,415. This study confirms these observations. We found that 




3.4.3 Weight Reduction and Risk Factor Management Effect on Reversal and 
Outcomes 
It has been shown that patients on rhythm control medications are much less likely to 
progress to more persistent forms of AF as opposed to those on rate control416,417. 
However, successful ablation alone did not halt the progression of the AF 
substrate207,418.  Whether earlier intervention may alter disease progression is a subject 
of ongoing evaluation. In the current study, aggressive weight and risk factor 
management was associated with reversal in AF progression. We found ≥10% weight-
loss with management of associated risk factors was associated with significant 
reversal of the disease state with 88% of AF patients having significant reduction in 
burden and reversing to paroxysmal AF or experiencing no further AF. In addition, 
weight reduction was associated with significant reduction in need for AF ablation; 
≥10% weight-loss was associated with 45% patients not requiring any ablation and 
further 37% requiring only single ablation. 
 
3.4.4 Risk Factor Management as Future Strategy for AF Reversal 
The recognition of AF as a progressive disease, determined by ongoing remodelling 
consequent to the various underlying risk factors, calls for early and aggressive weight 
and risk factor intervention. This study adds to a growing body of evidence that risk 
factor management to treat the primary cause of the disease halts this vicious cycle and 
improves the long-term freedom from AF (Figure 4). Given the rising epidemic of 






Findings from this study are subject to biases that are inherent in observational studies. 
Measurement bias has been minimized through standardized processes in our clinic 
and the evaluation by operators blinded to the patient’s weight management strategy. 
AF burden assessment using 7-day Holter may incompletely detect AF episodes, 
especially in patients with low AF burden. Continuous monitoring was not available 
in all patients, so this may lead to asymptomatic AF not able to be captured. This 
method was utilized in both groups and thus unlikely to introduce detection bias. 
Ascertainment bias was reduced through the collection of outcomes via routine data 
sources. Given the observational nature of the data being registry based the outcomes 
were not pre-specified apriori, this is a limitation which will be addressed in a 
randomized control study. This study looks at the association of weight loss on 
progression of AF. Considering the study design, it was statistically impossible to run 
a multivariate analysis or logistic regression with so many co-variates and therefore 
was avoided. Weight-loss results in improvement in various associated risk factors 
such as sleep apnea and hypertension, no adjustments for applied rhythm control 
therapies were made, which may have also influenced progression of AF. This study 
does not provide insight into the cause-effect relationship of individual risk factors to 
the change in AF type. 
 
3.6 CONCLUSIONS 
AF is a progressive disease. Sustained obesity is associated with progression from 
paroxysmal to persistent AF; however, weight-loss and management of risk factors 
may reverse the natural progression of AF disease, resulting in those with persistent 
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AF more frequently transiting to either paroxysmal AF or no AF. These findings 





3.7 TABLE AND FIGURE LEGEND 
 
TABLE 1: BASELINE CHARACTERISTICS 
Baseline characteristics of the 3 patient groups dichotomised by degree of weight-
loss 
TABLE 2: WEIGHT-LOSS 
Table demonstrating overall follow up results of weight-loss on AF progress and 
reversal, episode duration, and requirement for procedures.  
FIGURE 1: PATIENT SELECTION  
Consort diagram of the patient selection. AF=atrial fibrillation, BMI=body mass 
index, WL=weight-loss, Parox=paroxysmal, Persis=persistent. 
FIGURE 2: CHANGE IN AF TYPE BETWEEN GROUPS 
Pie graphs demonstrating baseline and follow up of patients change in AF type. 
Demonstrative of impact of risk factor management, those who achieve optimal weight 
loss reverse the AF type to paroxysmal or no AF as shown in the green and grey. 
FIGURE 3: AF DISEASE PROGRESSION AND REVERSAL 
Bar charts showing change in AF type at following weight-loss. With green 
representing Group 1, blue representing Group 2 and orange Group 3. There was a 
stepwise decline in progression of AF based on the degree of weight loss. Similarly 
there was a step wise improvement, those who lost <3% weight less likely to reverse 
AF disease compared to those who lost ≥10% weight. 
FIGURE 4: AF DISEASE PROGRESSION AND REVERSAL WITH 
WEIGHT-LOSS 
Showing the process of AF disease progression with increase weight-loss to BMI >27 
demonstrating the transition from paroxysmal to persistent. Following weight-loss and 
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risk factor management we see a reversal of AF type, from persistent to paroxysmal or 

















N = 104 
≥10%WL 
Group-3 
N = 135 
P 
Value 
Age (years) 61  11 63  11 65  11 0.06 
Male gender, n (%) 83 (71%) 65 (63%) 86 (64%) 0.37 
Anthropometric Measures and Blood Pressure 
BMI (Kgm-2) 32.94.8 32.74.4 33.64.7 0.24 
SBP (mmHg) 146 ± 17 144 ± 17 147 ± 17 0.33 
Atrial Fibrillation Type 
Paroxysmal AF, n (%) 61 (53%) 62 (60%) 73 (54%) 0.55 
Non-Paroxysmal, n (%) 55 (47%) 42 (40%) 62 (46%) 
Atrial Episode Burden 
48 hours 29 (25%) 13 (13%) 24 (18%) 
0.39 <1 Week with No DCC 48 (41%) 49 (47%) 56 (42%) 
>1 Week OR DCC 35 (30%) 37 (36%) 49 (36%) 
3 Months 4 (3%) 5 (5%) 6 (4%) 
Metabolic Risk Factors 
Hypertension, n (%) 90 (78%) 75 (73%) 109 (81%) 0.30 
DM, n (%) 34 (29%) 28 (27%) 41 (30%) 0.35 
IGT, n (%) 8 (7%) 8 (8%) 18 (13%) 
Hyperlipidemia, n (%) 56 (48%) 45 (44%) 66 (49%) 0.70 
Coronary artery disease, n (%) 11 (9%) 12 (12%) 21 (16%) 0.31 
AHI>30, n (%) 61 (52%) 52 (50%) 69 (51%) 0.97 
Alcohol excess (>30g/week), n 
(%) 
34 (29%) 35 (34%) 42 (31%) 0.73 
Smoker, n (%) 47 (40%) 41 (40%) 50 (37%) 0.86 
Medication Use 
Mean no. of Anti-Arrhythmic 
(±SD) 
0.9±0.8 1.0±0.7 1.1±0.7 0.10 
Mean no. of Anti-Hypertensive 
(±SD) 
1.1 ±1.0 1.0±0.8 1.0±0.9 0.08 
BMI = body mass index; SBP = systolic blood pressure; DCCV = direct current; DM 







TABLE 2: WEIGHT-LOSS 
Risk Factors <3% WL Group; N = 116 3-9% WL Group; N = 104 ≥10% WL Group; N = 135 P value† 
 Baseline Follow Up‡ P value* Baseline Follow Up‡ P value* Baseline Follow Up‡ P value*  
BMI (Kgm-2) 33.04.9 33.5±5.3 <0.001 32.7±4.4 30.8±4.2 <0.001 33.74.7 28.4±4.0 <0.001 <0.001 
Mean SBP (mmHg) 146±17 139±15 <0.001 144±17 13414 <0.001 14717 12912 <0.001 <0.001 
Medication Use 
Mean no. of Anti-HTN, n 0.8±1.0 1.0±0.7 0.01 0.7±0.8 0.7±0.6 0.74 1.0±0.9 0.5±0.6 <0.001 <0.001 
Mean no. of AAD, n 0.8±0.8 0.4±0.6 <0.001 1.0±0.7 0.5±0.6 <0.001 1.1±0.7 0.1±0.4 <0.001 <0.001 
AF Type 
Paroxysmal AF, n (%) 61 (53%) - 
 
62 (60%) - 
 
73 (54%) - 
 0.55 
Persistent AF, n (%) 55 (47%) - 42 (40%) - 62 (46%) - 
Paroxysmal to Persistent AF - 48 (41%) 
 
- 33 (32%) 
 
- 4 (3%) 
 <0.001 
Persistent to Paroxysmal AF - 1 (1%) - 18 (17%) - 49 (36%) 
No Change in AF Type - 37 (32%) - 20 (19%) - 12 (9%) 
No AF - 30 (25%) - 33 (32%) - 70 (52%) 
Last AF Episode Duration  
Paroxysmal 
AF 
48hrs, n (%) 20 (17%) 1 (1%) 
 
13 (14%) 5 (5%) 
 
21 (15%) 21 (15%) 
 <0.001 
Δ to <1wk  19 (16%)  8 (8%) - 0 (0%) 
<1wk, n (%) 41 (35%) 38 (33%) 49 (47%) 15 (14%) 52 (39%) 8 (6%) 
Δ to 48hrs, n (%)  3 (3%)  34 (33%) - 44 (33%) 
Persistent 
AF 
>1wk, n (%) 40 (34%) 21 (18%) 36 (34%) 15 (14%) 49 (36%) 39 (29%) 
Δ to >3m, n (%)  19 (16%)  21 (20%) - 10 (7%) 
>3m, n (%) 15 (13%) 12 (10%) 5 (5%) 1 (1%) 13 (10%) 0 (0%) 






TABLE 2: WEIGHT-LOSS CONT. 
 <3% WL Group; N = 116 3-9% WL Group; N = 104 ≥10% WL Group; N = 135 P value† 
Total AF Freedom and Ablation 
Total Freedom from AF - 45 (39%) 
 
- 69 (67%) 
 
- 116 (86%) 
 
<0.001 





53 (45.5%) 0.001 





44 (37.5%) 0.8 





19 (17%) 0.007 
*p-Value refers to within group differences (baseline to follow-up). †p-Value refers to difference between groups over time (group-time interaction). ‡Median follow up  
48.3±18.4, 46.0±16.7 and 48.4±18.2 months respectively 




































Chapter 4: SoCio-EcoNomic StatUS Impact 
on Risk Factor Management in 
Atrial Fibrillation: CENSUS-AF 
Study 
4.1 INTRODUCTION 
The association between socioeconomic status (SES) and atrial fibrillation (AF) has 
not been well characterised. Several studies have shown various links to AF, with early 
studies suggesting the link between life events, behaviour and stress impacting 
recurrence and reversion of AF.420 The AFFIRM study assessed some socioeconomic 
factors and found that asymptomatic patients had a higher quality of life using the 
‘Ladder-of-life’ based on questionnaire (p=0.005) compared to symptomatic patients. 
Although there were no significant differences in  work and living situations, patients 
in the asymptomatic group trended to possess higher education level (p=0.06).421 The 
Atherosclerosis Risk in Communities (ARIC) Study  demonstrated that lower income 
was associated with a higher risk of AF. In addition, the same study showed the link 
between lower education level was associated with increased AF risk  in females.218 A 
large Swedish AF cohort has shown that there was a higher relative risk of all-cause 
mortality in men living in low SES neighbourhood (HR 1.49, 95% CI; 1.13-1.96) 
compared to middleclass neighbourhoods, and that time to death was shorter for those 
in the middle SES compared to low SES areas.422  
In 2015, the American Heart Association released an eloquent statement on 
social determinants of risk and outcomes for cardiovascular disease, they focused on 
the social determinants of health such as socioeconomic position, race/ethnicity, social 
support, culture, access to care and residential environment. Additionally, this looked 
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at the markers for socioeconomic position such as income, health, education, access to 
activities, political voice, social connections, environment and physical insecurity. 
While this was not centred on AF but cardiovascular disease, it suggested that to treat 
this we need to broaden and improve study designs, research programs and policies to 
focus on the social determinants of health as these may be important contributors to 
cardiovascular disease.211  
Similarly, the relationship between obesity and SES has been shown both 
internationally and within Australia.220-222 The World Health Organization has also 
demonstrated that obesity rates in high income countries have not risen as fast as those 
in low and middle income countries.423 Given the impact socioeconomics has on 
obesity and subsequently can have on various health conditions we hypothesised that 
lower SES would adversely affect risk factor management in obese individuals. We 
aimed to evaluate this in patients with AF undergoing a structured risk factor clinic 
focusing on weight and individual risk factors and therefore AF burden 
 
4.2 METHODS 
4.2.1 Study Population 
This study comprised consecutive patients with symptomatic AF referred to the Centre 
for Heart Rhythm Disorders at the University of Adelaide, Australia. The details of 
this registry have been previously presented in the LEGACY registry,408 this study is 
a sub-analysis of the LEGACY cohort. In brief, patients included in the analysis had 
symptomatic AF referred for catheter ablation and a baseline body mass index (BMI) 
≥27kg/m2 plus at least one other cardiovascular risk factor. The study excluded those 
who had a history of myocardial infarction or cardiac surgery in the previous 12 
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months, significant cardiac valvulopathy or ventricular dysfunction, active 
malignancy, auto-immune or systemic inflammatory diseases, severe renal or hepatic 
failure, and <24 months of follow-up and/or from other states. 
The study was approved by the Human Research Ethics Committee of the 
Royal Adelaide Hospital and the University of Adelaide, Adelaide, Australia. 
ANZCTR Clinical Trial Registration: ACTRN12614001123639. 
 
4.2.2 AF Freedom 
AF freedom was determined by review of the clinical history, 12 lead ECG or device 
interrogation, and 7-day Holter monitoring. AF freedom was defined as the absence of 
atrial arrhythmia >30 seconds with the earliest documented date of AF deemed 
recurrence of atrial arrhythmia.  
 
4.2.3 Weight-loss Definition 
In order to assess the overall risk factor outcomes, weight-loss was used as an objective 
measure. Weight-loss (WL) groups were divided as follows:  
• Group-1: <3% WL or weight gain;  
• Group-2: 3-9% WL); and  
• Group-3: ≥10% WL.  
 
4.2.4 Socioeconomic Status Definition 
Patients were grouped based on their socioeconomic status according to the Australian 
Bureau of Statistics Socio-Economic Indexes for Areas (SEIFA) rankings which are 
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comprised from the Australian Census data. Individuals were ranked according to 
postcode with suburbs in the lowest socioeconomic ranking ranked 1 in the most 
disadvantaged area to those ranked 10 in the most advantaged. This score reflects 
household’s incomes, employment, education, qualifications and assets.  To enable 
appropriate analysis of this cohort we divided our patients into: 
• Group 1 (ranking 1-3): Low SES Area; 
• Group 2 (ranking 4-7): Medium SES Area; and  
• Group 3 (ranking 8-10): High SES Area. 
 
4.2.5 Questionnaire 
The questionnaire was presented to all patients and was voluntary with patients 
completing this either in person or via interview. Patients were given the option not to 
answer all questions if they did not wish to disclose this information relating to their 
income. Socioeconomic factors which were covered in the questionnaire included: 
marital status, number of children, birthplace, number of siblings, education level, 
employment status, type of employment, hours worked per week, annual income level, 
retirement status, housing status, parental ethnicity, parental cardiac health, sibling’s 
cardiac health, awareness of other relatives with AF or sudden cardiac death. 
 
4.2.6 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean ± SD. Differences in normally distributed 
continuous variables between SES groups were assessed using ANOVA procedures. 
For categorical variables, between-group differences in baseline proportions were 
114 
 
compared using the Chi-squared test. Two-tailed p<0.05, with adjustment for multiple 
comparisons where appropriate, was considered statistically significant. To investigate 
the influence of baseline socioeconomic variables on AF freedom, a using Cox 
proportional hazards regression model was used, with adjustment for age and gender. 




4.3.1 Baseline Characteristics 
Of the 1415 consecutive patients with symptomatic AF, 825 patients had a BMI ≥27 
kg/m2. Baseline characteristics as defined in the LEGACY Study and follow-up 
duration (48.3 ± 18.4, 46.0 ± 16.7 and 48.4 ± 18.2 months respectively, p=0.3) were 
similar for all groups. Of the 355 patients, 318 completed the questionnaire (Refused: 
33, moved overseas: 2, English difficulties: 1). Patients were divided into their SE area 
(SEA) levels, Low SEA (Group 1; 64), Medium SEA (Group 2; 116) and High SEA 
(Group 3; 138). 
There was no significant difference in age across the three groups, 67 ± 10, 67 
± 11, and 67 ± 11 (p=0.92) for low, medium and high SES respectively. There were 
less females than males 30 (46.9%), 40 (34.5%) and 41 (29.7%) (p=0.058) for low, 
medium and high SES respectively. Body mass index across the groups is 32 ± 3.7, 
33.8 ± 5.2 and 32.8 ± 4.4 (p=0.07) for low medium and high SES respectively. There 




4.3.2 Questionnaire Outcomes 
Of the 318 patients who completed the questionnaire, 228 (71.7%) were born in 
Australia. Majority of the patients in the cohort were married (68%), mean number of 
children was 2 ± 1.2, 61% completed secondary school as their highest level of 
education, with a further 28% completing higher degrees, 54% patients had retired 
with majority of the remainder 33% working full time. For those who worked over 
half (57%) worked more than 40 hours a week. Income levels varied with 66% earning 
<$80,000/annum, 35% earned $80-200,000/annum, and 9% earning $200,000+ 
(Figure 1).  
In terms of parental background, majority of patient’s fathers were 
white/Caucasian (301), Aboriginal (3), Asian (1), Hispanic (1), Middle Eastern (3). 
Mothers were also majority white/Caucasian (304), Aboriginal (0), Asian (1), Hispanic 
(2), Middle Eastern (2). Many parents were born overseas, fathers: 125 (39%), 
mothers: 118 (37.1%). While not all patients were aware of their parent’s health, those 
who knew reported their father having: Hypertension (64), diabetes (35), coronary 
artery disease (44), AF (25), myocardial infarction or transient ischemic attack (85), 
cancer of various forms (44) and other heart conditions such as pacemaker insertion, 
valve replacements, bypass (37). For their mother they reported: Hypertension (78), 
diabetes (44), coronary artery disease (24), AF (57), mitral infarction or transient 
ischemic attack (68), cancer of various forms (42) and other heart conditions such as 




4.3.3 Outcomes in Weight Loss and SES 
Based on the degree of weight-loss, there was no difference between the SES groups 
(p=0.4; Figure 2). However, based on degree of weight-loss, marital status was 
associated with more weight loss (Figure 3A). Relative weight loss was significantly 
higher for married patients compared to those who were not married (8.28.4 versus 
5.98.3%, p=0.02; Figure 3B). There was no significant difference in the extent of 
weight loss for patients grouped by SES (p=0.45), retirement (p=0.37), income 
(p=0.45), full-time employment (p=0.34) or education level (p=0.95; Figure 4). 
 
4.4 SOCIOECONOMIC FACTORS AND AF FREEDOM 
4.4.1 Total AF Freedom  
Marriage status, income, working hours, retirement status or education level did not 
contribute to determining freedom from AF (Figure 5). Additionally, there was no 
significant influence of socioeconomic area on total AF freedom (p=0.84). 
Furthermore, the proportion of patients undergoing AF ablation did not differ between 
patients stratified by SEA (p=0.66; Figure 7).  
 
4.4.2 Ablation-Free, Drug-Free (AFDF) Freedom 
There was a significant association between socioeconomic status groups and AFDF 
outcomes. Participants in the middle SEA group were significantly less likely to be in 
AF at follow-up (HR: 0.60, 95% CI; 0.42-0.84) compared to those in the low SEA 
group (Figure 6). The association between high SEA and AFDF outcomes did not 
reach statistical significance (HR: 0.75, 95% CI; 0.54-1.04; Figure 8). There was no 
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significant association between marriage status, employment, income, retirement 
status, and level of education with AF freedom, without rhythm control.  
 
4.5 DISCUSSION 
4.5.1 Major Findings 
In this prospectively collected registry of risk factor management in consecutive 
overweight or obese patients with symptomatic AF referred for catheter ablation, there 
was no association between socioeconomic factors such as income level, education 
level, employment status, marital status and degree of weight loss or long-term AF 
recurrence. Long-term AF freedom was significantly lower in the middle SES 
compared to low or high SES groups. Interestingly those who were married were more 
likely to have successful weight loss and better overall risk factor management 
compared to those who were not married.  
 
4.5.2 Cardiovascular Disease and SES 
Cardiovascular disease has been associated with four markers of SES: income, 
education, employment and environment.424 Previous studies have demonstrated low 
socioeconomic neighbourhoods are associated with increased heart disease and 
mortality.422 Similarly, the impact that SES has with obesity has been previously 
shown.220-222 To date it has been shown that following adjustment there is a lower risk 
of stroke if you reside in a higher socioeconomic neighbourhood (HR: 0.87, 95% CI; 
0.7-0.96) conversely if you are in a low socioeconomic neighbourhood you had a 




4.5.3 Obesity and Role of Socioeconomic Status 
Additionally, obesity which in turn leads to cardiovascular disease and atrial 
fibrillation has been rising significantly. Our previous studies have shown that 
undertaking dedicated risk factor clinics can not only reduce AF symptom burden but 
also result in maintenance of sinus rhythm following ablation.309,408 However trying to 
assess which patients are most likely to achieve adequate weight loss or best respond 
to these have not been presented. By undertaking this analysis, it was anticipated that 
it would help with perhaps providing the insight into which patients to target or provide 
more directed risk factor management to ensure all patients achieve optimal results.  
 
4.5.4 Socioeconomic Factors that Results in Risk Factor Modification in AF 
Unfortunately, despite assessing the primary factors for SES: Income, education, 
employment, environment424, and the many factors included in the questionnaire we 
have not been able to identify specific factors that could assist in providing targeted 
counselling suggesting that perhaps there may be more character or behavioural 
influences that could provide further insight. While we did see a relationship with those 
in the middle-socioeconomic group and AF freedom, it is hard to fully appreciate the 
causal relationship of this. To our knowledge there is limited data on the impact of 
socioeconomic status on risk factor modification for patients with AF.  
 
4.5.5 Role of Marital Status in Risk Factor Management 
Importantly, we did see the role of marital status on optimal risk factor management. 
Indeed, perhaps family support or the support of a partner to provide motivation may 
translate in the ability to achieve the better outcomes. This however did not translate 
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into reduction in AF burden, possibly due to the low number of patients in the study. 
This perhaps suggests further research in this area is warranted to better understand 
the patients who can achieve optimal results and those who may require more input 
into their strategies.   
 
4.6 LIMITATIONS 
Findings from this study are subject to biases that are inherent in observational studies. 
As this is a single centre cohort from one State in Australia there is limited racial 
differences as seen in other countries. The clinic did see patients from all levels of 
socioeconomic levels. AF burden assessment using 7-day Holter may incompletely 
detect AF episodes, especially in patients with low AF burden. Continuous monitoring 
was not available in all patients, so this may lead to asymptomatic AF not able to be 
captured. As this was based on patient knowledge, particularly of family members, this 
may have underestimated some of the health conditions. Ascertainment bias was 
reduced through the collection of outcomes via routine data sources.  
 
4.7 CONCLUSION 
Socioeconomic determinants of health are increasingly recognised. In this study on 
risk factor management in individuals with symptomatic AF we were able to 
demonstrate individuals who were married were significantly more likely to achieve 
more weight-loss and risk factor modification. This suggest perhaps the importance of 
immediate family to provide support and motivation to achieve the adequate goals. 
However, this did not translate into meaningful reduction in AF burden. Interestingly, 
individuals from middle socioeconomic areas had greater AF freedom compared to 
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those who were in a low-socioeconomic area. Further studies are required to determine 




4.8 TABLE AND FIGURE LEGEND 
 
TABLE 1: BASELINE CHARACTERISTICS 
Baseline characteristics of patients as dichotomised by socioeconomic status.  
FIGURE 1: RESULTS OF QUESTIONNAIRE 
Pie charts showing break down of marital status, number of children, level of 
education, employment status, hours worked, and income of patients. Majority of 
patients were married had between 2-3 children, completed secondary school were 
retired. For those that worked 57% worked 40+ hours and 57% were middle to high 
income earners. 
FIGURE 2: WEIGHT-LOSS BASED ON SES 
Bar chart weight-loss based on the SES group. There was no significant difference in 
the degree of weight-loss achieved based on the SES of the individuals. 
FIGURE 3: WEIGHT-LOSS BASED ON MARITAL STATUS 
Bar charts figure 3A demonstrates those married based on the degree of weight-loss, 
being married was associated with greater weight-loss. Figure 3B demonstrates the 
amount of weight-loss with those who were married able to achieve a greater degree 
of weight-loss. 
FIGURE 4: WEIGHT LOSS BASED ON EDUCATION AND EMPLOYMENT 
Bar charts demonstrating the impact education status, employment and retirement 
status had on the overall degree of weight-loss. There was no significant difference 
based on an individual’s level of education or employment status.   
 FIGURE 5: AF FREEDOM BASED ON SES PARAMETERS 




FIGURE 6: AF FREEDOM BASED ON SES GROUP 
Patients with medium socioeconomic status was associated with a greater likelihood 
of AF freedom compared to low or high socioeconomic status. 
FIGURE 7: TOTAL AF FREEDOM 
This Kaplan-Meier curve shows the total AF freedom over the duration of the study, 
there was no significant difference between the three groups based on socioeconomic 
status area.  
FIGURE 8: AF FREEDOM – ABLATION AND DRUG FREE 
Kaplan-Meier curve demonstrating AF free survival without the use of ablation or 
antiarrhythmic therapy, there was no significant differences across the three groups. 
However, there was significantly more freedom for patients in the medium 




TABLE 1: BASELINE CHARACTERISTICS 
 LOW SE GROUP 
N= 64 
MEDIUM SE GROUP 
N = 116 
HIGH SE GROUP 
N = 138 
P Value 
Age (years) 67  10 67  11 67  11 0.92 
Female gender, n (%) 50 (46.9) 40 (34.5) 41 (39.7) 0.06 
BMI (Kgm-2) 32.3  3.7 33.8  5.2 32.8  4.4 0.07 
Metabolic Risk Factors 
Hypertension, n (%) 52 (81.3) 94 (81) 100 (73) 0.23 
DM, n (%) 14 (21.9) 28 (24.1) 20 (14.5) 0.19 
Hyperlipidemia, n (%) 31 (49.2) 52 (46.1) 60 (44.1) 0.80 
Coronary artery disease, n (%) 8 (12.5) 15 (12.9) 17 (12.3) 0.99 
Obstructive sleep apnoea, n (%) 28 (43.8) 65 (56) 66 (47.8) 0.23 
Alcohol excess (>30g/week), n 
(%) 
18 (18.1) 28 (24.1) 49 (35.5) 0.29 
Smoking status: 
Current, n (%): 



























FIGURE 2: WEIGHT-LOSS BASED ON SES 
Bar chart weight-loss based on the SES group. There was no significant difference in 
















































Chapter 5: Role of GENDER in Long-term 
Outcomes of Atrial Fibrillation 
Ablation: GENDER-AF 
5.1 INTRODUCTION 
Atrial fibrillation (AF) is fast reaching epidemic numbers worldwide, estimated to 
affect more than an estimated 33 million individuals, and over 12 million of these 
being female.1 Female patients with AF are typically older, more symptomatic and 
carry a significantly stronger risk of stroke, cardiovascular and all-cause 
mortality.273,275-277  These observations perhaps justify the aggressive treatment of AF 
and its risk factors in women, yet large registry data suggests that women with AF 
have a lower history of rhythm control, including cardioversion and catheter 
ablation275 and may proceed to AF ablation at a later stage.258  
Catheter ablation is an effective rhythm control strategy in patients with 
symptomatic AF, refractory to anti-arrhythmic medications. Given the gender 
differences in clinical characteristics of AF patients, including more advanced age and 
burden of comorbidities, the outcomes of AF ablation may differ between males and 
females. Large registry data suggests that in patients undergoing radiofrequency 
ablation of paroxysmal or persistent AF, females may be referred later for ablation and 
have lower success rates in males.259,305 Similarly, the Fire and Ice trial demonstrated 
women had lower success rate with an almost 40% increased risk of recurrence and a 
36% increase risk of cardiovascular rehospitalisation post procedure, suggesting 
despite the ablation technique used, women still have worse outcomes.306 
 Although a number of smaller additional studies have attempted to compare 
procedural outcomes from AF ablation between men and women,307 these findings 
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should be interpreted with some caution due to the differing blanking periods, follow 
up durations, numbers of females, and limited description of baseline clinical 
characteristics. Indeed, many studies have included <70 females301,303,426,427 and 
blanking periods less than 3 months.301,305 Despite the advantage of larger sample sizes 
with registry data, these studies can be limited by the lack of baseline patient-level 
characteristics and/or standardized follow-up.258,259,275 
Based on the current short-term data we hypothesised that women would have 
worse outcomes to men. This study aimed to evaluate the long-term impact of gender 
on baseline clinical characteristics, single and multiple procedure outcomes in a single 
centre cohort of patients undergoing radiofrequency catheter ablation for paroxysmal 
or persistent AF.  
 
5.2 METHODS 
5.2.1 Study Population 
This study is an analysis of prospectively collected registry data and comprised 
consecutive AF patients from the Centre for Heart Rhythm Disorders at the University 
of Adelaide, Australia who were undergoing AF ablation. Patients who had less than 
12-months follow-up were excluded from the analysis. Baseline, follow-up, 
echocardiographic, and complication data was collected on patients, CHADs Scoring 
were calculated to assess stroke risk in patients in place of CHA2DS2-VASc, in order 
to avoid gender bias shown in CHA2DS2-VASc. All patients who were symptomatic 
and had failed anti-arrhythmic therapies were referred for AF ablation. This study has 





5.2.2 Ablation Technique 
The technique used for ablation in our laboratory has previously been described.411 In 
brief, all patients underwent pulmonary vein isolation. Additional substrate ablation in 
the form of linear ablation, targeting triggers or potential sources of AF was undertaken 
in individuals with non-paroxysmal AF, longest atrial dimension of >57 mm or if they 
had concurrent structural heart disease. The type and extent of substrate modification 
was undertaken at the operating physician’s discretion.  
All patients had a planning computed tomography prior to ablation. Intracardiac 
or trans-oesophageal echocardiogram was undertaken to ensure no thrombus was 
present at the time of the procedure. During ablation, radiofrequency energy was 
delivered at 15-40 Watts and was temperature limited to 48 degrees. Patients 
underwent oesophageal temperature monitoring and ablation on the posterior wall was 
interrupted with any rise in temperature of >0.5 degrees. Cryoablation was not used in 
this cohort. Echocardiogram was performed following ablation to ensure there was no 
pericardial effusion. 
 
5.2.3 Echocardiogram Protocol 
Transthoracic echocardiograms were undertaken using a 3.5 MHz probe. 
Measurements taken were a per the standardised protocol according to American 




5.2.4 Follow-up Protocol 
This study had a blanking period of 90 days from ablation in keeping with the Heart 
Rhythm Society Consensus Statement.410 Arrhythmia recurrence was determined by 
symptoms and ambulatory monitoring. In addition, asymptomatic arrhythmia 
recurrence was based on 12-lead electrocardiogram, and 7-day Holter monitoring or 
device interrogation performed every 3 months for the first year and then 6 monthly. 
Echocardiography and symptom limited exercise stress testing was performed at 6 and 
12 months and subsequently on a yearly basis. Patients symptoms were assessed using 
the AF Symptom Severity Score as described by the University of Toronto, every 3 
months for the first-year post-ablation, and every 6 to 12 months thereafter.  
 
5.2.5 AF Freedom Definition 
AF recurrence was defined as any documented atrial arrhythmia lasting >30 seconds 
in duration, in keeping with the Heart Rhythm Society Consensus Statement.410 The 
date of arrhythmia recurrence was defined as the earliest date with documented AF 
following the blanking period. AF freedom was determined by review of the clinical 
history, 12 lead ECG and 7-day Holter monitoring.  
 
5.2.6 Study Outcomes 
The primary outcome of this study was AF freedom differences between sexes off anti-
arrhythmic medication following a single ablation procedure. This was determined by 
patient reported symptoms, 7-day Holter monitoring, or ECG. Secondary outcomes 
included requirement for multiple ablations off and on anti-arrhythmic medications, 




5.2.7 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean ± SD or median and interquartile range as 
appropriate. For categorical variables, differences between groups was compared 
using a Chi-squared test. Continuous variables were compared by independent t-test 
or Mann-Whitney U test where appropriate. To investigate the impact of gender on 
ablation outcomes, a Cox proportional hazards regression model was used. The impact 
of gender was assessed using age and type of AF in model 1, with the additional of left 
atrial size and concomitant risk factors (coronary artery disease, obstructive sleep 
apnoea, hypertension, BMI, diabetes mellitus) in model 2. A p-value of p<0.05 was 
considered statistically significant. All statistical analysis was performed with SPSS 
version 24.0 (SPSS, Inc., Chicago, IL, USA).  
 
5.3 RESULTS 
5.3.1 Patient Population 
A total of 699 consecutive patients undergoing de novo primary ablation of AF were 
studied. Median follow-up was 6.1 [1-12.7] years. Of these 74 patients had <12 months 
follow-up. Six patients died within the first year of follow-up, 42 lived interstate or 
overseas, and 26 patients had <12 months follow-up. Of the remining 625 patients 
there were 207 (33.1%) females and 418 (66.9%) were male. Figure 1 presents the 




5.3.2 Baseline Characteristics 
At the time of first ablation, males were significantly younger than females 59 ± 10 
versus 62 ± 10.5 (p=<0.0001).  Females were more likely to present with paroxysmal 
AF compared to males (70.5% versus 59%, p<0.001), have less obstructive sleep 
apnoea (7.7% versus 15.6%, p=0.006), less alcohol excess (21.5% versus 3.4%, 
p<0.0001) and less coronary artery disease (6.8% versus 11.2%, p=0.076).  There were 
no other significant differences in baseline parameters between sexes. There was no 
difference seen in pharmacotherapy use between the sexes. Table 1 presents the 
differences in baseline characteristics between the genders. 
 
5.3.3 Echocardiography Differences 
In terms of echocardiographic measures, females presented with less ventricular wall 
thickening IVsd (1.0 ± 0.6 versus 1.1 ± 0.2, p=0.01), smaller left atrial diameter (3.7 ± 
0.6 versus 4.3 ± p=0.6), left atrial volume (61.5 ± 23.6 versus 77.5 ± 26.3, p<0.0001), 
left atria area (21.5 ± 2.9 versus 24.8 ± 7.5, p<0.0001), and a greater left ventricular 
ejection fraction (61 ± 9 versus 59 ± 11, p=0.02) compared to males (Table 1). 
 
5.3.4 AF Ablation Outcomes 
5.3.4.1 Number of procedures 
The mean number of procedures undertaken in this cohort was 1.6 ± 0.7. There was 
no significant difference in the number undertaken in females compared to males. In 
terms of number of procedures undertaken in each gender, 100 (48.3%) females had 1 
procedure, 88 (42.5%) had 2 procedures, 18 (8.7%) had 3 procedures and 1 (0.5%) 
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underwent 4. For males there was a similar result: 210 (50.2%) underwent single 
procedure, 157 (37.6%) had 2, 43 (10.3%) had 3 and 8 (1.9%) had 4.  
In terms of other outcomes, there was a similar number of females and males 
who underwent subsequent pacemaker implantation, 58 (28%) versus 100 (23.9%) 
(p=0.39). Also, those who require AV nodal ablation females 16 (7.7%) males 12 
(2.9%) (p=0.13).  
 
5.3.4.2 Single Procedure Outcomes – Males Compared to Females 
There was no statistical difference between sexes for single procedure success drug 
free (M: 28.9% versus F: 26.6%, p=0.57) or (M: 31% versus F: 32%, p=0.86) drug 
assisted. As demonstrated in table 2, in univariate analysis, female gender was not 
associated with single procedure recurrence either drug assisted (HR: 1.06, 95% CI: 
0.86-1.29) or drug free (HR: 1.14 .95% CI: 0.93-1.38). Furthermore, in adjusted 
analyses female gender was not associated with single procedure outcomes either drug 
assisted (Model 1, HR: 1.09, 95% CI: 0.92-1.44) or drug free (Model 1, HR: 1.17, 95% 
CI: 0.95-1.43). However, in a fully adjusted model, female gender was associated with 
an elevation in risk of AF recurrence drug free following a single procedure (HR: 1.26, 
95% CI: 1.01-1.58).  
 
5.3.4.3 Multiple Procedure Outcomes– Males Compared to Females 
Women fared worse following multiple procedure (68.6% versus 76.3%, p=0.041) 
drug assisted and (46.9% versus 54.4%, p=0.074) drug free. In univariate analysis, 
female gender was associated with multiple procedure recurrence drug assisted (HR: 
1.46 .95% CI: 1.06-1.99) and but not drug free (HR: 1.25, 95% CI: 0.98-1.58). In 
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adjusted analyses female gender was associated with multiple procedure recurrence 
drug assisted (Model 1, HR: 1.43, 95% CI: 1.03-1.98) but not drug free (Model 1, HR: 
1.21, 95% CI: 0.95-1.55). In a fully adjusted model, female gender was associated with 
a significantly increased risk of AF recurrence drug assisted following a multiple 
procedure (HR 1.53, 95% CI: 1.04-2.24). 
 
5.3.4.4 Predictors of AF Recurrence 
In multivariate regression model, age, type of AF and OSA were independent 
predictors of AF recurrence for single procedure drug assisted. These were also the 
predictors, along with gender for single procedure drug free. For multiple procedure, 
gender, age and type of AF were independent predictors of AF recurrence drug 
assisted, and age, type of AF and OSA for those drug free (Table 3).   
 
5.3.5 Complication Data 
Given previous studies have demonstrated females often present with more post-
procedural complications we assessed this within out cohort. There was a total of 51 
(8.1%) complications, there was no difference between genders (M: 35, 8.4% versus 
F: 16, 7.7%; p=0.9). There were no significant differences between the sexes in either 
major or moderate complications (Table 4).   
 
5.3.6 Mortality 
Over the course of follow-up, a total of 28 (4.5%) patients died, 11 were female. Two 
patients died as a result of atrio-esophageal fistula following the procedure. A further 
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9 died from carcinoma, 9 due to various non-cardiac conditions, 6 due to chronic heart 
failure, and 2 due to unknown reasons. 
 
5.4 DISCUSSION 
5.4.1 Major Findings 
In this single centre prospective cohort with detailed patient level data, and long-term 
data on ablation outcomes of up to 10 years we found the following:  
1. Women presented with more paroxysmal AF, smaller left atria and had 
more sleep apnoea; 
2. There was no difference in the antiarrhythmic use, number or procedures 
or pacemaker implantation between the sexes; 
3. Following adjustment for risk factors women had worse outcomes 
following multiple procedures and an increased risk of recurrence drug 
assisted  
 
5.4.2 Difference in Risk Factors Between Sexes 
Gender differences in disease profiles, treatment availability and outcomes have been 
determined about several cardiovascular conditions. There is emerging data from large 
registries that have suggested that there may be undertreatment of women with AF. In 
this cohort, 70.5% of women had paroxysmal AF, this was significantly higher than 
males 49%. Women had a significantly smaller left atria, were older and more sleep 
apnoea. Previous studies have demonstrated females are typically older and present 
with more risk factors including a higher prevalence of persistent AF, resulting in more 
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AF recurrence when they undergo AF ablation,259,302,305,429,430, The large German 
Ablation Registry which has one of the largest cohorts of females undergoing 
ablation.259 This study also demonstrated women had a greater presence of paroxysmal 
AF but were less likely to have freedom from AF following ablation and more 
complications post procedure. Of note however, this was a short-term study with data 
was taken after only 1 year of follow-up and was taken from a registry which lacked 
the basic patient level information. The current study provides long-term patient level 
follow-up which demonstrates a higher risk of recurrence in females only following 
adjustment, in addition there was no apparent difference in post procedural 
complications. 
 
5.4.3 Difference in Management Strategies Between Sexes 
Several registries have found women are undertreated with rhythm control and more 
likely to undergo AV nodal ablation.257,259,298 This data however is taken from 
registries and does lacks significant follow-up from a clinical perspective. The current 
study was able to show that management strategies between sexes was markedly 
similar. There were similar rates of ablation performed, no differences in the use of 
anti-arrhythmic therapies, no difference in females undergoing pacemaker 
implantation or AV nodal ablation. This is different to what has previously been 
suggested in which women are more likely to be undertreated. 
 
5.4.4 Outcome Differences Between Sexes 
As demonstrated by Vallakati et al the strength of data in the area of gender and AF 
ablation outcomes is very weak.307 This meta-analysis pooled together 20 studies 
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assessing gender difference in ablation outcomes. This demonstrated that women were 
significantly more likely to have less freedom from AF following ablation. Of 
significance is that when looking closer at the studies, 35% had short-term follow-up 
of around 12 months, and perhaps more strikingly, 65% of the studies included had 
<100 females. Winkle et al where they also showed that while women had the same 
rates of AF freedom as males following the initial ablation overall they success rates 
were lower302, highlighting there the success rates of females may indeed be 
approximately 10% lower than that of males undergoing ablation. Zhang et al once 
again presented a cohort of only persistent AF and in a relatively small cohort, however 
they demonstrated that women were more likely to present with lone AF but yet had a 
lower initial ablation success rate (HR: 1.66, 95% CI: 1.11-2.49).303 These studies 
however were not long-term and included small numbers of females. In the current 
long-term study, we were able to demonstrate overall there was no difference 
following single procedure outcomes, however women were more likely to fail 
multiple procedures. Women had a significantly higher risk of recurrence following 
multiple procedures on AAD. Similarly following adjustment for common factors 
which would influence AF recurrence women were more likely to experience recurrent 
following ablation. 
 
5.4.5 Complication Differences Post Ablation 
Complications following ablation have previously been shown to differ, in studies 
several it has been demonstrated that females have predominately more complications 
259,305,430, while other studies have reported similar complication rates.302,303,427 Our 
study however concurred with the later where we did not see any significant difference 
between males and females in terms of post procedural related complications. 
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These have mostly had relatively small cohorts and short follow-up. This study 
presents a large cohort over a long-follow up and shows outcomes between genders is 
equivocal to what has been published. It is interesting to note that despite studies 
highlighting that women have a higher risk of recurrence, mortality and 
strokes305,307,429 there is still a large discrepancy in the literature regarding women and 
ablation outcomes highlighting a clear gap in knowledge. 
 
5.5 LIMITATIONS 
This is a single centre cohort and observational study; however, the data emerges from 
a prospectively collected clinical registry. Measurement bias was reduced by use of 
standardised processes in the clinic. Additionally, while many of the patients had 
implantable devices, for those without the silent or asymptomatic AF could have 
occurred without our knowledge. Use of 7-day Holter monitoring and review of all 
implantable device checks was undertaken to enable us to capture AF recurrence as 
much as possible. 
 
5.6 CONCLUSION 
Data on gender outcomes has been varied and is predominantly taken from small 
cohorts of short duration. This study provides the longest follow-up of gender 
outcomes demonstrating that females present with more paroxysmal AF and a smaller 
atrium. Despite this, women are more likely to have AF recurrence following ablation. 




5.7 TABLE AND FIGURE LEGEND 
 
TABLE 1. BASELINE CHARACTERISTICS 
TABLE 2. RISK OF AF RECURRENCE 
Table demonstrating univariate and multivariate risk of AF recurrence for single and 
multiple procedures. 
TABLE 3. MULTIVARIATE PREDICTORS OF AF RECURRENCE 
Table demonstrating the multivariate predictors for single and multiple drug free and 
drug assisted outcomes. 
TABLE 4. TABLE OF COMPLICATION  
Table demonstrating the differences in complications post AF ablation between men 
and women, there was no significant difference between the groups. 
FIGURE 1: CONSORT DIAGRAM 
Consort diagram demonstrating the final cohort of patients included in the study. 
Also shown is the number of patients who underwent follow-up at 2-yearly intervals. 
FIGURE 2.  KAPLAN MEIER CURVE AF FREEDOM OFF AAD 
Kaplan Meier curves demonstrating outcomes between genders for AF freedom off 
anti-arrhythmic drugs for single and multiple procedures. 
FIGURE 3.  KAPLAN MEIER CURVE AF FREEDOM ON AAD 
Kaplan Meier curves demonstrating outcomes between genders for AF freedom on 












Age 59 ± 10 62 ± 10.5 <0.0001 
BMI 29.5 ± 4.9 30 ± 6.8 0.4 
Type of AF: 
Paroxysmal AF (%) 









Hypertension (%) 208 (49.8) 123 (59.4) 0.02 
Diabetes Mellitus (%) 31 (7.4) 20 (9.7) 0.3 
Obstructive Sleep Apnoea 
(%) 
65 (15.6) 16 (7.7) 0.006 
Alcohol excess (>30g/week) 90 (21.5) 7 (3.4) <0.0001 
Smoking 
         Never 
         Current 












Hyperlipidaemia (%) 150 (35.9) 75 (36.2) 0.9 
Coronary Artery Disease (%) 47 (11.2) 14 (6.8) 0.08 
ANTIARRHTYHMIC USE 
Flecainide (%) 78 (18.7) 44 (21.3) 0.4 
Sotalol (%) 117 (28.1) 52 (25.1) 0.6 
Amiodarone (%) 56 (13.4) 33 (15.9) 0.4 
ECHOCARDIOGRAPHIC MEASURES 
IVersusd (cm) 1.1 ± 0.2 1.0 ± 0.6 0.01 
LVID (cm) 29.5 ± 4.9  30 ± 6.8 0.1 
LVEF (%) 59 ± 11 61 ± 9 0.02 
LA Diameter (cm) 4.3 ± 0.6 3.7 ± 0.6 <0.0001 
LA Volume (mls) 77.5 ± 26.3 61.5 ± 23.6 <0.0001 
LA Area (cm2) 24.8 ± 7.5 21.5 ± 2.9 <0.0001 
LA Major (cm) 6.1 ± 2.9 5.5 ± 0.7 0.008 






TABLE 2. RISK OF AF RECURRENCE 
 




SINGLE PROC, DRUG ASSISTED 1.06 (0.86-1.29) 1.09 (0.88-1.34) 1.15 (0.92-1.44) 
SINGLE PROC, DRUG FREE 1.14 (0.93-1.38) 1.17 (0.95-1.43) 1.26 (1.01-1.58) 
MULTI PROC, DRUG ASSISTED 1.46 (1.06-1.99) 1.43 (1.03-1.98) 1.53 (1.04-2.24) 
MULTI PROC, DRUG FREE 1.25 (0.98-1.58) 1.21 (0.95-1.55) 1.28 (0.97-1.68) 
Reference group is male. *Model 1: Adjusted for age and type of AF. *ꬹ Model 2: Adjusted for model 1 and coronary artery disease, 




TABLE 3. MULTIVARIATE PREDICTORS OF AF RECURRENCE 
 
 ODDS RATIO 95% CI P-VALUE 
SINGLE PROCEDURE, DRUG FREE 
GENDER 1.23 1.01-1.58 0.04 
AGE 1.15 1.01-1.03 0.005 
TYPE OF AF 1.33 1.12-1.72 0.002 
OSA 1.37 1.08-1.92 0.012 
SINGLE PROCEDURE, DRUG ASSISTED 
AGE 1.01 1.00-1.02 0.18 
TYPE OF AF 1.35 1.15-1.77 0.001 
OSA 1.39 1.09-1.98 0.01 
MULTI PROCEDURE, DRUG FREE 
AGE 1.02 1.01-1.04 0.001 
TYPE OF AF 1.37 1.12-1.89 0.005 
OSA 1.56 1.24-2.45 0.001 
MULTI PROC PROCEDURE, DRUG ASSISTED 
GENDER 1.42 1.04-2.24 0.03 
AGE 1.03 1.01-1.05 0.004 















Major Complications 19 (4.5) 5 (2.4) 0.27 
Fistula 2 0 
Tamponade 2 3 
Stroke/TIA 2 0 
Pericarditis/Dresslers Syndrome 13 2 
Moderate Complications 16 (3.8) 11 (5.3) 0.4 
Pulmonary (Edema/Pneumonia) 5 2 
Groin Haematoma 7 5 
Major Effusion requiring 
intervention 
2 0 
Asystole/PPM Requirement 2 4 





































Chapter 6: ThrombogeneSIs Risk LatE 
FollowiNg AF AblaTion – 
SILENT Study 
6.1 INTRODUCTION 
Among the multiple complications resulting from AF, stroke remains the most 
devastating. It has been demonstrated that AF is responsible for one third of ischemic 
strokes.385  Whether the risk of stroke persists following successful ablation of AF and 
total elimination of arrhythmic episodes remains unknown.17 The mechanisms of 
thrombus formation are somewhat complex and poorly understood, factors such as 
mechanical dysfunction, endothelial dysfunction, clotting, inflammation and platelet 
activation as potential contributors.387 It has been described in Vichow’s triad that 
there are three factors responsible for thrombus development being abnormal blood 
flow and stasis, hypercoagulability and endothelial dysfunction.388 Further it suggests 
perhaps it is not only the abnormal blood flow but resultant due to the fibrillation in 
the left atrium. 
Several studies have assessed the risk of thromboembolism following AF 
ablation. Oral et al demonstrated a risk of TE to be 1.1% with these events all occurring 
within the first 12 months following ablation.431 A large registry has shown that AF 
elimination as a result of ablation did result in lower stroke rates than those medically 
treated, the rates were no different to the general population.389 A large multicentre 
study assessing cessation at 3-6 months following ablation demonstrated during follow 
up 0.07% of those off anticoagulation and 0.45% on anticoagulation had an ischemic 
stroke (p=0.06). While non-randomised this does suggest a benefit to continuation of 
anticoagulation following successful AF ablation.394 More recently, data has been 
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variable with one study suggesting that following successful ablation at 3 months, 
switching to aspirin in patients with a CHA2DS2-VASc ≥2 is as safe as long-term 
anticoagulation.432 Conversely a national survey performed in Canada demonstrated 
that 89% of physicians continued anticoagulation even after no AF recurrence at 12 
months.433 A recent study has demonstrated the rates of thromboembolic events 
beyond 3 months following ablation are quite low when compared to a non-ablation 
cohort.392 Additionally, it found that the risk of serious bleeding associated with 
anticoagulation outweighed the benefit of thromboembolic event. It has also been 
suggested that perhaps the type of AF is an important consideration with a meta-
analysis demonstrating that the risk of thromboembolism was higher in those with 
persistent AF.434 A recent meta-analysis addressing the role of subclinical ‘silent’ AF 
has found that this is a predictor of clinical AF, while it does pertain a risk of stroke it 
was demonstrated that this was indeed lower than that of subclinical AF.396 
Noseworthy et al have demonstrated that the overall risk of stroke post ablation is low. 
While discontinuation of anticoagulation was common, they were able to show that 
this was associated with an increased risk of cardioembolism within the first 3 months 
for all patients, however for high-risk patients this was also a long-term risk.435  
It is not clear if the stroke risk is eliminated by catheter ablation of AF. We 
hypothesised despite eliminating AF in a population undergoing ablation, there would 
still be individuals who experience a thrombogenic event. As such, the aim of this 
study was to characterise the stroke risk following AF ablation in a large single centre 





6.2.1 Study Population 
The study comprised consecutive patients undergoing AF ablation at the Centre for 
Heart Rhythm Disorders at the University of Adelaide, Australia. Patients who had 
less than 12-months follow-up were excluded from the analysis. Baseline, follow-up, 
echocardiographic, and complication data was collected on patients. As per the ESC 
guidelines, women with a CHA2DS2-VASc score of 1 for sex with no other stroke risk 
factors were scored 0.17 All patients were symptomatic and had failed anti-arrhythmic 
therapies were referred for AF ablation. This study had a blanking period of 90 days 
from ablation in accordance with the Heart Rhythm Society Consensus Statement.410 
Patients who experienced a thromboembolic event were recorded and the 
characteristics of the event along with investigations were collected. These events were 
established over the time course of the patient’s follow-up. Patient records including 
ECG, Holter Monitoring and device interrogations were obtained to establish if the 
event occurred due to arrhythmia or in the absence of arrhythmia. This study has been 
approved by the Human Research Ethic Committee of the Royal Adelaide Hospital.  
 
6.2.2 Ablation Technique 
The techniques used for ablation in our laboratory have previously been described.411 
In brief, all patients underwent pulmonary vein isolation. Additional substrate ablation 
in the form of linear ablation, targeting triggers or potential sources of AF was 
undertaken in individuals with non-paroxysmal AF, longest atrial dimension of >57 
mm or if they had concurrent structural heart disease. The extent and type of substrate 
modification undertaken was at the operating physician’s discretion.  
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All patients had computed tomography prior to ablation. Intracardiac or trans-
oesophageal echocardiogram was undertaken to ensure no thrombus was present at the 
time of the procedure. During ablation, radiofrequency energy was delivered at 15-40 
Watts and was temperature limited to 48 degrees. Patients underwent oesophageal 
temperature monitoring and ablation on the posterior wall was interrupted with any 
rise in temperature of >0.5 degrees. Cryoablation was not used in this cohort.  
 
6.2.3 Follow-up Protocol 
Arrhythmia recurrence was undertaken with 12-lead electrocardiogram, 7-day Holter 
monitoring and/or device interrogation every 3 months for the first-year post-ablation, 
and every 6 months thereafter. Anticoagulation was ceased in all patients with a 
CHADS2 <2 at 3 months following ablation. In all other patients the decision to stop 
anticoagulants was made on an individual basis after the absence of any arrhythmia 
for ≥12 months. 
 
6.2.4 AF Freedom 
AF recurrence was defined as any atrial arrhythmia lasting >30 seconds in duration in 
accordance with the Heart Rhythm Society Consensus Statement.410 The date of 
arrhythmia recurrence was defined as the earliest date with documented AF following 
the blanking period. AF freedom was determined by review of the clinical history, 12 




6.2.5 Thromboembolic Event Definition 
Events of stroke, transient ischaemic attack (TIA), or cerebrovascular attack (CVA) 
were captured at either routine follow-up or hospitalisation. Stroke was defined as a 
neurological deficit lasting longer than 24 hours due to cerebrovascular emboli. A TIA 
was defined as a neurological deficit lasting less than 24 hours due to cerebrovascular 
emboli. All patients underwent cerebral imaging to confirm diagnosis with CT or MRI 
and in some cases patients underwent transoesophageal echo or carotid ultrasound to 
rule out atheroma and carotid stenosis. All patients underwent review by a Neurologist 
who made the diagnosis.  
  Patients were defined as having a late event if this occurred more than 12 
months following the ablation. 
 
6.2.6 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean ± standard deviation (SD) or median and 
interquartile range as appropriate. For categorical variables, differences between 
groups was compared using a Chi-squared test. Continuous variables were compared 
by independent t-test or Mann-Whitney U test where appropriate. A p-value of p<0.05 
was considered statistically significant. All statistical analysis was performed with 





6.3.1 Baseline Characteristics 
A total of 700 consecutive patients undergoing de novo AF ablation were prospectively 
followed. A total of 628 patients completed at least 12 months of follow-up and were 
included in the analysis (Figure 1). Median follow-up was 2411 days [365-4645]. 
Table 1 presents the baseline characteristics of the cohort. Mean age of the cohort was 
66 ± 11, 419 were male, the mean BMI 30.2 ± 5.6. There were 56.4% of the cohort 
with paroxysmal AF, and 52.7% had hypertension.  
 
6.3.2 Clinical Factors Associated with Stroke 
No significant differences were present in baseline characteristics between patients 
who had embolic events (n=15) compared with those without events (n=613; Table 1). 
There were no major echocardiographic differences in LA sizes nor was there any 
significant difference in anticoagulation use between the groups. The mean CHA2DS2-
VASc was 1.6 ± 1.3, with non-stroke patient CHA2DS2-VASc 2 ± 1 and stoke patients 
CHA2DS2-VASc 3 ± 1. This was not statistically different between the groups (Table 
1). 
 
6.3.3 Timing of Events  
Of the 628 patients with at least 12 months follow up, a total of 15 (2.4%) presented 
with thromboembolic event following AF ablation. Two (13%) occurred within 12 
months of ablation; a further 5 (27%) within 1-2 years and 8 (60%) >2 years after 





6.3.4 Events and Arrhythmia  
There were 9 (60%) patients who experienced an event in the absence of arrhythmia 
following successful ablation. These patients underwent a median of 1176 [504-
13870] hours of monitoring for asymptomatic arrhythmias. These occurred at a median 
of 801 [421-2956] days post ablation. Five (55.5%) occurred very late, more than 2 
years following successful AF ablation in the absence of arrhythmia. Two patients had 
implantable pacemakers which confirmed the absences of arrhythmia. The remainder 
of the patients had ECG and were undergoing regular Holter monitoring as part of their 
post ablation follow-up. Figure 3 demonstrates example of the pacemaker 
interrogation. One patient had a CHA2DS2-VASc score of 4, three had a CHA2DS2-
VASc score of 3, four patients had a CHA2DS2-VASc score of 2 and one patient had 
a score of 1. Majority of patients scored for hypertension which was treated in all 
patients (Table 2).  
 There were six patients (40%) who had an embolic episode related to AF 
recurrence. This was documented on pacemaker interrogation, ECG and patient 
symptoms. Two patients had CHA2DS2-VASc score of ≥2, two patients had 
CHA2DS2-VASc score of 1 and two patients had CHA2DS2-VASc score of 0. These 
scores were predominantly due to hypertension (Table 3).  
 
6.3.5 Anticoagulation at Time of Event 
Eight patients who had no AF had ceased long-term anticoagulation for a mean of 
6.9±6.1 months prior to the thromboembolic event. Of note, one patient experienced 
his event while taking rivaroxaban despite appropriate dosage and compliance with 
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this medication. Two patients had ceased their anticoagulation for 1 week due to 
undergoing non-cardiac surgery (Table 2). 
For those who had AF recurrence, two patients (13.3%) experienced an event 
due to anticoagulation non-compliance. One patient had his event directly following 
his ablation while on anticoagulation, one patient had ceased his anticoagulation for 
30 days, one for 228 days, and one patient was on anticoagulation at the time of the 
event (Table 3).   
 
6.3.6 Type of Event 
In the patients who had an event in the absence of arrythmia, five patients experienced 
CVA, three had a TIA, and 1 patient had a gastrointestinal ischemic event. Symptoms 
for the patients were typical of CVA/TIA presentation, with dysphasia, left sided 
weakness and amaurosis fugax (Table 2). 
For those who had AF recurrence two experienced CVA and three had a TIA. 
Symptoms for the patients were typical of CVA/TIA presentation, with dysphasia, left 
sided weakness and diplopia (Table 3). 
 
6.3.7 Details of Investigations 
All patients underwent neurological evaluation to confirm diagnosis of stroke and 
exclude the possibility of lacunar infarcts based on the cerebral imaging. All patients 
underwent brain computed tomography (CT) and/or magnetic resonance imaging 
(MRI) to confirm diagnosis.  
Of those who had no AF eight underwent CT with four also undergoing MRI 
evaluation. In one patient only MRI imaging was undertaken to confirm the diagnosis. 
160 
 
Two patients were unable to have MRI due to non-MRI compatible pacemakers insitu, 
one patient refused to have MRI (Figure 3).  
 In the patients who had AF recurrence, three had CT scan, two didn’t have this 
as diagnosis made on MRI, one patient was overseas and therefore the CT was not 
performed. Four patients underwent MRI, with two patients were unable to have MRI 
due to non-MRI compatible pacemakers insitu (Figure 3). 
 
6.3.8 Management of Patients 
In total, two patient received acute thrombolysis. Transoesophageal echo (TEE) was 
performed in 5 patients: No intra-cardiac clot was seen but mild arch atheroma was 
seen in 3 patients, one patient had significant arch atheroma and one patient had no 
significant findings. Carotid ultrasound on 4 of the 6 patients did not demonstrate any 
significant carotid artery stenosis.  
In the group who had no AF recurrence, patients had repeat rhythm monitoring 
with 7-day Holters and ECGs except for 2 patients with implantable pacemakers. No 
AF was seen from these investigations with device interrogations also showing no 
evidence of atrial arrhythmia recurrence (Figure 4).  
Following the event, all patients who had an event were anticoagulated (5 with 
Warfarin and 10 with a non-vitamin K antagonist).  
One patient died as a result of the event. Fortunately, all remaining 14 patients 





6.4.1 Major Findings 
This study has some important findings: 
1. There were no significant baseline characteristics that contributed to a 
thromboembolic event following ablation. 
2. Events following ablation occur late with 27% occurring 1-2 years post 
ablation and 60% occurring more than two years post ablation 
3. A significant proportion of patients experienced an event in the absence of 
arrhythmia 
This study has shown that in patients undergoing ablation for AF, the risk of 
stroke remains low over a long-term follow-up. However, it also demonstrates that 
these events can present quite late following the apparent successful ablation in the 
absence of arrhythmia. It argues for meticulous monitoring and careful consideration 
if anticoagulant cessation is considered.   
 
6.4.2 Stroke Post AF Ablation 
The risk of AF recurrence following an apparent successful procedure confers an 
inherent risk of increased thromboembolic complications should anticoagulation be 
ceased based on initial results.436 Indeed, despite having had “successful” AF ablation, 
stroke risk may still be present given that the constellation of risk factors that led to 
AF in the same patients are also known risk factors for stroke and data is limited in 
this area.17 Saad et al demonstrated there was a low to moderate risk if a patient had a 
CHADS2 score of ≤3 but that remained on antiplatelets and that risk factors would 
need to be assessed to establish risk of stroke, they did however have 3 patients in their 
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cohort who experienced strokes whilst on anticoagulation.437 Yagishita et al suggests 
that with patients who maintained sinus rhythm following ablation there was a low risk 
from >3 years follow-up suggesting that AF ablation reduces the risk irrespective of 
the outcome, once again suggesting anticoagulation to be used based on risk factors.438 
A large multi-centre study demonstrated that those off anticoagulation had a higher 
rate of thromboembolic events in a short-term follow-up following AF ablation.394 
More recently Gaita et al published an observational study with a low incidence of 
thromboembolic events over 60.5 months of follow-up.439 They noted the incidence 
was lower in those who underwent AF ablation compared with the general population 
of anticoagulated patients. In their cohort they documented 6 of 267 patients who had 
events whist still anticoagulated and 5 of 499 patients who ceased their anticoagulation 
experienced events. The current study demonstrates that 87% of events occurred more 
than 1 year following their ablation. Of this 53% occurred more than 3 years following 
the procedure. The same held true for those who had an event in the absence of 
arrhythmia with 88% of the events occurring greater than 12 months follow successful 
ablation. 
 
6.4.3 Subclinical AF and Stroke 
A recent meta-analysis assessing the temporal association between subclinical AF and 
stroke found that following excluding patients without AF, only 17% strokes occur in 
the presence of ongoing AF.396 The type of AF has also been suggested as a potential 
to predict events post ablation, with persistent AF patients more likely to experience 
an event.434 This was demonstrated in a recent meta-analysis has demonstrated the 
unadjusted risk for thromboembolism in persistent compared to paroxysmal AF was 
1.355 (95% CI: 1.17-1.57, p<0.001). The risk of stroke being related to the burden of 
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AF has important implications. In the context following catheter ablation, in the 
absence of detectable arrhythmia, the risk of stroke could be considered low.  
 
6.4.4 Clinical Implications 
Perhaps due to the low number of events, this study was unable to isolate any 
individual risk factors that increased the risk of an event. It could be suggested that 
due to these patients receiving protocolised care with regular long-term follow-up this 
could indeed result in fewer events. This cohort has demonstrated that despite the 
absence of AF, cryptogenic stroke risk exists, and thromboembolic management needs 
to be considered following ablation. This study however does demonstrate that there 
is potentially the risk of a thrombogenic atria despite elimination of AF. While 
cessation of anticoagulation following apparent successful ablation seems relatively 
safe, there still remains a lack of conclusive data, particularly in the absence of large 
randomised clinical studies.  
 
6.5 LIMITATIONS 
This is a single centre cohort and observational study; however, the data was is 
obtained from a prospectively collected clinical registry. Measurement bias was 
reduced by use of standardised processes in the clinic. Additionally, while two of the 
patients had implantable devices which demonstrated no AF, for those without a 
device, silent/asymptomatic AF could have occurred without our knowledge. Standard 
protocolised follow-up with the use of 7-day Holter monitoring, ECGs and review of 
all implantable device checks was undertaken to provide the ability to capture AF 





Although AF ablation is a well-regarded treatment for AF, “successful” ablation does 
not abolish the risk of stroke. In this study a significant number of events occurred in 
the absence of arrythmia with two of these continuously monitored by pacing. This 
suggest that perhaps the thrombogenic atria exists despite sinus rhythm maintenance. 
Additionally, these events occurred quite late following successful ablation 
suggesting, while the risk seems low, caution is needed about cessation of 
anticoagulation following AF ablation. Further studies are needed to determine the 





6.7 TABLE AND FIGURE LEGEND 
 
TABLE 1. PATIENT CHARACTERISTICS 
TABLE 2. CHARACTERISTICS OF PATIENTS WHO HAD EVENTS IN 
THE ABSENSE OF AF 
Table demonstrating the patients divided by those who had event in the absence of 
arrhythmia. 
CHARACTERISTICS OF PATIENTS WHO HAD EVENTS WITH AF 
RECURRENCE  
Table demonstrating the patients divided by those who had event with AF 
recurrence. 
FIGURE 1. CONSORT DIAGRAM 
Diagram of patient selection 
FIGURE 2. TIMING OF EVENTS 
Pie chart demonstrating distribution of time of event occurring following ablation. 
With over half events occurring after 2 years post ablation. 
FIGURE 3. ACUTE MANAGEMENT FLOW DIAGRAM 
Patient management flow for patients who had stroke, evaluation undertaken and 
diagnosis.  
FIGURE 4. PACEMAKER INTERROGATION 
Pacemaker interrogation from patient who had event in the absence of arrhythmia. 

















AGE 66 ± 11 59.8 ± 10.4 62.7 ± 7.6 0.3 
BODY MASS INDEX 28.9 ± 5.6 29.8 ± 5.6 28 ± 4.5 0.27 
MALES (%) 419 (66.7) 409 (66.7) 10 (66.7) 0.98 















PRIOR STROKE (%) 48 (7.6) 47 (7.7) 1 (6.7) 0.87 
PRIOR MI (%) 21 (3.3) 21 (3.4) 0 (0) 0.47 
OSA (%) 81 (13) 79 (12.9) 2 (13.3) 0.96 
HYPERTENSION (%) 331 (52.7) 322 (52.5) 9 (60) 0.57 
HYPERLIPIDAEMIA 
(%) 
224 (35.7) 220 (36) 4 (26.7) 0.46 
CORONARY ARTERY 
DISEASE (%) 






















51 (8.1) 51 (8.3) 0 (0) 0.24 
CHA2DS2-VASc Score 1.6 ± 1.3 2 ± 1 3 ± 1 0.71 
ECHOCARDIOGRAM MEASURES 
LA VOLUME (mls) 72 ± 27 72 ± 27 61 ± 15  
LA AREA (cm2) 24 ± 7 23.8 ± 6.9 22.3 ± 6.6 0.4 
LA DIAMETER (cm) 4.1 ± 0.7 4.14 ± 0.67 3.93 ± 0.74 0.23 
LVEF (%) 60 ± 10 60 ± 10 62 ± 7 0.5 
ANTICOAGULATION USE 
NONE/ASPIRIN (%) 261 (41.6) 256 (41.7) 5 (33.3) 
0.46 WARFARIN (%) 311 (49.5) 302 (49.3) 9 (60) 
NOAC (%) 55 (8.8) 54 (8.8) 1 (6.7) 
AF = atrial fibrillation; MI = myocardial infarction; OSA = obstructive sleep 
apnoea; LA = left atrial; LVEF = left ventricular ejection fraction; NOAC = non-






TABLE 2. CHARACTERISTICS OF PATIENTS WHO HAD EVENTS IN THE ABSENSE OF AF 




















1 M 66 TIA 360 84 








2 F 66 CVA 442 52 





performed (no AF) 
Expressive 
dysphasia 
Left sided weakness 
and numbness 
78 
3 M 76 TIA 90 23 2 – AGE Paroxysmal 
Holters/ECG’s 













performed (no AF) 
Abdominal pain 72 
5 M 56 CVA 413 19 
2 – HTN, 
DM 
Persistent PPM – no AF Left sided weakness 78 
6 M 59 CVA 67 19 1 – HTN Paroxysmal 
Holters/ECG’s 
performed (no AF) 
Left sided weakness 66 
7 M 73 CVA 0 14 








8 F 77 TIA 7 8 
4 – HTN, 
AGE, 
FEMALE 





9 F 66 CVA 0 40 










CVA = Cerebrovascular event; TIA = Transient ischemic event; MCA = Middle cerebral artery GI = Gastrointestinal; HT = Hypertension; AF = Atrial fibrillation; PPM = 
Permanent pacemaker; OAC = Oral anticoagulation; DM = Diabetes mellitus 
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TABLE 3. CHARACTERISTICS OF PATIENTS WHO HAD EVENTS WITH AF RECURRENCE 




















EVENTS WITH AF RECURRENCE 
1 M 57 CVA 228 16 0 Persistent 
PPM-Brief episode 




2 F 75 CVA 2 99 




PPM – Brief 







3 M 62 TIA 30 23 1 – HTN Persistent 
Recurrent episode 
of AF 
Visual loss, Left 
sided weakness 
Recurrent AF 
4 M 56 TIA 897 37 0 Persistent 






5 F 74 TIA 0 4 




























































Chapter 7: Cessation of Non-vitamin K 
Antagonist Oral Anticoagulants 
in Atrial Fibrillation Patients 
7.1 INTRODUCTION 
The incidence of atrial fibrillation (AF) is growing to epidemic proportions, and set to 
rise exponentially over the years to come.1 One of the most devastating AF-related 
complications is stroke, with 15-40% of all strokes occurring in individuals with a 
history of AF.37 This risk increases with age, from 1.5% in 50-59 years up to 23.5% in 
individuals aged 80-89 years.440 Anticoagulation is the key management strategy for 
stroke prevention in individuals with AF. Although vitamin K antagonist (VKA) such 
as warfarin were for many years the anticoagulant of choice for stroke prevention, the 
more recent emergence of non-vitamin K antagonist oral anticoagulants (NOAC) has 
provided an effective alternative. This is largely due to greater ease of prescription 
with the lack of need for regular blood testing and reduced dietary interactions. The 
ease of use and efficacy have led to inclusion of NOACs in the recent European Society 
of Cardiology AF Guidelines as a Class I, level A recommendation in stroke 
prevention for eligible patients, as a preference over VKA.109  
However, despite the benefits of NOACs over VKA, recent trials have 
suggested that there is a large rate of cessation. The cessation rates reported in the 
Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY), Rivaroxaban 
versus Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF) and apixaban 
versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE) trials were 21% (2 
years follow-up), 14.3% (1.9 years follow-up), and 25.3% (1.8 years follow-up) for 
dabigatran, rivaroxaban and apixaban respectively. The primary cause of cessation was 
174 
 
major bleeding, gastrointestinal bleeding or dyspepsia.441-443 Indeed, the rates of 
discontinuation have been used to promote the need for alternative stroke prevention 
techniques such as left atrial appendage closure devices.444-446 Despite this, clinical 
experience suggests that NOAC use is safer than what has been reported by the larger 
studies.447 
These strikingly high cessation figures raise the question as to the safety of 
NOACs in a real-world setting. To assess this, we studied AF patients with an 
indication for long-term anticoagulation who were prescribed a NOAC in our centre 
between 2010 and 2017. We aimed to characterise the incidence and causes of NOAC 
cessation and serious adverse events leading in discontinuation of treatment. Further, 
we sought to describe the duration of treatment prior to cessation across the three main 
NOACs and identify predictors of cessation and serious adverse events. 
 
7.2 METHODS 
7.2.1 Study Population 
This study comprised 1415 consecutive AF patients, from a prospectively collected 
registry (Clinical Trial Registration: ACTRN12614001123639), at the Centre for 
Heart Rhythm Disorders, Adelaide, Australia between 2011 and 2017. The study 
included patients who were prescribed either dabigatran, apixaban or rivaroxaban 
(Figure 1A). Edoxaban was not included in this cohort as it is not available in Australia. 
The choice of NOAC prescribed was at the treating physicians’ discretion based on 
the patient’s needs, age, and renal function. Prescription in our clinic is an integrated 
care context, involving a specialist nurse and a pharmacist if required,  whereby the 
patient receives education about AF and the pharmacotherapy.448 While the NOAC’s 
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were available to limited patients on a physician familiarisation program from 2011, 
rivaroxaban was listed on the pharmaceutical benefits scheme in August 2013, 
followed by apixaban and dabigatran which were both listed in September 2013. 
Patients with a CHA2DS2-VASc score of 0 were excluded, as they had no indication 
for long-term anticoagulation. This included women without other stroke risk 
factors.404  
 
7.2.2 Patient Characteristics 
AF was confirmed by at least one 12-lead electrocardiogram (ECG) documentation. 
Type of AF was defined as per the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE 
expert consensus statement on catheter and surgical ablation of AF.401 Baseline 
characteristics including age, gender and body mass index (BMI) were recorded, and 
clinical risk factors at the time of NOAC initiation was collected. This included type 
of AF, hypertension, diabetes mellitus, hyperlipidaemia, smoking status. NOAC type 
at baseline and at final follow-up, date of commencement and cessation, cause of 
cessation, and adverse events resulting in cessation were collected for analysis.  
The study was approved by the Human Research Ethics Committee of the 
University of Adelaide and Royal Adelaide Hospital. 
 
7.2.3 Study Outcomes 
The main study outcome was the cessation of index NOAC (defined as NOAC type at 
baseline), either to another form of oral anticoagulation (OAC) or complete OAC 
cessation. Causes of cessation, duration-to-cessation and predictors of cessation are 
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reported. Additionally, we characterise the rate and type of serious adverse events 
resulting in NOAC cessation.  
 
7.2.4 Definitions 
Serious adverse events were defined as events leading to discontinuation of treatment. 
This included major bleeding, minor bleeding, ischaemic stroke and drug-related 
adverse reaction warranting discontinuation. Bleeding was defined as per the 
Thrombolysis in Myocardial Infarction bleeding criteria (TIMI)449. Major bleeding 
was defined as: any intracranial bleeding; clinically-overt signs of haemorrhage 
associated with a decrease in haemoglobin of ≥5 g/dL or a ≥15% absolute decrease in 
haematocrit; or fatal bleeding (bleeding that directly results in death within 7 days). 
Minor bleeding was defined as: clinically overt bleeding resulting in haemoglobin drop 
of 3 to <5 g/dL or ≥10% decrease in haematocrit; no observed blood loss but with ≥4 
g/dL decrease in the haemoglobin concentration or ≥12% decrease in haematocrit; or 
any overt sign of haemorrhage that does not meet the above criteria but is associated 
with any of the following: requiring medical or surgical intervention, leading to 
prolonging hospitalization or prompting evaluation. Renal impairment was defined as 
abnormal estimate glomerular filtration rate (eGFR) <60 mL/min/1.73m2. Some 
patients made an informed decision to stop their anticoagulation following a detailed 
discussion with their treating cardiologist and are represented as a ‘patient choice’ 
category in our study, of note no patients decided to stop their NOAC due to cost 




7.2.5 Statistical Analysis 
Categorical variables are represented as frequencies and percentages. Continuous 
variables are summarized as mean±SD or median and interquartile range as 
appropriate. For categorical variables, differences between groups was compared 
using a Chi-squared test. Continuous variables were compared by independent t-test 
or Mann-Whitney U test where appropriate. Duration-to-cessation in the population, 
stratified by NOAC type at baseline, was tested using a log rank test and presented 
using Kaplan-Meier curves. A multivariable cox regression model was constructed to 
assess the influence of clinical variables, selected a priori based on clinical consensus.  
Given the relatively low event rate of NOAC reaction, we limited these candidate 
variables to age, gender, common comorbidities (body mass index, hypertension, type 
II diabetes) and AF type (paroxysmal, persistent, or permanent). A p-value of p<0.05 
was considered statistically significant. All statistical analysis was performed with 
SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA). 
 
7.3 RESULTS 
7.3.1 Baseline Characteristics 
A total of 503 patients were prescribed a NOAC between 2011 – 2017, of whom 439 
(87.3%) patients had a CHA2DS2-VASc of ≥1 and were included in the study (Figure 
1), the remaining 64 patients with a CHA2DS2-VASc <1 received peri-procedural 
OAC for ablation or cardioversion with cessation planned once sinus rhythm was 
maintained. The mean age was 71.9 ± 8.7 years and 162 (36.9%) were females. Two-
hundred and thirty patients (52.4%) had paroxysmal AF, while 134 (30.5%) had 
persistent AF and 75 (17.1%) had permanent AF (Table 1). At baseline, 154 (35.1%) 
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of patients were prescribed dabigatran, 195 (44.4%) were prescribed apixaban and 90 
(20.5%) were prescribed rivaroxaban (Figure 2). Follow-up duration ranged from 0.2 
to 7 years, with a median follow-up of 3.6 years [IQR 2.7 – 5.3].  
 
7.3.2 Primary Outcomes 
Of the 439 patients, 292 (66.5%) remained on their index NOAC while 147 patients 
(33.5%) ceased their index NOAC. This group was composed of 113 (76.9%) patients 
who changed to an alternative NOAC or warfarin and 34 (23.1%) who ceased 
anticoagulation completely, resulting in a total cessation of index NOAC rate of 8.8 
events per 100 patient-years of follow-up. Patients who did not change their NOAC 
were significantly younger than those who changed or stopped OAC (71.2±7.9 versus 
73.2±9.9 years, respectively; p=0.02). AF type was different between the groups, with 
paroxysmal AF being present in 56.2% of those who remained on their index NOAC 
compared to 44.9% in the NOAC cessation or alteration group (p=0.008). Inversely, 
persistent AF was less common (25.7%) in the NOAC continuation group compared 
to 40.1% in the cessation group, with comparable levels of permanent AF (18.2% and 
15.0%, respectively; overall p=0.008). No major differences were seen between other 
risk factors (Table 1). 
 
7.3.3 Causes of Switching of Index NOAC 
Of those who switched their OAC patient choice was the most frequent cause (47/113, 
41.6%) (Table 2). Serious adverse events resulting in altering OAC type (either to a 
different NOAC or to warfarin) took place in 28 patients over the follow-up period, 
resulting in an adverse event rate of 1.6 per 100 patient-years. Event rate per NOAC 
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were: 1.7 per 100 patient-years for dabigatran; 1.1 per 100 patient-years for apixaban; 
and 2.3 per 100 patient-years for rivaroxaban.  
Overall, 3 patients experienced major bleeding, all in the form of non-fatal 
intracranial haemorrhages. A further 3 patients experienced cerebrovascular 
thromboembolic events, and 6 patients experienced minor bleeds. Over the course of 
the study, 13 (2.9%) patients died of non-NOAC related causes. 
Table 2 outlines the causes of altering treatment including alteration by other 
physicians involved in patient care, alteration due to AF ablation or surgical 
intervention, as well as alterations due to drug-related adverse reactions. 
 
7.3.4 Complete Cessation of OAC 
Complete cessation of OAC occurred in 34 patients. The most frequent reason for 
complete discontinuation was patient decision (23/34, 67.6%). Indeed, across the 
complete cessation and the switching groups, patient choice accounted for 78/147 
(53.1%) of all causes. In 8 patients (23.5%), age-related anticoagulation risk 
outweighed the benefits of anticoagulation resulting in cessation of treatment 
following an informed discussion with the treating cardiologist. Left atrial appendage 
occlusion (LAAO) took place in 2 patients and one patient discontinued oral 
anticoagulation due to undergoing treatment for cancer (Table 2). 
 
7.3.5 Duration to Cessation 
The mean duration to cessation was 4.9 (95% CI: 4.6-5.1) years. When stratified by 
NOAC type at baseline, there was a significant difference across the cohort (log-rank 
p=0.009) (Figure 2). Patients on apixaban had a significantly longer duration-to-
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cessation time compared with other NOAC users with a mean duration of 5.1 (95% 
CI: 4.8-5.4) years compared to rivaroxaban 4.6 (95% CI: 4.2-4.9) years for dabigatran 
(p=0.002) and 4.5 (95% CI: 3.9-5.1) years (p=0.025) (Figure 3). 
 
7.3.6 NOAC Use at Follow-up 
At final follow-up, 361 (82%) patients remained on a NOAC. Of those, 71 patients 
remained on index dabigatran and 3 patients crossed over from an alternative NOAC 
resulting in a total of 74 (20.5%) patients on dabigatran at final follow-up. Of the 
patients originally on apixaban, 162 (44.9%) remained on this without the need for 
cessation, however at final follow-up a further 56 patients crossed over from an 
alternative NOAC with a total of 218 patients (60.4%) on Apixaban. Rivaroxaban was 
prescribed to 69 patients (19.1%) at final follow-up, 59 of whom were on their index 
NOAC and 10 crossed over from other groups. Warfarin was commenced in 44 
patients (12.2%): 40.9% due to patient decision; 13.6% due to decline in renal 
function; 11.4% undergoing procedures; and the remainder 34.1% were due to drug-
related reactions (Figure 2).  
 
7.3.7 Predictors of Outcomes and Adverse Events 
In a multivariate cox regression model including BMI, AF type, gender, hypertension, 
and diabetes, age (HR 1.03, 95% CI: 1.008-1.05; p=0.006) was an independent 
predictor of cessation of index NOAC. Female gender (HR 2.2, 95% CI: 1.04-4.64; 





7.4.1 Major Findings 
This “real world” cohort of ambulatory AF patients demonstrate the following about 
NOAC use: 
1. Persistence of NOACs use was found to be high with only 8.8 cessations per 
100 patient-years of follow-up;  
2. The rate of serious adverse events rate was low at only 1.6 per 100 patient-
years of follow-up; 
3. Apixaban had the longest duration-to-cessation of all the NOACS of 5.1 (95% 
CI: 4.8-5.4) years, suggesting that apixaban is potentially better-tolerated in 
comparison to other NOACs; 
4. Age independently predicted cessation of index NOAC and importantly, 
female gender was an independent predictor of serious adverse events; 
5. Involvement of patients in the decision-making process of their care is 
paramount, with the most common cause of cessation of index NOAC (53.1%) 
being patient choice. 
 
7.4.2 Adverse Events and Cessation of NOACs 
Our study has demonstrated that NOACs are relatively safe and well tolerated, with 
two-thirds of patients remaining on their index NOAC following a median follow-up 
of 3.6 years. Additionally, only 28 patients (6.3%) experienced serious adverse events 
resulting in cessation of their treatment with a low adverse events rate of 1.6 per 100 
patient-years. Our data differs from that seen in the major studies with lower cessation 
and adverse events rates. While the cessation rates in the major NOAC studies were 
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reported as 21% for those on dabigatran, 25.3% for those on apixaban and 14.3% for 
rivaroxaban, this was only for the first year of follow-up and may increase if further 
follow-up is reported. Further, depending on the definition of adverse events, this 
ranged from 35% to 86.6% across the three major NOAC, possibly reflecting the 
variability of definition, as well as the differing reporting methods in phase 3 trials 
versus real-world clinical experience.441-443  
 
7.4.3 Duration to Cessation of NOAC 
In our study, patients on apixaban had the longest duration-to-cessation in comparison 
to other NOAC users, in addition to having a trend towards lower serious adverse 
events. This is in-line with other studies and adds to the growing body of evidence that 
apixaban may be better tolerated than other NOACs.450-452  
 
7.4.4 Factors and predictors of reactions and cessation 
Interestingly, we found that whilst there were fewer women in the study, they 
presented with 2.5-times more adverse reactions, indicating a potentially important 
gender implication. Additionally, age was found to be a significant predictor of 
cessation of index-NOAC, either to a different form of OAC or stopping altogether. 
The predictive value of these factors for NOAC cessation was not reported in the three 
major studies and to our knowledge have not been shown previously. Further studies 
are required to better understand the role that gender may play with regards to NOAC 
complications and whether a more personalized approach to NOAC choice and 




7.4.5 Approach to Management of Anticoagulation 
The importance of patient education and adopting an integrated approach to patient 
care is highlighted in our study, as it may well have had a significant role in the 
relatively low serious events rates, by facilitating early detection and management of 
adverse reactions. This echoes the recent 2018 EHRA practical guide453 for NOAC 
use, which recommends that at each clinic visit, adherence, thromboembolism, 
bleeding, other side effects, and co-medications are checked along with close 
monitoring of haemoglobin, renal and liver function. The monitoring is recommended 
to intensify from annually to six-monthly for patients aged ≥75 or those with renal 
complaints.404 Additionally, patient education and involvement in the decision-making 
process further empowers them to make informed choices regarding their care, as 
reflected in patient-choice accounting for over half (53.1%) of all treatment alterations. 
 
7.4.6 Safety of NOACs and Future Role 
The use of NOACs has increased in popularity due to the practical advantages 
compared to warfarin.454 One of the inherent risks with anticoagulation is that of 
bleeding which is potentially a major safety concern. NOACs appear to be more 
effective than warfarin without compromising safety. In a systematic review and meta-
analysis of 12 studies with 54875 patients, NOACs significantly reduced the relative 
risk of stroke and systemic embolism by 23%, and subsequently all-cause and 
cardiovascular mortality (RR of 0.89 for both), without increasing the risk of major 
bleeding.325 The popularity of NOACs is expected to increase given the development 
of reversal agents which can alleviate some of the concerns regarding major 
bleeding.455,456 Randomized-controlled trials directly comparing the efficacy and 
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safety of the main NOACs are lacking and may have a significant role in NOAC 
selection in the future. 
 
7.5 LIMITATIONS 
While this is a single centre observational study, it reflects real-world experience with 
NOAC use and achieved statistically-significant findings by virtue of the relatively 
long duration of follow-up. Due to geographical and medical prescription differences 
this may influence the outcomes given that cost of medications and prescription is 
different in other countries. Therefore, this data is representative of Australian 
prescription only. Data collection takes place prospectively whenever possible in our 




Use of NOAC is safe and well-tolerated in this cohort of real-world AF patients. An 
integrated approach to patient care enables safe use of NOACs through patient 
education and monitoring and empowers patients to make informed decisions 
regarding their care. Apixaban may be better tolerated in comparison to other NOACs, 





7.7 TABLE AND FIGURE LEGEND 
 
TABLE 1: PATIENT CHARACTERISTICS 
TABLE 2: CAUSES FOR CHANGE OR STOPPING ANTICOAGULATION 
Table highlighting causes for patients to cease their index NOAC and serious adverse 
events stratified by NOAC type.  
FIGURE 1: PATIENT SELECTION 
Consort diagram of the patient selection. Atrial fibrillation (AF), oral anticoagulation 
(OAC). 
FIGURE 2: OVERALL CESSATION/CHANGE OF NOAC 
Graph demonstrating the baseline prescription and use of oral anticoagulation (OAC) 
at final follow-up. Baseline use of non-vitamin K antagonist (NOAC): dabigatran 154 
(35.1%), apixaban 195 (44.4%) and rivaroxaban 90 (20.5%). At follow-up, 74 (16.9%) 
patients were on dabigatran, 218 (49.7%) on apixaban, 69 (15.7%) on rivaroxaban, 44 
(10%) on warfarin and 34 (7.7%) discontinued all oral anticoagulation. 
FIGURE 3: TIME TO EVENT CESSATION 
Kaplan-Meier curve demonstrating duration to cessation event. A log rank test was 
performed to determine if the type of non-vitamin K antagonist (NOAC) at baseline 
would affect the duration of remaining on the same index NOAC. Patients were 
stratified to dabigatran, apixaban and rivaroxaban. The mean duration-to-change in 
years for the entire population was 4.9 (95% CI=4.6-5.1). Apixaban had the longest 
duration-to-cessation compared to dabigatran (4.6, 95% CI: 4.2–4.9, p=0.002) and 











N: 292  
CHANGED OR 
STOPPED NOAC  
N: 147 
P value for 
CHANGE v 
NO CHANGE 
Age, years 71.9 ± 8.7 71.2 ± 7.9 73.2 ± 9.9 0.02 
Body mass index, 
kg/m2 
28.4 ± 8 28.7 ± 8.3 28 ± 7.4 0.12 
Female gender, n (%) 
162 (36.9) 102 (34.9) 60 (40.8) 0.23 
CHA2DS2-VASc Score     
1 92 (21) 63 (21.6) 29 (19.7)  
2 112 (25.5) 74 (25.3) 38 (25.9)  
3 88 (20) 57 (19.5) 31 (21.1)  
4 75 (17.1) 45 (15.4) 30 (20.4) NS 
5 50 (11.4) 39 (13.4) 11 (7.5)  
6 14 (3.2) 10 (3.4) 4 (2.7)  
7 6 (1.4) 4 (1.4) 2 (1.4)  
8 2 (0.5) 0 (0) 2 (1.4)  
Atrial fibrillation type     
   Paroxysmal, n (%) 230 (52.4) 164 (56.2) 66 (44.9)  
   Persistent, n (%) 134 (30.5) 75 (25.7) 59 (40.1) 0.008 
   Permanent, n (%) 75 (17.1) 53 (18.2) 22 (15)  
Hypertension, n (%) 341 (77.7) 230 (78.8) 111 (75.5) 0.44 
Diabetes, n (%) 69 (15.7) 46 (15.8) 23 (15.6) 0.84 
Sleep apnoea, n (%) 95 (21.6) 66 (22.6) 29 (19.7) 0.49 
Hyperlipidaemia (%) 226 (51.5) 161 (55.1) 65 (44.2) 0.031 
SMOKING     
    Non-smokers 335 (76.5) 220 (75.6) 115 (78.2)  
    Smokers 14 (3.2) 7 (2.4) 7 (4.8) 0.223 
    Ex-smokers   89 (20.3) 64 (22) 25 (17)  











TABLE 2: CAUSES FOR CHANGE OR STOPPING ANTICOAGULATION 
 DABIGATRAN APIXABAN RIVAROXABAN TOTAL 
Patient decision (%) 27 (43.5) 12 (52.2) 8 (28.6) 47 
Renal impairment (%) 13 (21) 1 (4.3) 2 (7.1) 16 
AF ablation (%) 5 (8.1) 0 (0) 5 (17.9) 10 
Other treating physician (%) 2 (3.2) 4 (17.4) 1 (3.6) 7 
Surgery (%) 1 (1.6) 0 (0) 4 (14.3) 5 
SERIOUS ADVERSE EVENTS 
Intracranial haemorrhage (%) 1 (1.6) 0 (0) 2 (7.1) 3 
Stroke/transient ischaemic 
attack (%) 2 (3.2) 1 (4.3) 0 (0) 3 
Minor bleed (%) 4 (6.5) 0 (0) 2 (7.1) 6 
Gastrointestinal upset (%) 4 (6.5) 2 (8.6) 1 (3.6) 7 
Rash (%) 0 (0) 2 (8.6) 1 (3.6) 3 
Unwell/myalgia (%) 2 (3.2) 1 (4.3) 2 (7.1) 5 
Anaphylaxis (%) 1 (1.6) 0 (0) 0 (0) 1 
TOTAL 62 (54.9) 23 (20.4) 28 (24.8) 113 
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Chapter 8: Conclusions 
This thesis addresses the identification and management of atrial fibrillation which is 
the most common heart rhythm disorder. It demonstrates the role of screening for AF 
and the ability to assess risk of AF in large population screening. Additionally, the 
importance of treating risk factors and the potential for reversal of the AF substrate for 
the first time. The role that socioeconomic status plays in risk factor management for 
AF. Also addressed is the role of gender differences in ablation outcomes. Further, the 
risk of stroke following ablation providing insight into the implications of a 
thrombogenic atria despite elimination of the arrhythmia and the use of NOACs 
regarding adherence, cessation and reactions. These findings help to further the 
understanding some of the mechanisms of atrial fibrillation and strategies to manage 
this condition. 
  Atrial fibrillation is rising in prevalence. Despite this it is a condition that many 
people in the general public are still unaware of this condition or the risk factors 
associated with it. The role of screening is one that is becoming clearer with time. In 
order to undertake screening to assess prevalence this should be done in a targeted 
cohort. However, screening as part of a National awareness campaign while resulting 
in a low detection rate did enable the ability to provide the public with a risk of atrial 
fibrillation based on their individual risk factors. In conjunction with this it enabled 
education as to the condition and the importance of atrial fibrillation specific risk 
factors. This method of screening provided individualised 5-year risk prediction on the 
development of AF based on the participants specific risk factors. This provides a 
crucial component of education for the individual but also a nationwide risk of AF 
score. This was lower in Caucasians compared to non-Caucasians.    
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It has been well established that atrial fibrillation is a condition that progresses 
with time. In fact, it is demonstrated that progression is determined by the number of 
risk factors that co-exist in a given individual. In Chapter 2 the findings of a dedicated 
risk factor and weight loss clinic and the impact on AF progression for the first time. 
It demonstrates that the better an individual’s risk factors are controlled (measured by 
the degree of weight reduction achieved), the more likely there is to be a reversal of 
the atrial fibrillation process by a change in the disease profile from persistent to 
paroxysmal atrial fibrillation. On the other hand, if risk factor control was not achieved 
there was more risk of progressing the disease to more persistent forms. This reversal 
in the atrial substrate leads the way in highlighting the importance of risk factors 
management for individuals with AF. To date there has been no study to demonstrate 
the potential for the reversal of the atrial substrate by the simple measures of 
addressing the risk factors of individuals. 
The role of socioeconomic status on this risk factor management in patients 
with atrial fibrillation is not well understood. While those who live in socially 
disadvantaged areas are seen to have less access to education, employment, and 
medical treatments. Indeed, lower SES has been attributed to greater risk factors and 
therefore potentially a greater burden of AF. In Chapter 3 we assessed the 
socioeconomic impact on individuals who were attending the risk factor clinic and 
whether this would affect the ability to lose weight or result in more freedom from 
atrial fibrillation. Interestingly, we did find that individuals who were married were 
more likely to lose significantly more weight than those who were unmarried. Perhaps 
this therefore would highlight the importance of family support, motivation and 
encouragement when it comes to weight-loss and improvement of risk factors. This 
study showed that being in a middle socioeconomic status was associated with greater 
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freedom from atrial fibrillation. This suggests that the ability to improve weight and 
risk factors is not in fact limited to the area you live in, the type of lifestyle you live or 
the level of education one obtains. This study has provided initial insights into these 
important potential determinants for risk factor management and needs to be further 
explored prospectively.    
For patients who are highly symptomatic and in which antiarrhythmic therapy 
has not been successful, ablation has become primary means of therapy. Many studies 
have shown that women have much different treatment to men, with significantly 
worse outcomes from ablation. Chapter 4 presents a large cohort of consecutive 
patients undergoing ablation, over a long-term follow-up, with the aim to assess the 
difference in outcomes between sexes. This study demonstrated some interesting 
results. Females presented with more paroxysmal AF, less sleep apnoea, a smaller left 
atria and coronary artery disease compared to males, there was no other significant 
difference in baseline comorbidities. There were no significant differences in single 
procedure outcomes, however women were more likely to have worse outcomes 
following multiple procedures on and off antiarrhythmic therapies. Similarly, 
following adjustment for risk factors, women were more likely to have a recurrence 
following single procedure off AAD and multiple procedure on AAD.  
Thromboembolic events remain the most devastating complications of atrial 
fibrillation. The mechanisms which promote thrombus formation is believed to be due 
to decreased blood flow in the left atrial appendage, resulting in a thrombus forming, 
this primarily occurs in the left atrium. While ablation proves to be effective in the 
elimination of atrial fibrillation the subsequent ability to eliminate the risk of stroke is 
not well understood. The study in Chapter 6 presents a large cohort of patients 
undergoing ablation for symptomatic atrial fibrillation A total of fifteen patients had a 
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stroke following ablation. In this cohort there were no difference in risk factors 
between the patients who experienced a stroke and those who did not. Importantly, 
there were nine patients who had a thromboembolic event in the absence of arrhythmia. 
Interestingly these events occurred quite late following the apparent successful 
ablation. Seven of these occurred more than 12 months following successful ablation, 
with two of these occurring after 4 years. This would suggest that perhaps the 
arrythmia itself is not the cause of the stroke. These may be cryptogenic in nature and 
this is not well understood. 
One of the key management strategies for patients with atrial fibrillation is that 
of anticoagulation to assist with stroke prevention. In recent years the introduction of 
non-vitamin K antagonist has led to an ease in the management of anticoagulation. 
These require less maintenance, with no major food restrictions, avoidance of regular 
blood testing, and ease in dosing. Large pharmaceutical driven studies have shown that 
despite the ease of these drugs there is a large cessation rate and similarly many 
reactions. In Chapter 7, real-world data is presented which addresses the number of 
cessation rates in three of the popular non-vitamin K antagonists. This study found that 
majority of the causes for cessation is in fact patient choice. The rate of cessation is 
low in the real work as is that of the adverse events. Age was an independent predictor 
of cessation and female gender was an independent predictor of adverse reaction. This 
perhaps demonstrates that it is the selection of the patient is of importance and more 




Chapter 9: Future Directions 
This thesis has provided some important insights into the risk factors, management 
strategies, screening for detection and risk of AF, and substrate progression. There are 
many questions that still require further research some of which are discussed below. 
Detection rate of AF in the general population is low. More targeted screening 
of certain populations may be useful to better assess AF prevalence. AF screening is 
cumbersome with not much return, better strategies need to be implemented to 
improve the undertaking of such events. With advancing technology large scale 
national and potentially international studies with the use of device worn daily such as 
smart watches may provide some interesting insight into AF prevalence, detection 
rates, heart rate variability and management strategies. The use of screening to provide 
5-year risk prediction scores may assist with targeting individuals at risk of 
development of AF and provide early preventative education. 
This thesis has provided important findings regarding the potential of substrate 
reversal. Previous studies have shown progression of the AF substrate over time. This 
has been demonstrated to be due to underlying risk factors. While in chapter 3, the 
study was able to show potential reversal of the AF substrate, additional studies are 
required to assess this further. Undertaking mapping studies may help us verify the 
reversal of the substrate. More studies are required to better understand risk factor 
management strategies in the treatment of patients with atrial fibrillation. The role of 
gender and AF remains variable. Greater representation of women in large ablation 
studies may assist with a better understanding as to the impact of gender and AF. It 
would be important to perhaps evaluate the potential mechanisms and structural 
differences to enable better management of females with AF. Studies to evaluate the 
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difference in triggers and location of drivers in women compared to men may as well 
as evaluating rate and rhythm control usage, may also assist with knowledge as to 
ablation outcomes. Furthermore, trials to evaluate the underlying causes of stroke and 
thromboembolism, genetic associations, mortality outcomes and hormonal influences 
could provide the insight into ablation outcomes and better targeted management 
between sexes. While stroke post AF ablation is a reality, it is not well understood as 
to the mechanisms of cryptogenic stroke. Despite being a common and relatively 
successful management strategy for patients with AF, it is apparent that ‘successful 
AF ablation does not abolish stroke risk. Larger and randomised trials may assist with 
the many remaining questions as to the timepoint of anticoagulation cessation safety 
following apparent successful AF ablation. With the use of cardiac implantable 
monitors, it is possible some of these questions may be answered. Appropriate 
anticoagulation needs further evaluation. NOACs use is rising in popularity. Ongoing 
evaluation is needed to fully understand the complication, cessation and adverse 
reaction rate. To date this has only been shown in large pharmaceutical driven studies. 
Our study demonstrated that gender and age were predictors for cessation of the 
NOACs. Independent studies with larger cohorts will be required to understand the 
potential predictors for cessation which may assist with more targeted management of 
patients who are prescribed anticoagulation. Additional studies assessing the 
differences between NOACs once again independent of pharmaceutical companies 
may assist with answers on the safety of each NOAC.  
There is a role for further evaluation into the substrate, many mechanisms, and 
risk factors that underly and drive AF. Delivery of AF management and use of 
dedicated risk factor clinics in other centres both nationally and internationally is 
pinitol moving forward. Incorporation of risk factor management is an essential 
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element to assist with reduction of AF and improve outcomes for patients diagnosed 
with AF to stem the rising epidemic. 
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